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Summary
RNA polymerase III (pol III) is dedicated to the transcription of genes involved in protein 
synthesis (5S rRNA and tRNA genes). Cell division is dependent on the rate o f growth, 
which is dependent on the rate o f protein synthesis. Therefore, the rate o f pol III 
transcription plays a fundamental role in cellular growth and proliferation. Regulation is 
mediated via a number of different mechanisms that can alter the activities of 
transcription factors, which direct pol III transcription. Work in this project was directed 
at uncovering potential mechanisms for pol III regulation. A primary target was the 
mTOR pathway, as it coordinates nutrient availability with cell growth.
Addition of the mTOR inhibitor rapamycin resulted in a decrease in the level of pol III 
transcripts. Furthermore, inhibition o f the mTOR pathway resulted in a decrease in the 
promoter occupancy of pol III and TFIIIB. This occurred without any changes in the 
abundance of these two factors. Past studies have shown that mTOR regulates the 
expression o f pol I-transcribed genes through the kinase S6K. Consistent with this, 
knockdown o f S6K reduced the expression o f pol I-transcribed genes. However, 
knockdown o f S6K had no effect on the abundance o f pol III transcripts. This highlights 
a difference in the regulation of pol I- and pol Ill-transcribed genes.
mTOR may regulate gene expression through its direct recruitment to the transcriptional 
machinery, as raptor, a component o f the mTOR complex, was found to co- 
immunoprecipitate with TFIIIC in this present study. Furthermore, chromatin 
immunoprécipitation revealed that mTOR is associated with pol Ill-transcribed genes.
Ill
1
TSC2, Rheb and PKB, upstream components of the mTOR pathway, were all shown to 
regulate the expression of pol Ill-transcribed genes. TSC2, a tumour suppressor, was 
found to have a negative effect on the expression of pol Ill-transcribed genes. Loss of 
TSC2 in a knockout cell line resulted in an increase in abundance of the 1 lOkDa subunit 
o f TFIIIC. This is consistent with previous studies where TFIIIC 110 was suggested to be 
the rate-limiting component o f pol III transcription. However, work in the present study 
using a TFIIIC 110 inducible cell line was unable to substantiate these claims.
Blocking the mTOR pathway also resulted in a decrease in the acétylation of histone H3 
found on pol Ill-transcribed genes. Furthermore, addition of the drug trichostatin A 
(TSA), which promotes the acétylation o f histones and other cellular proteins, increased 
the level of pol III transcripts. TSA also increased the promoter occupancy of pol III and 
TFIIIB, while at the same time increasing the acétylation of histones H3 and H4 on pol 
Ill-transcribed genes. In addition to being acetylated, histones are also methylated on pol 
Ill-transcribed gene. ChIP analysis has demonstrated the presence histone H3 lysine 4 
méthylation and histone H3 lysine 9 méthylation on pol Ill-transcribed genes. Further 
work is needed to characterize the role o f these covalent modifications.
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Chapter 1 -Introduction
1.1 Transcription
An important step in understanding the human genome is the identification of transcribed 
units, and more importantly how they are transcriptionally regulated in relation to cellular 
function. In eukaryotic cells the task o f transcribing nuclear genes has been shared 
between RNA polymerase I, II and III. This list has been extended recently with the 
discovery of a fourth nuclear eukaryotic RNA polymerase (Kravchenko et al., 2005). 
The specificity of the polymerases is often aided by other proteins known as transcription 
factors, which bind to DNA sequences known as promoters, directing the transcription of 
specific genes within the genome.
Each polymerase is committed to the transcription o f a specific set o f genes. RNA 
polymerase I (pol I) is responsible for the transcription of genes encoding the 45S 
ribosomal (r)RNA, which is subsequently processed into 5.8S, 18S and 28S. 
Transcription by pol I accounts for 60% of total cellular RNA synthesis (Moss and 
Stefanovsky, 2002). RNA polymerase II (pol II) transcribes protein-coding genes to 
produce messenger RNAs (mRNAs) (White, 2001a). mRNAs form targets for the 
translational machinery where they are subsequently translated into proteins (White, 
2001a). Pol II also transcribes many small nuclear (sn)RNAs, which have a role in 
mRNA processing (White, 2001a). RNA polymerase III (pol III) is dedicated to the 
transcription of an eclectic mix o f genes involved in protein synthesis (5S rRNA and 
tRNA) and a variety of other essential functions. Pol III accounts for 10% of all nuclear 
transcription (Moss and Stefanovsky, 2002). RNA polymerase IV (pol IV), a recently 
discovered nuclear polymerase, is expressed from an alternative transcript of the 
mitochondrial RNA polymerase gene (Kravchenko et al., 2005), Pol IV is responsible for
the transcription of a number of mRNAs (Kravchenko et ai., 2005). Tight control must 
be exerted over these polymerases to regulate cellular function through coordinated gene 
expression.
1.2 Transcription and ceil growth
The rate o f protein synthesis is an important determinant of cellular growth. In animal 
cells the rate of cellular growth has been shown to be directly proportional to the rate of 
protein accumulation (Baxter and Stanners, 1978). The process of translation mediates 
protein synthesis, where ribosomes synthesise proteins from mRNA templates. 
Therefore, ribosomes play a central role in cellular growth. In faet, ribosomal content is 
proportional to the rate o f growth (Kief and Warner, 1981). This is observed when 
mitogenic stimulation causes an increase in the synthesis o f rRNA and ribosomal 
proteins, which helps facilitate an increase in protein production and growth (Johnson et 
ak, 1974; K ief and Warner, 1981; Mauck and Green, 1974). During mitogenic 
stimulation the transcriptional activity of both pol I and pol III increases, this is due to 
their role in the synthesis of rRNAs (Clarke et al., 1996; Felton-Edkins et al., 2003a; 
Scott et al., 2001; Stefanovsky et al., 2006; White et al., 1995). Furthermore, the levels of 
the pol Ill-transcribed tRNAs have also been shown to play an important role in protein 
synthesis and growth (Francis and Rajbhandary, 1990). A number o f other short 
untranslated RNAs that play fundamental roles in the biosynthetic capacity o f the cell are 
also synthesised by pol III. Therefore, the regulation of pol III is important in 
determining the translational aptitude and growth of a cell.
1.3 Class III Genes
Genes transcribed by pol III encode a number o f different small RNA molecules, which 
are not translated. Typically they are less than 400 nucleotides in length and are involved 
in a number of essential functions in cellular metabolism. Table 1 lists these roles and 
they are discussed further in the following section.
Pol III Products Known Functions
tRNA Protein synthesis as a translational adaptor
5SrRNA Protein synthesis as a component of ribosomes
U6 RNA mRNA splicing
HI RNA tRNA processing
MRP RNA rRNA splicing
7SL RNA Intracellular protein transport (component o f SRP)
7SK RNA Controlling transcriptional elongation by pol II
SINE transcripts Unknown function
VA RNA Adenovirus translational control
EBER RNA Thought to be involved in Epstein-Barr virus translational control
Table 1.1
1.3.1 5S rRNA
The ribosome requires all three RNA polymerases for Its synthesis. Pol I makes the 28S, 
18S, and 5.8S rRNAs, pol II produces messenger RNAs encoding ribosomal proteins and
pol III synthesises the remaining 5S rRNA. 5S rRNA is 120 bp transcript which is 
transported to the nucleus where it is processed and integrated into the large ribosomal 
subunit. Eukaryotic genomes contain multiple copies of 5S rRNA genes, ranging from 
140 in the hapioid genome of Saccharomyces cerevisiae, to more than 20 000 copies in 
Xenopus /aev/.s.(Brown et al., 1971; Elion and Warner, 1984). The majority of X. laevis 
5S genes are only expressed to sustain rapid gi'owth during development of the oocyte 
(Wolffe and Brown, 1988). Human cells contain 200-300 5S rRNA genes, with many of 
these clustering in tandem repeats (Consortium, 2001).
1.3.2 tRNA
tRNAs function as adaptor molecules, which translate genetic information contained 
within mRNA into a specific amino acid sequence of a protein. Once transcribed, tRNAs 
are processed into mature tRNAs between 70 to 90 nucleotides in length. Eukaryotic 
cells contain 50 to 100 distinct tRNA species (Sharp et al., 1984). The human hapioid 
genome contains 497 tRNA genes, though there is considerable redundancy as the 
average copy number for each amino acid tRNA adaptor is around 10 genes (Consortium, 
2001). Each tRNA is covalently linked to specific amino acids. The specificity of 
tRNAs is determined by a trinucleotide sequence, the anti-codon, which is specific for a 
particular amino acid. This enables the tRNA to recognise the codon, found in mRNA, 
via complementary base pairing. This ensures the accurate synthesis o f the polypeptide 
chain encoded by the mRNA nucleotide sequence.
1.3.3 HI and MRP
Mitochondrial RNA processing (MRP) RNA is found predominately in the nucleolus, 
where it has an important role in the processing o f pre-rRNA (Morrissey and Tollervey, 
1995; Schmitt and Clayton, 1993). It is 265 nucleotides in length and forms part of an 
endoribonuclease called RNase MRP. Another endoribonuclease that shares sequence 
homology with MRP is HI (Gold et al., 1989). HI is a 369 nucleotide RNA that forms 
part of RNase P, which is involved in processing the 5’ termini of pre-tRNA (Lee and 
Engelke, 1989; Morrissey and Tollervey, 1995).
1.3.4 U6 snRNA
Spliceosomes are multi-subunit complexes consisting of five snRNAs and many proteins 
that assemble on pre-RNA. Their role is to remove non-coding introns to generate 
mature mRNAs that are compatible with the translational machinery. Four o f these genes 
are synthesized by pol II, whereas the smallest, U6 at 106 nucleotides is transcribed by 
pol III (Reddy et al., 1987). Between different organisms U6 is the most highly conserved 
o f the spliceosomal RNAs, highlighting its importance in the splicing process.
1.3.5 7SL
7SL, a pol Ill-transcribed gene, encodes a 300bp transcript that forms the RNA 
component of the signal recognition particle. The signal recognition particle plays an 
essential role in the intracellular localisation o f proteins. This is achieved through its 
involvement in the insertion of nascent polypeptides into the endoplasmic reticulum 
(Walter and Blobel, 1982), where they can be directed to their final destination.
1.3.6 SINEs
Short interspersed nuclear elements (SINEs) constitute the majority o f pol III templates in 
mammals. Examples include the Alu genes, found in primates, and the B1 and B2 
elements, which are found within the rodent genome. Alu elements are the most 
predominant SINE within the human genome. They make up 10% to 11% of the 
genomic DNA and consists o f about 1.2 million copies (Consortium, 2001). Human Alu 
elements are dimeric, consisting of about 300 bp comprised of two non-identical 
monomers that are derived from 7SL RNA (Ullu and Tschudi, 1984). In rodents B l, and 
B2 are the most abundant SINEs, numbering approximately 384,000 and 328,000, 
respectively. B l is homologous to Alu and is also thought to have evolved from the 7SL 
gene, whereas B2 is rodent specific and appears to have evolved from tRNA genes. The 
dispersion and propagation o f these SINEs is believed to occur via retrotransposition, 
where pol III transcripts are reversed transcribed and converted to DNA. The DNA copy 
of the pol Ill-synthesised RNA is then integrated into the genome (Weiner et al., 1986).
Despite the abundance o f SINEs, little is known about their function. A proposed role is 
that they are involved in cellular stress responses, as a number o f stress stimuli, such as 
DNA-damaging agents and heat shock have been shown to induce the transcription of 
SINEs (Liu et al., 1995; Rudin and Thompson, 2001). The relevance o f this has been 
highlighted in recent studies showing that B2 RNA is involved in the repression of class 
II gene expression in response to heat shock (Allen et ak, 2004; Espinoza et ak, 2004). 
Furthermore, a role for Alu has also been proposed, regulating translation through its
interaction with double stranded RNA-activated kinase PKR (Chu et al., 1998). These 
studies provide a functional role for SINEs and challenge the notion of them being ‘junk 
DNA’ (Makalowski, 2003).
1.3.7 Viral genes transcribed by pol III
A number of viruses that infect cells utilise pol III to transcribe short units within their 
genome. The best-characterised example is that o f the adenovirus, which encodes two 
pol Ill-transcribed transcripts, VAI and VAIL Both are approximately 160 nucleotides in 
length. The role o f these transcripts is to stimulate the translation o f adenoviral mRNA 
during the late stages of infection (Soderlund et al., 1976; Thimmappaya et al., 1982). 
The Epstein-Barr virus (EBV) contains two genes; EBERl and EBER2, which are also 
transcribed by pol III. EBERl and EBER2 are thought to have a similar role to the VA 
RNAs in subverting the cells translational machinery to allow the synthesis of viral 
proteins. Furthermore, EBERl and EBER2 share regions of homology with VA genes 
and can functionally substitute for VAI during adenovirus infection (Bhat and 
Thimmappaya, 1985; Rosa et al., 1981).
The list of genes above illustrates the integral role of pol III in protein synthesis. The 
assembly of transcription factors at their promoters mediates specificity and recruitment 
of pol III to these genes. The next section will discus how this specificity and 
recruitment is achieved.
1.4 Promoter structure
The role o f gene promoters is to aet as a platform for the recruitment o f transcription 
factors that help facilitate transcription through the recmitment of a speeiflc polymerase. 
Promoters employed by pol III can be divided into three groups, type 1, 2 and 3 (see 
figure 1.1 for a schematic representation o f promoter structures). Type 1 and 2 promoters 
are gene internal, which means that they are downstream of the transcriptional start site. 
Type 3 promoters are different, with their crucial sequence elements found upstream of 
the transcriptional start site. Each promoter contains a unique set o f elements that 
organise the formation o f a stable transcriptional unit able to perform multiple rounds of 
transcription.
1.4.1 Typel promoters:
Type 1 promoters consist o f three gene internal elements that are unique to the 5S rRNA 
gene. Its promoter was initially characterised in Xenopus laevis, consisting of an A- 
block (+50 to +64), an intermediate element (+67 to +72), and a C-block (+80 to +97), 
collectively known as the internal control region (ICR) (Pieler et al., 1987). These 
elements are highly conserved between species. Mutations or alterations in the spacing 
of the elements considerably reduce transcriptional efficiency (Keller et al., 1990). This 
is in contrast to the flanking regions that display little conservation, showing greater 
resilience to mutations (White, 2001b).
Type 1 promoter: 5S rRNA gene
I.C .R
w
M “ U lO C l\
I.E.
+1
C -b lock T T T T
+120
Type 2 promoter: tRNA gene
TTTT
+80
B -blockA -block
Type 3 promoter: U6 genes (human)
T T T T -
+106
P S ED S E TATA
Figure 1.1 Structure of the three main types of pol 111 promoters.
The transcription start site is indicated by +1 and the termination site by 4 thymine 
residues (TTTT). Various promoter elem ents are also depicted: I.E., intermediate 
element; I.C.R., internal control region; PSE, proximal sequence element; DSE, 
distal sequence element; TATA. TATA box.
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1.4.2 Type 2 promoters:
Type 2 promoters consist of two highly conserved sequence elements o f about lObp each; 
an A- and a B- block (Galli et al., 1981), It is this arrangement that is the most 
commonly observed in pol Ill-transcribed genes, including the tRNA genes, the 
adenovirus VA genes and a number of middle repetitive genes such as Alu, BI and B2 
(White, 2001b). The A-block is homologous to a type 1 promoter A-block, and in some 
species it is functionally interchangeable (Ciliberto et ai., 1983). The B-block is 
positioned downstream of the A-block, though its positioning is highly variable (Baker et 
al., 1987). The A- and the B- blocks are typically separated by 30-60bp; however, a 
distance o f up to 365bp can still support transcription (Baker et ah, 1987; Fabrizio et ah, 
1987).
1.4.3 Type 3 promoters:
Type 3 promoters consist of three elements: a TATA box, a proximal sequence element 
(PSE) and a distal sequence element (DSE). As previously stated these elements are 
found upstream of the transcriptional start site. Type 3 promoter structures encompass 
7SK, MRP and U6 genes. The human U6 promoter is the best-characterised type 3 
promoter. Its TATA box is found approximately -27 upstream of the transcriptional start 
site, this is followed by the PSE at -56.
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1.5 Transcription of class III genes
For transcription to take place, a number o f  processes must occur. Initial steps require 
the recruitment o f transcription factors to a gene’s promoter. This pre-initiation complex 
provides a platform for the polymerase to be brought in, where first initiation, then 
elongation occurs which is then followed by transcriptional termination.
1.5.1 Complex assembly on type 2 promoters (see figure 1.2)
Transcription factor IIIC (TFIIIC) is a multi-subunit complex that binds directly to the 
intragenic promoter sequence o f type II promoters (Lassar et al., 1983). Fluman TFIIIC 
was originally resolved into two components, TFIIICl and TFIIIC2 (Yoshinaga et al.,
1987). In vitro, both are required for the transcription o f 5S and tRNA genes (type I and 
2 promoters), whereas only TFIIICl is required for the transcription o f 7SK and U6 
genes (type 3 promoters) (Lagna et al., 1994; Oettel et al., 1997; Yoon et al., 1995). 
TFIIIC2 is composed of five polypeptides, known as TFIIIC220, 110, 102, 90 and 63 
according to their molecular mass (Kovelman and Roeder, 1992). TFIIIC220 and 
TFIIICl 10 form a sub-complex that is capable o f DNA-binding via the B-block. The 
TFIIIC-DNA interaction is thought to be further aided by TFITIC63 interaction with the 
A-block (Hsieh et al., 1999b). TFIIIC90 interacts with TFIIIC220, TFIIICl 10 and 
TFIIIC63, providing a bridge between the two DNA binding components o f TFIIIC 
(Hsieh et al., 1999a). Although both the A- and the B- blocks are contacted by TFIIIC, it 
is the B- block that is the predominant determinant of binding affinity (Baker et al., 
1986). In contrast to TFIIIC2, TFIIICl is relatively ill-defined in terms of its precise 
function and composition.
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Figure 1.2 T ranscriptional com plex on a type 2 prom oter. TFIIIC binds to the 
A- and B-block directly. This acts as a platform to recruit TFIIIB, via protein- 
protein interactions. Following recuitment, pol III can be brought in, and 
transcription is initiated at the transcriptional start site (+1).
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Once TFIIIC is at the promoter, it serves to recruit TFIIIB, positioning it just upstream of 
the transcriptional start site. TFIIIB consists o f three components: TATA-binding protein 
(TBP), TFlIB-related factor (Brfl) and B double prime (Bdpl), with molecular masses of 
34, 90 and 160kDa, respectively. TBP is a general factor, used by pol I, II and III 
(Cormack and Struhl, 1992; Kim and Roeder, 1994), whereas Brfl and Bdpl are 
specifically required for pol III transcription (Schramm and Hernandez, 2002). TBP and 
Brfl form a tight association with each other (Wang and Roeder, 1995). This is in 
contrast to B dpl, which has a weak interaction with this complex (Kassavetis et al.,
1995).
Work in both yeast and human cells have demonstrated the high degree o f homology in 
the recruitment and interaction o f TFIIIC, TFIIIB and pol III. DNA-bound TFIIIC was 
initially shown to contact B rfl, a subunit o f TFIIIB. The TFIIIC subunit responsible for 
this interaction was identified in S. cerevisiae as the human equivalent of TFIIIC 102 
(Schramm and Hernandez, 2002). Subsequently, a number o f other interactions were 
also identified between TFIIIC and TFIIIB. In human cells, TFIIIC63 and TFIIIC90 
interact with B rfl. TBP also directly interacts with TFIIIC, with both TFIIIC 102 and 
TFIIIC63 binding to this subunit of TFIIIB (Hsieh et al., 1999a; Hsieh et al., 1999b).
Pol III recruitment can only take place once TFIIIB is bound to TFIIIC. All three 
subunits of TFIIIB are required for polymerase recruitment. However, only Brfl and 
TBP have been shown to make direct contact. Brfl directly interacts with three pol III 
subunits, RPC32, RPC39 and RPC63, with TBP also binding to RPC39 (Wang and
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Roeder, 1995). In addition to these interactions, TFIIIC has been shown to interact with 
the pol III subunit RPC62 via TFIIIC63 (Hsieh et al., 1999b).
1.5.2 Complex assembly on Type 1 (5S rRNA) promoters (see figure 1.3)
Type 1 promoters differ from type 2 promoters, as they require the presence of an 
additional factor, TFIIIA. This is due to the fact that type 1 promoters lack a functional 
B-block, which is the major determinant of TFIIIC DNA binding affinity. As a result, 
TFIIIA serves as an adaptor factor that facilitates TFIIIC recruitment (Schramm and 
Hernandez, 2002; White, 2002). TFIIIA is a single polypeptide of approximately 40kDa 
that contains 9 zinc finger domains. Separate clusters of these zinc fingers bind to the A- 
block, the intermediate element and the C-block (Clemens et al., 1992; Nolte et al., 
1998). However, it is its interaction o f three zinc fingers with the C-block that 
contributes the majority of its DNA binding affinity (Clemens et al., 1992; Nolte et al., 
1998). Once TFIIIA is bound, TFIIIC can be recruited, though the way in which this 
occurs remains unclear. TFIIIC recruitment allows TFIIIB to bind just upstream of the 
transcriptional start site, which is then followed by the recruitment of pol III.
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Figure 1.3 T ranscriptional com plex on a type 1 prom oter. TFIIIA binds to the 
internal control region o f  the gene. TFIIIC can then be recruited, followed  
sequentially by TFIIIB and pol 111. Transcription can then begin at the 
transcriptional start site (+1 ).
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1.5.3 Complex assembly on type 3 promoters (see figure 1.4)
The recruitment of TFIIIB to type 3 promoters occurs independently o f TFIIIC, which 
distinguishes it from most pol III templates. Furthermore, TFIIIB is different from the 
one present at type 1 and 2 promoters as Brfl is replaced with a related factor known as 
Brf2 (Schramm et al., 2000). Type 3 promoters contain two sequences upstream of the 
transcriptional start site; TATA box and PSE. The TATA box and PSE elements are 
recognised by TBP (a component of TFIIIB) and SNAPc (a five-unit factor), respectively. 
The independent DNA binding affinity o f these factors is weak. However, the protein- 
protein interactions between TFIIIB and SNAPc greatly enhance their recruitment to the 
promoter (Mittal and Hernandez, 1997). TFIIIB and SNAPc recruitment is further 
enhanced by an additional transcription factor known as Oct-1. Oct-1 binds to the DSE, a 
sequence found upstream of the PSE and TATA box. It enhances the recruitment o f the 
TFIIIB/SNAPc complex via its direct interaction with SNAPc (Mittal et al., 1996). 
However, its presence is not essential for basal transcription from type 3 promoters (Hu 
et a l ,  2003). Once the TFIIIB/SNAPc complex is in place, pol III can be recruited and 
transcription can occur.
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Figure 1.4 T ranscriptional com plex on a type 3 prom oter. TFIIIB and SNAPc 
cooperatively bind to the TATA box and PSE o f  type 3 promoters, respectively. 
Binding o f  O ctl to the DSE enhances SNAPc/ TFIIIB recruitment. Following  
SNAPc/TFllIB recruitment, pol III binds and transcription com ences from the 
transcriptional start site (+1).
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1.6POIUI
Pol III is the largest and most complex nuclear RNA polymerase. It consists o f 17 
subunits in yeast and humans, amassing a size of 600-700Kda (Geiduschek and 
Kassavetis, 2001; Schramm and Hernandez, 2002; White, 2002). O f the 17 subunits 
identified in yeast, 16 have been demonstrated to be essential for function and yeast 
viability (Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002; White,
2002). Pol III shares a number o f common subunits with pol I and pol II. This is of no 
surprise, as each performs a similar role in the faithful transcription o f DNA to produce a 
complementary RNA strand. Five of the 17 subunits are shared between all three RNA 
polymerases. A further two are common to both pol I and pol III, and the ten remaining 
subunits are unique to pol III (Geiduschek and Kassavetis, 2001; Schramm and 
Hernandez, 2002; White, 2002).
1.7 Transcription, initiation to termination
Once the transcription complex is in place, pol III melts the double stranded DNA around 
the initiation site (Kassavetis et al., 1992; Kassavetis et al., 1990). TFIIIB is also thought 
to be o f importance in strand separation, because some mutations in Bdpl and Brfl 
prevent strand separation at the promoter complex even though normal polymerase 
recruitment has taken place (Geiduschek and Kassavetis, 2001; Kassavetis et al., 1998).
Once transcription begins, pol III can dissociate from the promoter-bound TFIIIB and 
progress along the DNA. The polymerase continues until it encounters the termination 
signal, which for pol III genes consists o f a cluster o f four or more T residues. This is in
19
contrast to pol I and pol II, where accessory factors are required to terminate transcription 
(Geiduschek and Kassavetis, 2001). At the point of termination, pol III can be recycled, 
so that multiple rounds o f transcription o f the same gene can take place. This is much 
quicker than the original round of replication, because pol III does not have to dissociate 
from the template, avoiding the slow step o f polymerase recruitment (Dieci and Sentenac,
1996). Recycling is aided by TFIIIB and, under certain circumstances, TFIIIC is also 
required (Ferrari et al., 2004). It is thought that pol III transcription factors facilitate a 
bend in the DNA that brings the transcriptional start site close to the end o f the gene. 
This allows multiple rounds of transcription once the transcriptional complexes are 
assembled.
1.8 Regulation of pol III activity
1.8.1 Regulation of pol III activity in proliferating cells:
Cell growth (increased cell mass and size) is a prerequisite for proliferation (increased 
cell number). The rate o f transcription by pol III plays a fundamental role in cellular 
growth and proliferation. Pol III produces molecules such as tRNA and 5S rRNA, both 
required for protein synthesis in growing cells. Protein production varies at different 
points in the cell cycle, therefore the relationship between the cell cycle regulators and 
the transcriptional activity o f pol III is o f no surprise.
The retinoblastoma protein (RB) is a negative regulator o f cellular proliferation. Its 
regulation is tightly linked to the cell cycle. Loss or inactivation o f RB is a major 
mechanism by which tumour formation occurs. RB binds and regulates a variety of
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transcription factors that are required for a ce ils  entry into S phase. A prominent 
example is the E2F family o f transcription factors that regulate the transcription of a 
number of pol Il-transcribed genes (Dyson, 1998). In addition to regulating genes 
transcribed by pol II, RB can also repress transcription by pol I and pol III (Cavanaugh et 
al., 1995; Sutcliffe et al., 2000). RB regulates pol III activity by its ability to bind and 
sequester TFIIIB (Scott et al., 2001; Sutcliffe et al., 2000). RB-TFIIIB interaction is 
controled by the phosphorylation of RB (Scott et al., 2001). During Go and early Gi, RB 
is in a hypophosphorylated state and is bound to TFIIIB. This blocks TFIIIB interaction 
with TFIIIC and disrupts its’ interaction with pol III (Sutcliffe et al., 2000), thus 
preventing the expression of genes transcribed by pol III. Repression is relieved during 
the G l-S phase transition of the cell cycle, when RB becomes phosphorylated by cyclin 
D- and E-dependent kinases, TFIIIB is released, leading to an increase in the expression 
o f genes transcribed by pol III prior to S phase entry (Scott et al., 2001).
Another protein that regulates pol III activity and one that has an extensive role in cancer 
is the oncogene c-Myc. Its involvement in cellular transformation is achieved through its 
diverse roles in cell cycle regulation, apoptosis, metabolism, differentiation and cell 
adhesion (Eisenman, 2001). c-Myc is recruited to the pol III transcription machinery via 
TFIIIB, where it activates the expression of pol III transcribed genes (Gomez-Roman et 
al., 2003).
A number o f different kinases have been identified as having a direct role in the 
regulation of pol III activity. These respond to mitogenic stimuli and are part of a
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signalling cascade that communicates with the pol III transcriptional machinery through 
phosphorylation. One such example is Erk (extracellular signal-regulated kinase). Erk 
responds to mitogens through a signalling cascade consisting o f Ras, Raf and MEK 
(Downward, 2002). Erk mediates its effect through the phosphorylation of Brfl a 
component of TFIIIB. This results in an increase in the expression o f genes transcribed 
by pol III (Felton-Edkins et al., 2003a). TFIIIB appears to be an important target of 
another kinase, CK2, also phosphorylates Brfl (Johnston et al., 2002). CK2 is a highly 
conserved enzyme that forms part o f the Wnt signalling pathway (Song et al., 2000). It is 
associated with cellular growth and proliferation. Overexpression o f CK2 is associated 
with cellular transformation and tumourigenesis (Faust et al., 1996b; Munstermann et al.,
1990). It therefore follows that the phosphorylation o f Brfl by CK2 leads to an increase 
in the transcription of genes transcribed by pol III (Johnston et a l , 2002). The effect of 
kinases on pol III transcriptional activity is not only limited to a positive effect, as 
phosphorylation can decrease pol III transcriptional activity in mitotic cells. Cyclin 
dependent kinases (cdks) from mitotic frog extracts inhibit the expression of pol Ill- 
transcribed genes through their kinase activity (Gottesfeld et a l , 1994; Haiti et a l , 1993; 
Leresche et a l ,  1996). In comparison, repression is not observed in cdks derived from 
interphase extracts (Gottesfeld et a l , 1994; Haiti et a l , 1993). Work in human cells has 
shown that repression during mitosis is the result of the phosphorylation o f Brfl (Fairley 
et a l , 2003). This results in the structure o f TFIIIB being compromised, with Bdpl being 
selectively released from the TFIIIB complex (Fairley et a l ,  2003). Although the kinase 
responsible is not defined, it is clear that kinases help modulate the expression of pol Ill- 
transcribed genes at specific points o f the cell’s cycle.
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1.8.2 Regulation of pol Ill-transcribed genes in response to cellular stress
Stress responses can be defined as a change in cellular activity in response to a condition 
that deviates from the norm. This may include nutrient deprivation, hypoxia or genotoxic 
stress. Nutrient deprivation or stress lead to a rapid decrease in the transcription of pol III 
transcribed genes (Ghavidel and Schultz, 2001; Roberts et al., 2006).
Mammalian target o f rapamycin (mTOR) acts as a key nodal point at which a number o f 
different nutrient and mitogenic signalling pathways converge. mTOR responds to these 
inputs by regulating growth and proliferation (Inoki et al., 2005; Wullschleger et al., 
2006). Key downstream targets o f mTOR are proteins involved in protein synthesis, such 
as S6K and 4E-BPI (Inoki et al., 2005; Wullschleger et al., 2006). However, work in 
mammals indicates it has a direct role in regulating ribosomal gene transcription, and that 
synthesis o f rRNA is rapamycin sensitive (Majahan, 1994). Recent studies have 
demonstrated that mTOR regulates rRNA gene expression by the phosphorylation o f two 
components of the pol I transcriptional machinery (Hannan et al., 2003; James and 
Zomerdijk, 2004; Mayer et al., 2004; Zang et al., 2005). Yeast TOR regulates pol III 
transcription (Zaragoza et al., 1998). Both rapamycin and TOR mutants cause the 
transcriptional repression of genes transcribed by pol III (Zaragoza et al., 1998). 
However, the mechanism that is responsible for pol III activation by TOR has yet to be 
determined.
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M afl, a protein identified in S. cerevisiae, is another example of a factor that regulates 
pol III in response to stress (Upadhya et al., 2002b). Cells that lack M afl are unable to 
repress the transcription o f pol Ill-transcribed genes when exposed to nutrient 
deprivation, DNA damage or oxidative stress (Desai et al., 2005; Upadhya et al., 2002b). 
Recent studies have demonstrated that under favourable conditions M afl is 
phosphorylated, whereas diverse unfavourable conditions lead to the rapid 
dephosphorylation o f M afl (Oficjalska-Pham et al., 2006; Roberts et al., 2006). 
Déphosphorylation is mediated by the protein phosphatase type 2A (PP2A) (Oficjalska- 
Pham et al., 2006). In its dephosphorylated state, Mafl accumulates in the nucleus and 
represses pol III via a direct interaction (Oficjalska-Pham et al., 2006). Although 
homologues o f Mafl have been discovered in higher eukaryotes (Pluta et al., 2001), a 
role for its regulation thus far has only been seen in yeast.
p53 can induce cell cycle arrest or cell death in response to a number of different stresses, 
including hypoxia, radiation and oncogenic stimuli (Vousden and Lu, 2002). More than 
half o f all cancers either have lost p53 or have a mutated form o f p53 (Hollstein et al.,
1991), highlighting its importance as a tumour suppressor. As with RB, p53 plays an 
important role in Gl arrest (El-Deiry et al., 1993) and has the ability to alter the 
transcriptional activity o f a number of genes (Vousden and Lu, 2002). Pol III 
transcriptional activity is repressed by p53 (Crighton et al., 2003). p53 acts in a similar 
manner to RB, binding and sequestering TFIIIB away from the promoter (Crighton et al.,
2003). This interaction is mediated through TBP (Crighton et al., 2003).
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For a summary o f pol III regulators, see figure 1.5
1.8.3 Pol III and cancer:
Many of the proteins involved in pol III regulation are either oncogenes or tumour 
suppressors. The link between pol III and cancer has been observed in vivo, with pol III 
transcription showing a level o f deregulation in tumours. This would make sense, as pol 
III regulation is tightly linked to cellular growth and proliferation (Larminie et a l , 1998), 
both important factors in tumour progression.
A partial explanation for this deregulation is found in the tumour suppressors RB and 
p53. It has been well-established that RB function is compromised in many human 
malignancies (Mulligan and Jacks, 1998). Further to this, mutations found within RB in 
carcinomas prevent its function of inhibiting transcription by pol III (White et a l , 1996). 
Transforming factors, such as the adenovirus oncoprotein El A and the large T antigen of 
the DNA virus SV40, disrupt RB function, releasing TFIIIB from repression (Larminie et 
a l ,  1999; Mulligan and Jacks, 1998; White et a l , 1996). Therefore, infection by 
adenovirus or SV40 decreases the level of RB-mediated pol III repression. As with RB, 
mutations found within p53 can diminish its ability to inhibit pol III transcription. One 
such mutation, R175H, a common mutation in cancer, converts p53 from a pol III 
repressor to an activator (Stein et a l , 2002). Oncoproteins also play a role, with 
papillomavirus E6 and cellular hdm2 being able to reduce the inhibition of pol III, via the 
neutralisation of p53 (Stein et a l ,  2002). Recent work has also shown that infection by
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high-risk types of human papillomavirus (HPV), such as HPV16, cause an increase in the 
expression of genes transcribed by pol III (Daly et al., 2005), HPV16 expresses the 
oncoproteins E6 and E7, which can inactivate p53 and RB, respectively (Dyson et al,, 
1989; Munger et al., 1989; Werness et al., 1990). HPV16 is associated with cervical 
cancers and their progression to an invasive state (zur Hausen, 2000; zur Hausen, 2002). 
Another example o f an oncogene with a prominent role in regulating pol Ill-transcribed 
genes is c-Myc (Gomez-Roman et al., 2003). c-Myc is different from the oncoproteins 
mentioned above, in that it directly binds to the pol III transcriptional machinery. As 
mentioned previously, c-Myc exerts a positive effect on pol 111 transcriptional activity 
through its interaction with TFIIIB (Gomez-Roman et ah, 2003). In transformed cervieal 
cells, c-Myc binds to the promoters o f tRNA and 5S rRNA genes through its interaction 
with TFIIIB, leading to an elevation in the transcription of these genes (Felton-Edkins et 
al., 2003b; Gomez-Roman et al., 2003).
Kinases CK2 and ERK, both regulators o f pol 111, are known to display a level of 
deregulation in many tumours. For instance, CK2 is abnormally active in a variety of 
cancers, including leukemias and solid tumours (Faust et al., 1996a; Munstermann et al., 
1990; Notterman et al., 2001). Additionally, oncogenic Ras is known to cooperate with 
CK2 in the transformation o f primary fibroblasts (Oiiandini et al., 1998). Ras is 
upstream o f ERK in the MAP kinase-signalling pathway. Therefore, it may also be the 
case that a deregulation o f Ras results in the deregulation of ERK, which alters pol III 
activity.
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Pol III transcriptional activity can be increased by raising the levels of limiting 
transcription factors which coordinate its recruitment to gene promoters. Overexpression 
of transcription factors is observed in a number o f transformed cells types. For example, 
levels o f all five subunits of TFIIIC are elevated (at the mRNA and protein level) in 
fibroblasts transformed by SV40 or polyomavirus (Felton-Edkins and White, 2002; 
Larminie et al., 1999). In ovarian tumors, there is an increased abundance of TFIIIC 
(Winter et al., 2000). This is thought to promote the transcription of pol III templates 
(Winter et al., 2000). TFIIIC 110, a subunit o f the TFIIIC complex, is thought to play an 
important role in pol Ill 's  transcriptional activity. Two TFIIIC complexes have been 
identified, with or without TFIIIC 110, dubbed TFIIIC2a and TFIIIC2b, respectively 
(Kovelman and Roeder, 1992; Sinn et al., 1995). Both TFIIIC complexes have similar 
DNA-binding affinities (Hoeffler et al., 1988; Kovelman and Roeder, 1992). However, 
the complex without TFIIIC 110 is unable to support transcription (Hoeffler et al., 1988; 
Kovelman and Roeder, 1992). HeLa cells infected with the E l A oncoprotein have an 
elevated level of the active TFIIIC2a compared to the inactive TFIIIC2b (Hoeffler et ah,
1988). This is thought to increase the transcriptional activity of pol III. Overexpression 
of pol III transcription factors is not restricted to TFIIIC, with both Brfl and Bdpl being 
elevated in a subset of cervical carcinomas (Daly et ah, 2005).
1.8.4 Coordinated regulation of pol I and pol III
Organisms must coordinate their translational capacity to relate in response need for 
protein synthesis. Both pol III and pol I synthesise molecules involved in translation. 
Pol I synthesizes 28S, 18S and 5.8S ribosomal RNAs, whereas pol III synthesizes 5S
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rRNA and tRNA. Therefore, it is of no surprise that pol I and pol III share similar modes 
of regulation, so that they can act in a coordinated manner (White, 2005). Although pol I 
and pol III have different components in their transcriptional machinery, regulators such 
as Erk, Myc, RB and the over expression of component of the transcriptional machinery 
regulate both pol I and pol III by similar mechanisms (White, 2005). Therefore, when a 
difference is observed in the regulation o f pol I and III, this is seen as an exception and 
not the rule.
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1.9 Aims of PhD
Previous work in yeast and in a mammalian system has demonstrated that use of 
rapamycin, the specific mTOR inhibitor reduced the expression of pol Ill-transcribed 
genes (Graham, Data not published; Zaragoza et al., 1998). However, little is known 
about the way in which mTOR control the activity o f pol III. Therefore, work in this 
study will focus on the mechanism by which mTOR controls the expression o f pol Ill- 
transcribed genes. A number of studies have shown that mTOR controls pol I 
transcription through the kinase S6K (Hannan et al., 2003; James and Zomerdijk, 2004; 
Mayer et a l , 2004; Zhang et al., 2005). Consequently, initial experiments will be carried 
out to see if pol I and pol III are regulated in a similar manner by mTOR.
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Chapter 2-Materials and
Methods
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2.1 Cell Culture
Cell culture was performed in a class II hood using standard aseptic technique and sterile 
reagents and conditions.
2.1.1 Growth conditions
HeLa, MEF and A31 cells were maintained in DMEM (Cambrex) supplemented with 
10% foetal bovine serum (Sigma), 2mM L-Glutamine (Sigma), 50 units/ml penicillin 
(Sigma) and 50pg/ml streptomycin (Sigma). Cells were passaged when 80-90% 
confluent (3-4 days between passages) using buffered trypsin (Sigma).
For rapamycin (Calbiochem) treatment, cells were grown to 70% confluency and treated 
with 100 nM final concentration o f rapamycin for specific times. Rapamycin stock was 
diluted in DMSO.
HeLa TET-ON cells were cultured in 10% FBS (tetracycline free), 100 jig/ml 
streptomycin, 100 pg/ml G418, 100 pg/ml hygromycin and 100 U/ml penicillin. 
Expression of HA-TFIIICl 10 was induced by the addition of 1 pg/ml doxycycline for 48 
hrs. Cells were passaged when 80-90% confluent (3-4 days between passages) using 
buffered trypsin (Sigma).
Rat lA  cells were maintained in DMEM supplemented with 10% foetal bovine serum, 
2mM L-Glutamine, 50 units/ml penicillin and 50pg/ml streptomycin. Rat lA  c-Myc"''" 
cells were maintained in DMEM supplemented with 10% foetal bovine serum, 2mM L-
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Glutamine, 50 units/ml penicillin, 50pg/ml streptomycin and 300 pg/ml G418 (Promega) 
(Matek et al, 1997). Cells were passaged when 80-90% confluent (3-4 days between 
passages) using buffered trypsin (Sigma).
2.1.2 Cryo-storage of cells
Live cells were subjected to long-term storage by resuspending near subconfluent 75cm^ 
flasks in 2ml of maintenance media containing 10% DMSO. This suspension was 
aliquoted into cryotubes and placed at -80°C overnight to ensure slow freezing, before 
being transferred to liquid nitrogen for long-term storage.
Cells were recovered by rapid thawing at 37“C and were then added to 9 ml of pre­
warmed media. The resultant mixture was then centrifuged at 298g for 5 minutes at room 
temperature. After centrifugation, the supernatant was removed and the cells 
resuspended in 12 ml o f fresh media before being transferred to a 75 cm^ flask.
2.2 Preparation of Extracts
2.2.1 Preparation of extracts for western blots, co-immunoprecipitations and in 
vitro transcription assays
Cultured cells were placed on ice and the maintenance media aspirated. The cells were 
then washed twice in PBS. Cells were then scraped into PBS (2ml per 10cm dish: 0.5ml 
per 2cm well) and transferred to 50ml Falcon tubes. Cells were centrifuged at 500g for 
5min at 4°C, and the PBS discarded. Cells were resuspended in 1ml of PBS and 
transferred to a microfuge tube. The tube was then centrifuged at I3,000g for 30 sec, and
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the PBS discarded. The cell pellet was then resuspended in freshly made microextraction 
buffer (450 mM NaCl, 50mM NaF, 20 mM HEPES pH 7.8, 25% glycerol, 1 mM DTT, 
0.5mM phenylmethylsulphonyl fluoride (PMSF), 0.2 mM EDTA, 40pg/ml bestatin), the 
volume used being equivalent to the volume o f the pellet. The resuspended sample was 
then snap frozen on dry ice, and immediately thawed in a 30°C water bath. This freeze 
thaw cycle was repeated three times to lyse the ceils. Following the final thaw, the tubes 
were then centrifuged at 13,000g at 4°C for 10 min to separate the cell debris. The 
supernatant was quickly removed and snap frozen on dry ice. Microextracts were stored 
at -80°C.
2.2.2 Preparation of nuclear and cytoplasmic fractions
Two 10cm dishes of cultured cells were placed on ice and the maintenance media 
aspirated. The cells were then washed twice in PBS. Cells were then scraped into PBS 
(2ml per 10cm dish) and transferred to 15ml Falcon tubes. Cells were centrifuged at 
500g for 5min at 4°C, and the PBS discarded. The pellet was resuspended in 1 ml of 
hypertonic buffer (20 mM HEPES pH 7.0, 10 mM KCl, 1 mM DTT, 0.1 % triton X-100, 
20 % glycerol, 2 mM PMSF, 5 pg/mi aprotinin, 5 pg/ml leupeptin). The cell suspension 
was then subjected to 10 slow strokes in a Dounce homogenizer and centrifuged at 800 g 
for 5 min. The resultant supernatant is the cytoplasmic fraction. The supernatant was 
removed, aliquoted and snap frozen on dry ice. The cytoplasmic extracts were stored at - 
80°C. The pellet was resuspended in 100 pi cold extraction buffer (20 mM HEPES pH 
7.0, 10 mM KCl, 1 mM DTT, 0.1 % Triton X-100, 20 % glycerol, 2 mM PMSF, 5 pg/ml 
aprotinin, 5 pg/ml leupeptin, 420 mM NaCl). The suspension was then placed on a
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spinning wheel for 20 min at 4 °C and then centrifuged at 16,000 g for 10 min. The 
supernatant contains the nuclear extract and the pellet is the nuclear matrix. The 
supernatant was removed, aliquoted and snap frozen on dry ice. The extracts were stored 
at -80°C.
2.2.3 Determination of protein concentrations
Protein concentrations were determined using Bradford’s reagent (BioRad) diluted 1 in 5 
with distilled H2O. The colour change produced in this reagent in response to being 
mixed with protein can be quantified by absorbance at 595 nm, and these values are 
directly proportional to the concentration of protein in the sample. For each experiment, 
a standard curve was constructed by measuring absorbance o f 0,2,4,6,8,10 and 12 pg of 
BSA in 1ml of Bradford’s reagent. 2pl of each microextract was added to 1ml of 
reagent. Absorbance readings at 595nm were performed in duplicate, and the protein 
concentration of each sample was determined from the standard curve.
2.3 Separation of proteins by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting
2.3.1 SDS-PAGE
Protein extracts, as prepared in section 2,4, were resolved by denaturing SDS-PAGE on 
10% (unless otherwise indicated) polyacrylamide gels (375mM Tris pH 8.8, 0.1% SDS), 
with 4% polyacrylamide stacking gels (125mM Tris pH 6.8, 0.1% SDS). Prior to 
loading, samples were boiled for 2 minutes in Ix protein sample buffer (62.5 mM Tris pH 
6.8, 0.5% SDS, 5% p-mercaptoethanol, 10% glycerol, 0.125% bromophenol blue).
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Electrophoresis was performed in SDS running buffer (0.1% SDS, 76.8 mM glycine, 
lOmM Tris pH 8.3) at 200V. Electrophoresis was continued for approximately 60 
minutes, until the bromophenol dye had moved to the bottom of the gel.
2.3.2 Western Blot Analysis
Followed SDS-PAGE, proteins were transferred to a nitrocellulose membrane (BioRad) 
using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell system. Transfer was 
carried out in 1 X transfer buffer (76.8 mM glycine, lOmM Tris pH 8.3, 20% methanol) 
at 50V, overnight at 4°C. Membranes were then stained using 1 x Ponceau S to ensure 
efficient transfer o f the protein to the membrane, and subsequently washed with PBS. 
Membranes were then blocked in milk buffer (32.5 mM Tris, 150 mM NaCl, 0.2% 
Tween-20, 5% skimmed milk powder (Maiwel)) for 2 hours at room temperature. The 
membranes were then incubated in the presence of the appropriate primary antibody 
diluted in milk buffer for 2 hours at room temperature. Primary antibodies and their 
appropriate concentrations are listed in table 2.1. Membranes were washed three times in 
milk buffer to remove excess primary antibody. Membranes were then incubated in the 
presence of the appropriate secondary antibody (Dako) at a dilution of 1:1000 in milk 
buffer. Subsequently, membranes were washed five times with western wash buffer 
(32.5 mM Tris, 150 mM NaCl, 0.2% Tween-20), to remove excess secondary antibody. 
The bound antibodies were then detected using enhanced chemiluminescence (ECL), as 
directed by the manufacturer (Amersham).
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Antibodies used in western blot analysis
Protein Antibody Type Dilution Source
Brfl 128 Serum 1:1000 In house
TFIIIC 90 1898 Serum 1:1000 In house
TFIIIC 102 3238 Serum 1:1000 In house
TFIIIC n o 3208 Serum 1:1000 In house
TFIIIC 220 A b7 Serum 1:1000 In house
RPC 155 1900 Serum 1:1000 In house
S6K1 9202 Polyclonal 1:1000 Santa Cruz
Phospho-S6Kl 9202 Polyclonal 1:1000 Cell signalling technologies
c-Jun Sc-44 Polyclonal 1:1000 Santa Cruz
HA-tag Sc-7392 Monoclonal 1:2000 Santa Cruz
Acetyl Hi stone H4 06-866 Polyclonal 1:5000 Upstate
Acetyl Histone H3 06-599 Polyclonal 1:5000 Upstate
Raptor Ab5454 Polyclonal 1:1000 Abeam
Actin C -ll Polyclonal 1:5000 Santa Cruz
Table 2.1
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2.4 Co-immunoprecipitation
Anti-TFIIlCllO (4286) antibody was coupled to protein-G sepharose beads. 25 pi of 
packed beads was used per immunoprécipitation (IP); these beads were washed twice 
with 200 pi 1 X TBS, prior to incubation with 5 pi anti-TFIIICl 10 antibody, made up to a 
total volume of 50 pi with TBS on a shaker for 1 hour at 4°C. Following antibody 
binding, beads were washed twice with 1 x TBS to remove excess antibody. For co- 
immunoprecipitation reactions, 250 pg o f protein extract was added to the beads and 
incubated end over end for 2 hours at 4°C. The beads were then washed five times with 1 
X TBS (25 mM Tris pH 7.6, 150mM NaCl) before the bound material was released by the 
addition of an equal volume of 2 x protein sample buffer. Samples were then analysed by 
SDS-PAGE and subsequent western blot analysis.
2.5 Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)
2.5.1 RNA Extraction
Total cellular RNA was extracted from tissue culture cells grown in 10cm dishes using 
TRI reagent (Sigma). Culture media was removed from the cells and the cells were 
scraped into 1ml o f TRI and transferred into sterile microfuge tubes. The tubes were 
incubated for 1 min at room temperature before 200pl of chloroform was added to each 
sample, which was subsequently mixed by vortexing for 15 seconds. Samples were 
incubated for a further 5min at room temperature before being centrifuged at I3,000g for 
15 minutes. The centrifugation step separated the samples into 3 phases: the lower red
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organic phase containing the proteins, the intermediate phase which contained the DNA, 
and the upper clear aqueous phase containing the RNA. The RNA-containing aqueous 
phase was carefully removed and transferred to a clean microfuge tube 0.5 ml of 
isopropanol was added to the sample to precipitate the RNA, the tubes were then mixed 
by vortexing, incubated for lOmin at room temperature and centrifuged for lOmin at 
13,000 rpm at 4°C. The pellet was washed with 75% ethanol and centrifuged again for 
lOmin at 13,000 rpm at 4°C. The wash was removed and the pellet dried at room 
temperature for approx lOmin. The RNA was redissolved in approximately 20pl DEPC 
H2O and samples were heated to 50°C to facilitate resuspension. All RNA samples were 
stored at -80°C. The concentration of the RNA was determined spectrophotometrically 
using a quartz cuvette, using the formulai A260 = 40 pg/pl RNA.
2.5.2 cDNA production
3pg o f RNA, prepared as outlined in the section above, was added to 200ng of 
hexanucleotide primers (Roche) made up to a final volume o f 24pi. Tubes were 
incubated at 80°C for 10 minutes for primer annealing. Tubes were transferred to ice, 
then 8pi of 5 X First Strand Buffer (Invitrogen Life Technologies), 4pl of O.IM 
dithiolthreitol (DTT) (Invitrogen Life Technologies), 2pl of a dNTP mix containing all 
four dNTPs at a concentration o f lOmM each (Promega) and I pi o f Superscript II 
reverse transcriptase (Invitrogen Life Technologies) were added. Reverse transcription 
reaction was incubated at 42'^C for 1 hour. The reaction was terminated by incubating 
tubes at 70°C for 15 min to denaturing the enzyme.
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2.5.3 Polymerase Chain Reaction (FCR)
Each FCR was performed using 2pl o f cDNA or 2pi of ChIP DNA. Each PCR reaction 
had a total volume of 20pl containing Ix Mg^'^-free taq DNA polymerase buffer 
(Promega), 1.5mM MgCIz, 0.2mM of each o f dATP, dCTP, dGTP and dXTP, and l.SpCi 
of [a-^^P] dCTP (Amersham). Primer sequences and cycling parameters are described in 
table 2.2, Reaction products were diluted 1:1 with formamide loading buffer (98% 
formamide, 0.01% bromophenol blue, 0.01% xylene cyanol, 5mM EDTA), and resolved 
on 7% polyacrylamide sequencing gels containing 7% urea and Ix TBE (45 mM Tris, 45 
mM boric acid, 0.625 mM EDTA pH 8.0). Gels were pre-run at 40W for 30 minutes in 1 
X TBE prior to loading 2 pi o f samples. Before loading, samples were heated at 95°C for 
2 minutes. Electrophoresis was carried out for 1 hour at 40W, and then gels were 
vacuum dried for 1 hour at 80°C. PCR products were visualised by autoradiography.
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Primers for RT-PCR
Transcript Primer Cycle
Number
Product
Length
PCR Conditions 
(denaturing; 
cycling; final 
elongation)
5S rRNA 5’ GGCCATACCACCCTGAACGC 3’ 
5’ CAGCACCCGGTATTCCCAGG 3’
18-20 107 bp 95®C for 3 min; 95"C 
for 30 s, 58°C for 30 
s, 72°C for I min; 
72°C for 5inin
ARPPPO
niRNA
5’ GCACTGGAAGTCCAACTACTTC 3’ 
5’ TGAGGTCCTCCTTGGTGAACAC 3’
18-20 266 bp 95"C for2m in; 95“C 
for Ï min, 58°C for 
30 s, 72“C for 1 min; 
12°C  for 5 min
tRNA^"" 5’ GAGGACAACGGGGACAGTAA 3’ 
5’ TCCACCAGAAAAACTCCAGC 3’
25-27 88 bp 95“C for 3 min; 95“C 
for 30 s, 68“C for 30 
s, 72°C for 30 s; 
72“C for 5 min
Pre Pol I- 
rRNA
5’ GCTTGGGTCTGTCGCGGT 3’
5 ’ CACCTCGGGGAAATCGGGA 3’
15-20 151 bp 95°C for 3 min; 95"C 
for 1 rain, 65“C for 
30 s, 12°C for 15 s; 
72“C for 1 rain
TFIIIC 110 
mRNA
5’ CCAGAAGGGGTCTCAAAAGTCC 3 ’ 
5 ’ CTTTCTTCAGAGATGTCAAAGG 3 ’
25-30 300 bp 95°C fbr3 min; 95"C 
for 1 min, 62°C for 
40 s, 72°C for 40 s; 
72°C for 5 min
P21 mRNA 5 ’ GCCTTAGCCCTCACTCTGTG 3 ’ 
5’ AGGGCCCTACCGTCCTACTA 3 ’
25-30 257 bp 95“C for 3 rain; 95”C 
for 30 s, 58“C for 30 
s, 7 2 T  for 30 s; 
72“C for 5 min
B2 RNA 5 ’ GGGGCTGGAGAGATGGCT 3 ’ 
5 ’ CCATGTGGTTGCTGGGAT 3'
12-15 90 bp 95“C for 3 min; 95®C 
for 30 s, 58"C for 30 
s, 72“C for 30 s; 
72“C for 5 rain
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2.6 Chromatin immunoprécipitation (ChIP) assay
Cells were grown in 10cm tissue culture dishes until approaching confluency for ChIP 
assays. One 10cm dish o f cells was used per IP. Formaldehyde was added to the culture 
medium to a final concentration of 1% to cross-link the protein DNA complexes. 
Crosslinking was allowed to proceed for 10 minutes at 37°C. Excess glycine was then 
added at a final concentration o f 0.I25M, to stop the cross linking, and the plates 
transferred to ice for harvesting. The cells were harvested in the plating 
media/formaldehyde/glycine mix and transferred to 50ml Falcon tubes. The pellets were 
then harvested by centrifugation at 500g for 5 minutes at 4°C. The cell pellets were 
washed in Ice cold PBS, followed by centrifugation at 500g for 5min at 4°C (The pellets 
could then be snap frozen at this stage on dry ice, and stored at -80°C, for analysis at a 
later date).
The cell pellets were washed with ice cold PBS/0.5% NP-40, then centrifuged at 500g for 
5 minutes at 4°C. Following removal o f the supernatant from this wash, cells were then 
resuspended in 40ml o f high salt buffer (0.5% NP-40, PBS, IM NaCl), and incubated on 
ice for 30 minutes. Following the incubation, the cells were centrifuged at 1500rpm for 5 
minutes at 4°C and washed with 40ml PBS/1 % NP-40. The cell pellets were then 
resuspended in 40ml o f low salt buffer (0.5% NP-40, lOmM Tris HCl, pH 8.0, 1 mM 
EDTA, 0.1 M NaCl) and incubated on ice for 30 minutes. Following the incubation, the 
tubes were centrifuged at 500g for 5 minutes at 4°C. Pellets were then resuspended in 
1ml of low salt buffer and passed through a 26g needle three times. Low salt buffer was
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then added to the suspension to a final volume of 2.7ml. 300fxl ot 20% sarcosyl was then 
added to the cell suspension to lyse the nuclei. The lysed nuclei were then transferred to 
a sucrose cushion and centrifuged at 4000g for 10 minutes at 4°C. The supeinatant was 
discarded and the pellet resuspended in 3ml TE. The suspension was then transferred to a 
second sucrose cushion, and centrifuged at 4000g for 10 minutes at 4°C. The final pellet 
containing the genomic DNA and cross-linked proteins was resuspended in 2ml TE (10 
mM Tris pH 8.0, ImM EDTA), and the DNA then sheared into smaller fragments by 
sonication (Branson sonifier 250, 10 x 10 s, duty cycle 30%). 0.2 ml of 1 Ix NET Buffer 
(1.56 M NaCl, 5.5 mM EDTA, 5.5% NP-40, 550 mM Tris HCl, pH 7.4) was added to the 
2ml sample, which was then transferred to microfuge tubes and centrifuged at 13,000g 
for 5 minutes. The supernatant was then aliquoted evenly in microfuge tubes. The 
indicated amount o f antibody was added per aliquot (Table 2.4), and these were 
incubated, end over end, overnight at 4°C.
The following day, 50pl of protein G sepharose beads was added to each tube, and these 
were left to incubate for a further 2 hours. The beads were then recovered on 
polypropylene columns (Pierce), and washed twice with 10ml RIPA (50 mM Tris HCl, 
pH 8.0, 150mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40) buffer, twice with 
10ml LiCl buffer (10 mM Tris HCl, 250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 
mM EDTA, pH 8.0) and finally twice with TE. The beads were then transferred to 
microfuge tubes and the protein/DNA complexes eluted with 200pl TE/1%SDS by 
incubating end over end for 10 minutes at room temperature. This elution was repeated 
and the supernatants pooled. The pooled supernatants, along with the inputs, were
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incubated overnight at 42°C in the presence of proteinase K to degrade the antibodies and 
proteins. The DNA was then extraeted twice using 400pl phenol/ chloroform/ 
isoamylalchohol (25:24:1) and once using chloroform alone. 1 ml o f ethanol (2,5x 
volume) and 40pl o f 3M sodium acetate was added and the tubes were thoroughly mixed 
by inversion. The DNA was precipitated at -20°C overnight. Samples were centrifuged 
at 13,000g for 20 minutes to pellet the precipitated DNA, The supernatant was removed 
and the pellets were washed with 150pl 70% ethanol and re-centrifuged at 13,000g for 5 
minutes. The supernatant was removed and the pellets were air dried before adding 50pl 
o f TE to resuspend the DNA. The samples were then analysed by PCR. Primer 
sequences and conditions are displayed in the table below (Table 2.3)
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Primers used in PCR analysis o f ChIP samples
Gene Primers Cycle
Nunber
Product
Size
PCR Conditions 
(denaturing; cycling; 
final elongation)
5S rRNA 5 ’ GGCCATACCACCCTGAACGC 3’ 
5 ’ CAGCACCCGGTATTCCCAGG 3 ’
20-25 107 bp 95"C for 3 min; 95'’C for 30 
s, 58“C for 30 s, 72”C for 1 
min; 72°C for 5min
ARPPPO 5 ’ GCACTGGAAGTCCAACTACTTC 3 ’ 
5 ’ TGAGGTCCTCCTTGGTGAACAC 3 ’
20-25 266 bp 9S"C for 2 min; 95"C for 1 
min, 58°C for 30 s, 72“C for 
1 min; 72"C for 5 min
Cyclin D2 
Promoter
5 ’ GGCATAACCTTTATCCCTGGTT 3 ’
5’ AACCCCATGGATTCCTATTGA'rT 3’
25-30 252 bp 95°C for 3 min; 95°C for 1 
min, 60“C for 30 s, 72“C for 
1 min; 72“C for 5 min
P21 Coding Region 5 ’ CTCTGGGAAGCCAGAAGTTGTT 3 ’ 
5’ GGTCCAGTCCCTGCATCTAAGT 3’
25-30 257bp 95"C for 3 min; 95°C for 1 
min, 55°C for 30 s, 72“C for 
1 min; 72"C for 5 min
A lu Chromosome 6 5 ’ CCAGAAAAATTACCAATTAGTTC 3 ’ 
5 ’ GGGCCTATTGACTATGCTTAC 3 ’
25-30 396 bp 95“C for 3 min; 95=C for 30 
s, 53“C for 1 min, 72“C for 1 
mill; 72“C for 5 min
A lu Chromosome 8 5’ GCACTCCATAAGAAATGrri'TT 3 ’ 
5 ’ GAATTTTGGTTCAG3TGTGTTA 3 ’
25-30 431 bp 95°C for 3 min; 95'C for 30 
s, 53'C for 1 min, 72°C for 1 
min; 72"C for 5 min
All! Chromosome 
10
5 ’ GATTCTCAACAGCAGAATTCCA 3 ’ 
5 ’ CATGTTTGAGAATGTCTACTTC 3 ’
25-30 442 bp 95"C for 3 min; 95'C for 30 
s, 53"C for 1 min, 72“C for 1 
min; 72°C for 5 min
Alu Chromosome 
19
5 ’ CCACGTGTTTATCTGTAAGGTG 3 ’ 
5 ’ GTTAGGAGCTAGAAGGAGCCT 3 ’
25-30 381 bp 9 5 T  for 3 min; 95°C for 30 
s, 58“C for 1 min, 72"C for I 
min; 72®C for 5 min
Alu Chromosome 
20
S’ GTTTATTTAGAGAAGCAAATGC 3 ’ 
5 ’ CCAGATAATTTTATCATGTCCT 3 ’
25-30 456 bp 95"C for 3 min; 95°C for 30 
s, 5S"C for 1 min, I T C  for 1 
min; I T C  for 5 min
45
Alu Chromosome 
22
5 ’ GTTCTGACACACTTGGAGAAA 3 ’ 
5’ GTTGTTGTTATTGCACAACTCA 3 ’
25-30 370 bp 95°C for 3 min; 95"C for 30 
s, 58“C for 1 min, 72“C for 1 
min; 72“C for 5 min
^ R N A L e u 5 ’ GAGGACAACGGGGACAGTAA 3 ’ 
5 ’ TCCACCAGAAAAACTCCAGC 3 ’
25-30 88 bp 95"C for 3 min; 95°C for 30 
s, 68“C for 30 s, I T C  for 30 
s; 72°C for 5 min
5 ’ GGCTCTGTGGCGCAATGGATA 3 ’
5 ’ TTCGAACCCACAACCTTTGAATT 3 ’
25-30 74 bp 94“C for 2 min; 95“C for 30 
s, 66"C for 30 s, 12°C for 15 
s; 72"C for 5 min
MRP 5 ’ CGTGCTGAAGGCCTGTATC 3 ’ 
5 ’ GGTGCGCGGACACGCAC 3 ’
25-30 232 bp 95“C for 3 min; 95“C for 30 
s, 58"C for 30 s, 72°C for 30 
s; 12°C for 5 min
B2 5 ’ GGGGCTGGAGAGATGGCT 3 ’ 
5 ’ CCATGTGGTTGCTGGGAT 3 ’
12-15 90 bp 95”C for 3 min; 95"C for 30 
s, 58“C for 30 s, 72=C for 30 
s; 12°C for 5 min
7SL 5 ’ GTGCCGCACTAAGTTCGGCATC 3 ’
5 ’
TATTCACAGGCGCGATCCCAC'IACTGAGA
T C 3 ’
150 bp 10-20 94“C for 2 min; 9 4 T  for 20 
s, 62=C for 30 s, 12°C for 30 
s; 72“C for 10 min
TF1IIC220 5 ’ TCCAGCGAGACCl'TCACAAA 3’ 
5 ’ GGATTGAGTGTTGCTGGGCT 3 ’
25-30 144 bp 95“C for 3 min; 9 4 T  for 20  
s, 62°C for 30 s, 72"C for 30 
s; 12°C  for 10 min
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Antibodies for ChIP analysis
Protein Antibody Type Source Quantity used per IP
Brfl 128 Serum In house 20 pi
TBP mTBP-6 Monoclonal In house 200 pi
TFIIIC 110 4286 Serum In house 20 pi
TFBIC 220 A b7 Serum In house 20 pi
RPC 155 1900 Serum In house 20 pi
TFIIIC 110 3208 Serum In house 20 pi
MTOR T2949 Polyclonal Sigma 4 pg
Acetyl Histone H4 06-866 Polyclonal Upstate 4 pg
Acetyl Histone H3 06-599 Polyclonal Upstate 4 p g
T rimethyl-histone 
H3 (Lys 4)
07-473 Polyclonal Upstate 4 pg
T rimethyl-histone 
H3 (Lys 9)
07-523 Polyclonal Upstate 4 p g
TAFi48 M19 Polyclonal Santa Cruz 4 pg
TFIIA FL-109 Polyclonal Santa Cruz 4 p g
TFIIB C18 Polyclonal Santa Cruz 4 pg
Table 2.4
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2.7 Pol III in vitro transcription assay
In vitro transcription of class III genes was reconstituted using 15pg o f HeLa nuclear 
extract (Computer Cell Culture Center, Mons, Belgium) or 15pg of A31 mouse fibroblast 
microextract. This was supplemented with the addition of 250ng o f plasmid DNA to 
supply specific pol III templates and reactions were earried out in a 25pl volume with a 
final concentration o f 12 mM HEPES pH 7,9, 60 mM KCl, 7.2 mM MgCb, 0.28 mM 
EDTA, 1.2 mM DTT, 10% (v/v) glycerol, 1 mM creatine phosphate, 0.5 mM each o f 
rATP, rCTP and rGTP and 10 pCi [a-^^P] UTP (400 mCi/mmol) (Amersham). 
Transcription components were assembled on ice and the reaction was performed at 30“C 
for 1 hour. Transcription was terminated by the addition o f 250 pi of 1 M ammonium 
acetate/0.1% SDS containing 20 pg o f yeast tRNA, which acts as a carrier for synthesised 
RNA. Phenol-chloroform extraction of the samples was performed to remove protein 
and DNA by adding 250 pi o f a 25:24:1 ratio o f PhOH/CHCL/IAA. The samples were 
vortexed, microcentrifuged at 13,000g for 5 minutes, and 200 pi o f the upper aqueous 
layer was then transferred to a fresh epppendorf tube containing 750 pi o f 96% ethanol in 
order to precipitate the RNA. The samples were thoroughly mixed by repeated inversion, 
left at -20 ®C overnight before being microcentrifuged at I3,000g for 30 minutes to pellet 
the precipitated RNA. The supernantant was carefully removed and 750 pi o f 70% 
ethanol was added to each sample to wash the pellet. This was also carefully removed to 
avoid dislodging the pellet and the samples were heated at 50 °C for 5-10 minutes to dry. 
4pi o f formamide loading buffer (98% formamide, 10 mM EDTA pH 8.0, 0.025% 
bromophenol blue, 0.025% xylene cyanol FF) was added to each sample, which was then
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vortexed for 1 hour to ensure the RNA was fully re-dissolved. 1.5 pi of each sample was 
loaded on a pre-run 7% polyacrylamide sequencing gel containing 7 M urea and 0.5 x 
TBE after being boiled at 95 °C for 2 minutes and quenched on ice. Electrophoresis was 
performed at 40 W for 1 hour in 0.5 x TBE before being dried and exposed to 
autoradiography film in order to detect the radiolabelled transcripts.
2.7.1 Peptide substrate inhibitors and drugs used in in vitro transcription assays 
The peptide substrate inhibitors used for in vitro transcription were PKB substrate peptide 
inhibitor GRPRTSSFAEG (Biomol) or PKA phospho-acceptor peptide LRRASLG 
(Upstate). The phosphatase inhibitors used in in vitro transcription assay were Okadaic 
acid (Sigma) and Calyculin A (Sigma).
2.8 Plasmid Preparation
2.8.1 Transformation of competent cells
For plasmid propagation, E. coli XL-1 blue competent cells were transformed 
(Stratagene). Cells were stored at -80”C and were thawed on ice before transformation. 
10-20ng o f plasmid DNA was added to 50pl of thawed cells and mixed by gentle 
agitation. The cells were then incubated on ice for 20 minutes. Following this, the cells 
were heat-shocked at 42°C for 30 seconds. The cells were then recovered by adding 500 
pi o f SOC medium (LB Broth, 0.05% glucose, lOmM MgS0 4 , lOmM MgCfr), which had 
been pre-heated to 37“C, and then incubated at 37°C for 30 minutes. lOOpl of the cells
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were then plated onto LB-agar plates (LB-broth, 2% agar, 100 pg/ml ampicillin) and then 
incubated at 37®C overnight.
2.8.2 Isolation and storage of plasmid DNA
A single colony was selected from the LB-agar plates and was used to inoculate 10 ml of 
LB-broth containing 100 pg/ml ampicillin. The culture was incubated at 37°C in an 
orbital shaker for 8 hours. The mini culture was then transferred into 500ml of LB-broth 
containing 100 pg/ml ampicillin, and incubated at 37°C in an orbital shaker overnight. 
The following day the bacterial cells were harvested by centrifugation at 5100 rpm for 20 
minutes at 4°C (in Sigma Laboratory Centrifuge 4K15), The plasmid DNA was isolated 
from the bacterial cells using the Qiagen Maxi-Prep Kit, according to the manufacturer’s 
instructions.
The bacterial pellet was resuspended in 10 ml of buffer PI (50 mM Tris pH 8.0, 10 mM 
EDTA, 100 pg/ml RNase A) and then gently mixed with 10 ml of buffer P2 (200 mM 
NaOH, 1% SDS) to lyse the cells. This reaction was allowed to proceed for 5 minutes at 
room temperature before neutralisation with 10 ml o f buffer P3 (3 M potassium acetate, 
pH5.5), which results in the formation o f a precipitate o f potassium dodecyl sulphate. 
The bacterial proteins and chromosomal DNA were co-precipitated with the detergent 
whilst the plasmid DNA remained in solution due to a lack o f close protein interactions. 
Precipitation was enhanced by a 20 minute incubation on ice, before being centrifuged at 
20,000g for 30 minutes at 4°C (in Sigma Laboratory Centrifuge 4K15). The supernatant 
was then added to a Qiagen-tip 500, which had previously been equilibrated with 10 ml
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of buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton X- 
100). The Qiagen-tip 500 contains an anion-exchange resin to which the plasmid binds 
tightly, allowing the supernatant to pass through. The resin was then washed twice with 
30 ml o f buffer QC (IM  NaCl, 50 mM MOPS pH 7.0, 15% isopropanol) and the plasmid 
DNA was subsequently eluted with 15 ml of buffer QF (1.25 M NaCl, 50 mM Tris pH 
8.5, 15% isopropanol) and precipitated with 10.5 ml o f room temperature isopropanol. 
This was immediately centrifuged at 15,000g at 4°C for 30 minutes. The plasmid DNA 
pellet was then washed with 70% ethanol, dried at room temperature for 10 minutes and 
resuspended in an appropriate volume of sterile dH2 0 .
Plasmids were stored at -20^C. The concentration o f the plasmid DNA was determined 
spectrophotometrically in a quartz cuvette, using the equation I A260 = 50 pg/pl dsDNA.
51
Description o f plasmids used in in vitro transcription assays
Plasmid Description
tRNA^^" pLeu is a 240 bp EcoRl-Hindlll fragment o f human 
genomic DNA carrying a tRNA^^^ gene, subcloned into 
pAT153 (McLaren and Goddard, 1986).
7SL P7L30.1 contains a H indl\\-EcoR\ fragment carrying a 
human 7SL gene subcloned into pUC13 (Ullu and Weiner, 
1985).
5SrRNA Phu5S3.1 is a 638bp BamW\-Sac\ fragment o f human 
genomic DNA containing a 5S rRNA gene, subcloned into 
pBluescript SK+.
Table 2.5
All experiments were carried out three times unless otherwise stated.
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Chapter 3-The mTOR
pathway regulates expression 
of pol Ill-transcribed genes
53
3.1 Introduction
3.1.1 TOR
Yeast TORI and T0R2 were originally identified as targets o f Rapamycin (Kunz et al., 
1993). Rapamycin is an antifungal agent originally purified from Streptomyces 
hygroscopicus (Abraham and Wiederrecht, 1996). Analogues of Rapamycin have been 
used clinically to inhibit host rejection following organ transplantation (Garaza et a l , 
2002). More recent studies have highlighted its potent growth inhibitory activity, giving 
it the potential for use in anticancer treatment (Inoki et a l , 2005)
Mutations in TORI and TOR2 genes show similar growth inhibitory properties to those 
seen with rapamycin treatment (Kunz et a l , 1993). In yeast and mammalian cells, TOR 
proteins can regulate cell growth by controlling transcription, translation and ribosome 
biogenesis (Inoki et a l , 2005). Inhibition o f TOR by rapamycin is not a direct effect as 
another protein, FK506-binding protein (FKBP12), is required for repression to take 
place. Rapamycin forms a complex with FKBP12, which binds to TOR and inhibits its 
function (Abraham and Wiederrecht, 1996). Mammalian TOR or mTOR was 
subsequently identified due to its ability to bind to FKBP12 (Chiu et a l , 1994). 
Mammals contain a single TOR gene (mTOR) compared to two found in yeast. mTOR is 
a 289kDa protein that belongs to the phophoinositide 3-kinase related kinase (PIKKs) 
family. PIKKs are involved in a diverse array of cellular functions including gene 
expression, cell cycle control, DNA damage checkpoint regulation and cell growth 
control
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The best-studied targets of the mTOR pathway are proteins that regulate the translational 
machinery. One such protein is the translational repressor 4E-BP1 (eukaryotic initiation 
factor 4E-binding protein 1). 4E-BP1 inhibits translation by binding to eukaryotic 
translation factor 4E (eIF4E). eIF4E recognises the 5’-end cap o f the majority o f 
eukaryotic mRNAs. Repression is relieved when mTOR phosphorylates 4E-BP1, 
releasing eIF4E, which is then free to associate with eIF4G and initiate translation 
(Wullschleger et al., 2006).
S6K1 is another prominent example of a protein that is directly phosphorylated by 
mTOR. S6K1, when active, phosphorylates the 40S ribosomal protein S6. This was 
thought to promote the translation o f a subset o f mRNAs that contain a 5’ tract of 
oligopyrimidine (TOP). However, recent studies have shown that although 
phosphorylation of S6 is essential for regulating cell size, it is dispensable for 
translational control o f TOP mRNAs (Ruvinsky et al., 2006). An alternative explanation 
for S6K’s ability to control translation can be found in its regulation o f eukaryotic 
elongation factor 2 kinase (eEF2K). S6K phosphorylates and inactivates eEF2K, a factor 
that mediates the translocation step o f translational elongation. Therefore, S6K 
phosphorylates and inactivates eEF2K, thus promoting translational elongation (Wang et 
al., 2001).
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3.1.2 TSCl/2 and Rheb
TSCl/2 and Rheb form two key components o f the mTOR-signalling pathway. Both are 
found upstream of mTOR and are regulated by a number of different pathways that feed 
into the mTOR pathway.
3.1.2.1 TSC1/TSC2
TSCl and TSC2 genes encode the proteins hamartin and tuberin. Mutations within TSCl 
and TSC2 are responsible for the disease Tuberous sclerosis. Tuberous sclerosis is a 
relatively common autosomal dominant disorder. It occurs with a frequency o f 1 in 6,000 
to 10,000 of the population. It is characterised by the development of benign tumours 
called hamartomas. Common symptoms include seizures, autism, mental retardation, 
kidney failure, facial angiofibromas, and cardial rhabdomyomas (Gomez, 1991). 
Hamartin and tuberin interact to form a functional tumour suppressor (TSC l-2) (Morry 
and Harding, 1986; van Slegtenhorst et al., 1998). TSC2 encodes a putative GTPase- 
activating protein (GAP), whereas TSC1 encodes a protein that contains two coiled-coil 
domains. Studies in Drosophila have shown that the loss-of-function of either TSC gene 
leads to an increase in cell size and proliferation (Potter et al., 2001). Homozygous 
inactivation of either TSCl or TSC2 in mice is lethal at the embryo stage (Kobayashi et 
al., 2001), while heterozygous animals are tumour-prone (Onda et al., 1999).
3.1.2.2 Rheb
Ras homology enriched in brain (Rheb) is a direct target o f TSC2. Rheb is a small 
GTPase and is a member o f the Ras superfamily o f GTP-binding proteins. Active TSC2
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converts Rheb from a GTP to a GDP-bound state, thereby inactivating it. Point mutations 
within the GAP domain o f TSC2 disrupt its ability to regulate Rheb. This occurs without 
affecting TSC2’s ability to form a complex with TSCl (Zhang et ah, 2003b). Thus, Rheb 
is found downstream of the TSC1-TSC2 complex. In relation to mTOR, biochemical 
analysis would indicate that Rheb functions upstream of mTOR (Saucedo et al., 2003). 
Recent studies have indicated this is through a direct interaction, where Rheb binds 
directly to the amino-terminal lobe o f the mTOR catalytic domain (Long et al., 2005a; 
Long et al., 2005b). This interaction is not attributed to changes in Rheb-GTP charging 
(Long et ah, 2005a; Long et ah, 2005b).
3.1.3 Upstream regulators of mTOR signalling
TSCl/2 and Rheb form targets for a number o f signalling pathways. This allows mTOR 
to respond to cellular energy levels, the presence o f nutrients and growth factors.
3.1.3.1 Energy sensing
Cell growth is dependent on the rate o f protein synthesis, a process that requires a large 
amount o f energy. Therefore, mTOR must be regulated in response to cellular energy 
levels. mTOR senses cellular energy levels through AMP-activated protein kinase 
(AMPK). AMPK is a kinase that is activated by a high AMP/ATP ratio. The tumour 
suppressor LKB1 also regulates AMPK. Individuals who have mutations within LKB1 
develop Peutz-Jeghers syndrome, characterized by the formation o f hamartomas in the 
gastrointestinal tract (Boudeau et al., 2003). Under low ATP conditions, LKBl 
phosphorylates AMPK, contributing to AMPKs activation (Shaw et ah, 2004). Active
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AMPK represses mTOR, resulting in a decrease in mTOR-dependent phosphorylation of 
4E-BP1 and S6K (Inoki et ak, 2003b). Repression of mTOR is mediated by AMPK’s 
phosphorylation of TSC2, which enhances TSC2 GAP activity (Inoki et ak, 2003b). 
Thus, when cellular energy levels are low, cell growth is inhibited through AMPK’s 
repression o f the mTOR pathway.
3.1.3.2 Growth factors
mTOR senses the presence o f growth factors through the P13K pathway. Many growth 
factors, including insulin, bind to their receptors and promote recruitment and 
phosphorylation o f insulin receptor substrate (1RS). Following the phosphorylation of 
1RS, PI3K binds to 1RS, stimulating PI3K’s ability to covert phosphatidyIinositol-4,5- 
phosphate (PIP2) to phophatidylinositol-3,4,5-phosphate (PIP3). PIP3 recruits 3- 
phosphoinositide-dependent protein kinase 1 (PDK l) and protein kinase B (PKB, also 
known as Akt) through their pleckstrin homology domains. This results in the 
phosphorylation and activation o f PKB by PDKl.
Both PI3K and PKB have been shown to regulate mTOR activity. Overexpression of 
PKB promotes the phosphorylation o f 4E-BP1 in a rapamycin-sensitive manner (Gingras 
et ak, 1998). Furthermore, the phosphorylation o f 4E-BP1 is sensitive to wortmannin, an 
inhibitor o f PI3K (Gingras et ak, 1998). These findings place the PI3K pathway 
upstream of mTOR. The bridge between these two pathways is mediated by PKB kinase 
activity (Cai et ak, 2006). Hypophosphorylated TSC2 is associated with TSCl at the 
membrane where it represses Rheb through its GAP activity. Active PKB phosphorylates
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TSC2, which promotes TSC1/TSC2 interaction with 14-3-3 (Cai et ak, 2006). 14-3-3 
sequesters TSC2 in the cytosol, preventing its repression of its membrane bound target 
Rheb (Cai et ak, 2006). Thus, growth factors activate PKB, which activates mTOR by its 
repression o f TSC2.
3.1.3.3 Nutrients
Nutrients such as glucose and amino acids play an important role in the regulation of 
mTOR signalling. In mammalian cells, amino acid deprivation results in 4E-BP1 and 
S6K become rapidly dephosphorylated, whereas amino acid supplements stimulate 4E- 
BPl and S6K phosphorylation (Hara et ak, 1998). Rheb has been shown to play a role in 
regulating mTOR activity in response to the presence or absence o f amino acids (Long et 
ak, 2005b). Rhebs interaction with mTOR is stimulated by the presence o f amino acids, 
most notably leucine (Long et ak, 2005b). This interaction is independent o f Rheb GTP 
charging (Long et ak, 2005a; Long et ak, 2005b). Furthermore, inactive TSC1/TSC2 
renders cells resistant to amino acid starvation (Gao et ak, 2003), demonstrating that the 
TSC1/TSC2 complex is also important in amino acid sensing. However, a number o f 
other studies have proposed a TSCl/TSC2-independent mechanism whereby amino acids 
regulate the mTOR pathway (Kim et ak, 2002; Smith et ak, 2004). One such mechanism 
involves mTOR directly sensing the presence of amino acids (Kim et ak, 2002). 
Therefore, the role o f nutrients is important in the regulation o f mTOR, though a clear 
mechanism has yet to be defined. For a summary of the mTOR pathway and the various 
pathways that feed into it see figure. 3.1.
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Figure 3.1 Model of mTOR signalling in mammalian cells
mTOR responds to a number o f growth factors (insulin/IGF), nutrients (amino acids) 
and energy levels (AMPrATP ratio), controlling pathways that collectively determine 
cell mass. Arrows represent activation, whereas bars represent repression.
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As discussed previously, rapamycin was shown to have a repressive effect on pol III 
transcription in S. cerevisiae (Zaragoza et ak, 1998). Therefore, rapamycin was used to 
investigate the role of mTOR on the transcription o f pol III transcribed genes in 
mammals. Further to this, various components of the mTOR-signalling pathway were 
investigated to determine their regulatory effect on pol III activity.
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3.2 Results
3.2.1 Inhibition of mTOR by rapamycin reduces pol III transcriptional activity
Initial experiments were performed to see if the effect o f rapamycin on pol III in S. 
cerevisiae (Zaragoza et a l ,  1998) was mirrored in mammalian cells, Asynchronously 
grown mouse fibroblasts were treated with rapamycin for the times indicated. An in vitro 
transcription assay was performed using extracts derived from these cells to measure pol 
III transcriptional activity (figure 3.2). After one hour of rapamyein treatment, there is a 
decrease in the level of pol 111 transcriptional activity. This effect is seen on both 7SL 
and tRNA^" genes.
In a second experiment, RNA was harvested from asynchronous grown cells either 
treated with a vehicle or rapamycin for 4 hours. RT-PCR analysis revealed that levels of 
tRNA’"*^  ^ and B2 transcripts were reduced after the addition o f rapamycin (figure 3.3). 
This effect is specific, as the level o f the pol 11 transcript encoding ARPP PO remains 
unchanged. Type 3 promoters were ignored as previous data from Emma Graham had 
shown that rapamycin had no effect on the transcription of U6.
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Figure 3.2 mTOR inhibition by rapamycin reduces pol III transcriptional 
activity.
Whole cell extracts were made from A31 mouse fibroblasts treated with rapamycin 
(lOOnM) for 1, 2 and 4 hours (lanes 2-4) or with vehicle (lane 1). 15pg o f extract was
used in an in vitro transcription assay using a tRNA 
template.
Leu (250ng) and 7SL (250ng)
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Figure 3.3 Inhibition o f mTOR by rapamycin reduces the levels of pol III 
transcripts
RNA was harvested from A31 mouse fibrobroblasts treated with rapamycin (lOOnM) or 
vehicle control for 4 hours. RNA was analysed by RT-PCR for the expression o f B2,
LeutRNA , and ARPP PO mRNA(control).
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3.2.2 Inhibition of mTOR by rapamycin reduces the promoter occupancy of pol III 
and TFIIIB
mTOR has been shown to regulate gene expression by controlling the promoter 
occupancy of transcription factors (James and Zomerdijk, 2004; Zhang et ah, 2005). 
Therefore, to determine the effects o f rapamycin on the promoter occupancy o f the pol III 
transcriptional machinery a ChIP assay was performed (figure 3.4). Formaldehyde cross- 
linked chromatin was prepared from asynchronously growing cells either treated for 4his 
with lOOnM rapamycin or a vehicle control. Antibodies against RPC 155 (a component 
o f pol III), TFIlICllO  and the TFIIIB subunit Brfl were used to determine their 
occupancy. TFIIA was used as a negative control as it is not present on pol Ill- 
transcribed genes. PCR analysis showed that the promoter occupancy o f pol III and 
TFIIIB (Brfl) were diminished after the addition o f rapamycin. In contrast, the levels of 
TFIllC remain comparable in both rapamycin-tieated and vehicle-treated cells.
3.2.3 Knockdown of endogenous Rheb in MEF cells by siRNA decreases the levels of 
pol III transcripts
Use o f the mTOR specific inhibitor rapamycin has highlighted a new role for mTOR in 
regulation of pol III. As previously stated, Rheb is the direct upstream regulator of 
mTOR (Long et ak, 2005a; Long et ak, 2005b). To examine the role o f Rheb in the 
regulation o f pol 111, Rheb was knocked down using small interfering RNA (siRNA). 
RNA was obtained from Richard Lamb at The Institute of Cancer Research, London 
(figure 3.5). RT-PCR analysis o f RNA derived from the Rheb knockdown experiments 
showed that the levels o f pol III transcribed tRNA^"" and B2 RNA are down compared to
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Figure 3.4 mTOR inhibition by rapamycin reduces promoter occupancy by pol 
III and TFIIIB
Promoter occupancy o f  the pol III transcriptional machinery was measured in A31 
mouse fibroblasts treated with either rapamycin (lOOnM) or vehicle control for 4 
hours. ChlPs were performed using antibodies against TFIIlC llO , Brfl (TFIIIB), 
RPC 155 (pol III) and TFIIA (negative control). Samples were normalized by 
comparing the genom ic DNA inputs and adjusting the samples accordingly. The 
samples were then analysed by PCR, alongside genom ic DNA (10%, 2% and 0.4%),
Leuusing 5S rRNA, tRNA " and B2 primers.
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Figure 3.5 Knockdown of endogenous Rheb in MEF cells by siRNA decreased 
the levels of pol III transcripts
Knockdown o f  Rheb in MEF cells was performed by Richard Lamb’s group at the 
Institue o f  Cancer Research, London (data unpublished). MEFs were transfected 
with Rheb (lane 2) or scrambled siRNA (control; lane 1). RNA was harvested and 
analysed by RT-PCR for the expression o f  5S rRNA, tRNALeu, B2, pre rRNA and 
ARPP PO m RNA(control) (n = l).
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the control siRNA transfection. The effect is specific, as the pol II transcribed ARPP PO 
mRNA does not change in response to Rheb knock down. The levels o f the pol I- 
transcribed, pre-rRNA was analysed, as previous work has shown that pol I is controlled 
by various components o f the mTOR pathway (Hannan et al., 2003; James and 
Zomerdijk, 2004; Mayer et al., 2004; Zang et al., 2005). As expected, the level o f pre- 
rRNA is reduced when Rheb is knocked-down. Thus, Rheb regulates the levels o f both 
pol I and pol III transcripts.
3.2.4 TSC2 negatively regulates the levels of pol III transcripts
Rheb is the direct target for TSC2 GAP activity, which converts Rheb from an active 
GTP bound form to an inactive GDP form. To determine whether TSC2 regulates the 
levels o f pol III transcripts, control TSC2'*''^ mouse embryonic fibroblasts (MEFs) were 
compared to TSC2'" '^ MEF knockouts (figure 3.6). RT-PCR analysis o f these cells 
revealed that both 5S rRNA and tRNA^^" are elevated in the TSC2'^' MEFs compared to 
the control TSC2’^ '^^  MEFs (lanes 1 and 2, respectively). This effect is reversed when 
TSC2 is reintroduced via transient transfection in the knockout cells (lane 3). A TSC2 
mutant with compromised GTPase activity partially reversed the effect o f TSC2 
knockout (lane 4). These effects are specific, as the levels o f the pol Il-transcribed ARPP 
PO transcript remain constant.
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Figure 3.6 TSC2 negative regulates the levels of pol III transcripts
RNA was harvested from wild type MEFs (lane 1), TSC2-/- MEF knockouts (lane 
2), TSC2-/- MEF knockouts transiently transfected with wild type TSC2 (lane 3) and 
TSC2-/- knockout MEFs transiently transfected with TSC2 with GAP mutant (lane 
4). RNA was analysed by RT-PCR for the expression o f  5S rRNA, tRNA^", and 
ARPP PO (control) (n = l).
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3.2.5 Knockout of TSC2 increases the promoter occupancy of TFIIIC, pol III and 
TFIIIB
The role o f TSC2 in the regulation o f pol III is accordant with that o f mTOR function in 
this study. Therefore, a ChIP assay was performed to determine if there are any changes 
in the promoter occupancy o f the pol III transcriptional machinery in response to the 
knockout o f TSC2 (figure 3.7). To do this, control TSC2^^^ MEFs were compared to 
TSC2 '^ " MEF knockouts using antibodies against TFIIIC 110, RPC 155 (a component of 
pol III) and Brfl (a component o f TFIIIB). In agreement with the rapamycin ChIP, 
promoter occupancy o f TFIIIB and pol III is greater in the TSC2''^' MEF knockouts 
compared to the wild type cell line. However, promoter occupancy of TFIIIC is also 
elevated; this is in contrast to the rapamycin ChIP, where no changes in the promoter 
occupancy o f TFIIIC were observed.
A problem with ChIP assays is that conformational changes or the recruitment of other 
factors could block the binding of antibodies to their intended target. Thus, the result 
gained could be a result o f epitope masking and not changes in the promoter occupancy 
on the target protein. In an attempt to overcome this, three antibodies, two against 
TFIIIC 110 and one against TFIIIC220, were used to determine if  the change in TFIIIC 
detection was as a result o f its promoter occupancy (figure 3.8). This proved to be the 
case, as all three antibodies detected a greater presence o f TFIIIC in TSC2''^' MEF 
knockouts compared to the wild type cell line.
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Figure 3.7 TSC2 negatively regulates the promoter occupancy of TFIIIC, pol III 
and TFIIIB on pol III transcribed genes.
Promoter occupancy o f  the pol III transcriptional machinery was measured in TSC2-/- 
MEF knockouts compared to TSC 2+/+ MEF wild types. ChlPs were performed using 
antibodies against TFIIICl 10, Brfl (TFIIIB) and RPC 155 (pol III). Samples were 
normalized by comparing the genom ic D NA inputs and adjusting the samples 
accordingly. The samples were then analysed by PCR, alongside genomic DNA  (10%,Uu X r2% and 0.4%), using 5S rRNA and tRNA (n=2).
71
to>•
TSC2
noX<vco
to
X
JD<
rsi X) <
o  o
fS I I—I04 «—t
>' y  y  yO) =  =
<  t  h H
I + I +
4 -  I 4 -  I 4 -  I Z p ' T  +
Inputs
# #
m  # e m *
5S rDNA
tRNALeu
Figure 3.8 Knockout of TSC2 increases the promoter occupancy of TFIIIC on 
pol Ill-transcribed genes
Promoter occupancy o f  TFIIIC was measure in TSC2-/- MEF knockouts compared 
to TSC2+/+ MEF wild types. ChlPs were performed using antibodies against 
acetylated hi stone H3 L y sl4 , TFIIICl 10, TF1IIC220, TFIIICl 10 (recognises 
different epitope to the first TFIIICl 10 antibody) and TFIIA (negative control). 
Samples were normalized by comparing the genom ic DNA inputs and adjusting the 
samples accordingly. The samples were then analysed by PCR, alongside genom ic
LeuDNA (10%, 2% and 0.4% ), using 5S rRNA and tR N A ^ “ (n=2).
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3.2.6 Pol III transcriptional activity is blocked specifically by a substrate inhibitor 
for PKB
PKB phosphorylates and represses TSC2 in response to the presence o f growth factors 
(Cai et a f, 2006). To test if  PKB has an effect on pol III activity, a substrate peptide 
inhibitor of PKB was used in an in vitro transcription assay (figure 3.9). tRNA*^^“ 
transcription was reduced in a dose-dependent manner by the substrate peptide containing 
the PKB consensus phospho-acceptor site. This response was deemed specific, since a 
substrate peptide for protein kinase A (PKA) had no effect on tRNA^^" transcription.
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Figure 3.9 Pol III transcription is blocked by a substrate inhibitor for PKB.
In vitro transcription assay was performed using 15pg of HeLa nuclear extract. Pre 
incubation was carried out with buffer (lanes 1 and 6) or with 10,20, 30, 40pg of PKB 
substrate peptide inhibitor (lanes 2-5) or with 10, 20, 30, 40pg o f PKA phospho- 
acceptor peptide (lanes 7-10). 250ng tRNA^“ template was used to transcribe.
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3.3 Discussion
Use o f  rapamycin demonstrates that mTOR is a positive regulator of pol 111 activity. 
Further to this, Rheb and TSC2, components o f the mTOR-signalling pathway, have been 
shown to regulate the transcription o f pol Ill-transcribed genes.
mTOR coordinates nutrient availability with cellular growth. This is achieved through its 
ability to regulate the activity o f  various components of the cell’s translational 
machinery. Both pol I and pol III are involved in the transcription of genes encoding 
components o f the translational machinery and are often co-ordinately regulated (White,
2005). Previous studies in mammals have shown that pol I is regulated by the mTOR 
pathway (Hannan et al., 2003; James and Zomerdijk, 2004; Mayer et al., 2004; Zhang et 
al., 2005). TOR also regulates pol III transcription in yeast (Zaragoza et al., 1998). 
Evidence provided here shows for the first time that in mammalian cells pol III 
transcription is regulated by mTOR. This highlights the coordinated regulation o f both 
pol I and pol III in mammalian cells, reinforcing the link between growth factor 
signalling and ribosome biogenesis.
TSC2 and Rheb are two prominent examples o f upstream regulators o f mTOR. Rheb in 
its GTP bound form activates mTOR, whereas TSC2 represses mTOR (Gao et al., 2003). 
TSC2 represses mTOR through its GAP activity towards Rheb, converting Rheb from an 
active GTP-bound form into an inactive GDP-bound form (Zhang et al., 2003b). In this 
study, knockouts o f TSC2 compared to wild type TSC2'*"'^  ^MEF, demonstrated that TSC2 
negatively regulates the levels o f pol III transcripts, highlighting a novel role for this
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tumour suppressor. This is consistent with a study that identified TSCl and TSC2 as 
negative regulators o f poi I transcription (Zhang et ai., 2005), again reinforcing the link 
between pol I and pol III regulation. The ability o f TSC2 to repress pol III transcripts is 
in part mediated by TSC2 GAP activity. Transient transfection o f wild type TSC2 into 
TSC2'^' MEFs resulted in a recovery o f TSC2 function in these cells, as the levels o f pol 
III transcripts were similar to those of the wild type TSC2’^ ^^  cells. However, transient 
transfection o f a mutant TSC2 with compromised GAP activity was unable to regain the 
full activity o f TSC2 in repressing the level o f pol III transcripts. This highlights the 
importance of TSC2 GAP activity in the regulation o f pol 111.
Consistent with TSC2 inhibitory effect, knockdown o f Rheb reduces the levels o f pol III 
transcripts. TSC2 inhibits the activity o f mTOR through its repression o f Rheb, which is 
a positive regulator o f mTOR (Li et al., 2004). TSC2’s ability to inhibit mTOR is lost 
when its GAP activity is lost (Li et al., 2004). The only target identified for TSC2 GAP 
activity thus far is the GTPase Rheb. Therefore, knockdown o f Rheb produces a 
response similar to that when TSC2 is active, resulting in a decrease in mTOR activity 
and a repression o f mTOR’s downstream targets. In this study, knockdown o f Rheb 
resulted in a decrease in the levels o f pol III transcripts, demonstrating that the small 
GTPase Rheb positively regulates pol III. Furthermore, pol I was also shown to be 
regulated by Rheb, again highlighting the similarity by which both pol I and pol III are 
regulated. Although previous studies have highlighted the role o f mTOR in the 
regulation o f pol I (Hannan et al., 2003; James and Zomerdijk, 2004; Mayer et al., 2004;
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Zhang et al., 2005), this is the first time that Rheb has been shown to regulate the level of 
pol I transcripts.
Use o f rapamycin and a TSC2 knockout cell line have shown that both mTOR and TSC2 
control the promoter occupancy o f the pol III transcriptional machinery. Repression of 
mTOR results in a decrease in the promoter occupancy o f TFIIIB and pol III, whereas 
TFIIIC remains unaffected. In contrast, promoter occupancy of TFIIIC, along with 
TFIIIB and pol 111, are altered in response to the presence or absence o f TSC2. This may 
reflect the two conditions observed, demonstrating the short and the long-term effects o f 
mTOR regulation. Rapamycin was used to inhibit mTOR over a period of 4 hours, 
whereas the knockout o f TSC2 is a permanent effect. Therefore, further work is needed 
to determine the long-term mechanism by which the promoter occupancy o f TFIIIC is 
regulated via TSC2.
PKB phosphorylates and inactivates TSC2 in response to the presence o f gi'owth factors 
(Cai et al., 2006). Inactivation o f TSC2 promotes the accumulation o f active GTP bound 
Rheb, which in turn activates mTOR (Cai et al., 2006). Manipulation o f PKB has shown 
that it plays an important role in the regulation of the phosphorylation o f 4E-BP1, a 
downstream target of mTOR (Gingras et al., 1998). When a competitive substrate 
inhibitor for PKB was used in an in vitro transcription assay, tRNA^^" transcription was 
reduced in a dose-dependent manner. This suggests that PKB can regulate the 
transcription o f a tRNA^^" gene in vitro. Whether this is through the mTOR pathway or 
through an alternative mechanism is yet to be determined.
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Addition o f rapamycin resulted in substantial changes in the promoter occupancy o f both 
TFIIIB and pol III on pol III transcribed genes. In comparison, only mild changes in the 
promoter occupancy of TFIIIB and pol III were observed when TSC2 knockout cells 
were compared to the wild type. A potential explanation is that tuberous sclerosis is a 
largely benign tumour syndrome, with progression to malignancy being very rare. Loss 
o f TSC2 results in the inappropriate activation of the Rlieb/mTOR/S6K pathway (Shah et 
al., 2004). However, the unrestrained activation o f S6K results in a negative feedback 
loop, which inactivates IRS-1, via repression o f gene expression and the direct 
phosphorylation of IRS-1 (Harrington et al., 2006; Manning et al., 2006; Shah et al., 
2004; Zhang et al., 2003a). The inactivation o f 1RS-1 results in the reduced activity of 
PI3K and its downstream effectors such as PKB (Harrington et al., 2006; Manning et al., 
2006; Shah et al., 2004; Zhang et al., 2003a). Repression o f the PI3K-PKB pathway in 
tumours lacking TSC2 contributes to their benign nature (Manning et al., 2006). 
Previous studies have shown that TSC2'^' MEF knockouts display reduced PKB activity 
compared to the TSC2^^^ MEF wild types (Harrington et al., 2006; Shah et al., 2004; 
Zhang et al., 2003a). Furthermore, heterozygous TSC2'^ '^ mice also have diminished 
PKB activity (Manning et al., 2006). Regulation o f pol III by PKB was suggested by an 
m vitro transcription assay, where a competitive substrate inhibitor o f  PKB reduced 
tRNA^^“ transcription in a dose-dependent manner. Therefore, PKB’s ability to activate 
pol III transcription may be compromised in the TSC2 knockout cell line. This may have 
effects on the expression o f pol III transcribed genes and the promoter occupancy o f the 
transcriptional complex.
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Chapter 4-Mechanisms of 
pol III regulation by mTOR
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4.1 introduction
The previous chapter demonstrated that various regulators o f mTOR control the 
expression o f pol Ill-transcribed genes. This is achieved through alterations in promoter 
occupancy of pol III, TFIIIB and TFIIIC. Therefore, this chapter will focus on the 
mechanisms that control the recruitment o f these transcription factors.
4.1.2 The mTOR complex
mTOR regulates a number of proteins through a direct protein-protein interaction. 
Phosphorylation o f mTOR targets is optimised via scaffold proteins that help facilitate its 
binding to its target protein. Two such proteins. Raptor (regulatory associated protein o f 
mTOR) and mLst8/G(3L (Hara et al., 2002; Kim et al., 2003), positively regulate mTOR 
and target mTOR to its substrates. The mTOR-Raptor-GpL complex contains a total of 
14 WD40 motifs and 23 FIEAT motifs (Inoki et al., 2005). Both WD40 and HEAT 
domains are important for protein-protein interactions, suggesting that this complex 
serves as a central nexus for TOR signaling. Raptor interacts with its target protein via 
TOR signalling (TOS) motifs (Nojima et al., 2003). The integrity o f TOS motifs is vital 
for mTOR phosphorylation (Nojima et al., 2003). A single mutation within this motif 
can result in a dramatic decrease in S6K1 and 4E-BP1 phosphorylation by mTOR in vitro 
(Nojima et al., 2003).
4.1.2 mTOR regulates transcription and ribosome biogenesis
Work in both yeast and mammals has identified a number o f transcription factors that are 
regulated by TOR/mTOR in a nutrient- and stress-responsive manner (Wullschleger et
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al., 2006). Two such examples can be found within the pol I transcriptional machinery; 
UBF and TIF-IA (Hannan et ah, 2003; Mayer et ah, 2004). mTOR inhibition by 
rapamycin results in the dephosphorylation o f these two proteins, leading to a decrease in 
the expression o f 45S ribosomal genes (rRNA transcription) (Hannan et ah, 2003; Mayer 
et ah, 2004). Phosphorylation controls TIF-IA cytoplasmic and nuclear localisation 
(Mayer et ah, 2004). Under favourable conditions, mTOR promotes the Cdk-mediated 
phosphorylation o f TIF-IA (Mayer et ah, 2004), This modification tethers TIF-IA to pol 
I and retains TIF-IA in the nucleus, promoting rRNA synthesis (Mayer et ah, 2004). 
During unfavourable conditions or after the addition of rapamycin, mTOR is inactive, 
resulting in a decrease in TIF-IA phosphorylation and sequestration of TIF-IA in the 
cytoplasm (Mayer et ah, 2004). Dephosphorylation is mediated by Protein phosphatase 
2A (PP2A), which is active when mTOR is in a repressed state (Mayer et ah, 2004). In a 
different study, UBF was also shown to be a downstream target of mTOR regulation 
(Hannan et ah, 2003). This is mediated by the kinase S6K1, which promotes the 
transcriptional activity o f pol I (Hannan et ah, 2003). Other studies have highlighted the 
importance o f other signalling components upstream of mTOR involved in the regulation 
o f pol I. Examples include PTEN, Akt/PKB and PI(3)K (James and Zomerdijk, 2004; 
Zang et ah, 2005). One such study demonstrated that overexpression o f PTEN results in 
changes in the promoter occupancy o f a number of SLl subunits on the promoters of 
genes transcribed by pol I (Zhang et ah, 2005). For a summary o f pol I regulation by 
mTOR, see figure 4.1.
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Figure 4.1 mTOR controls the transcription of pol I transcribed genes through the 
regulation of UBF and T lF -lA .
mTOR promotes phosphorylation o f TIF-IA through the activation o f cdk2/cyclin E and 
the repression of PP2A. When TIF-IA is hyperphosphorylated, it is present in the 
nucleus. When hypophosphorylated it is sequestered in the cytoplasm. mTOR also 
promotes UBF phosphorylation through the kinase S6K. Phosphorylation of both UBF 
and TIF-IA promote pol I activity.
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Studies in yeast have highlighted a further mechanism by which TOR controls the 
expression o f pol I-transcribed genes. Inhibition o f TOR changes the acétylation pattern 
o f histones found on pol I-transcribed genes, identifying a chromatin-mediated 
mechanism by which TOR regulates transcription (Tsang et ah, 2003). The nucleosome 
is the basic unit of chromatin, consisting o f two copies of H2A, H2B, H3 and H4 core 
histones that bind to 146 base pairs o f DNA (Luger et ah, 1997). Transcription is 
inhibited by the nucleosome’s ability to hide DNA sequences required for the binding of 
transcription factors (Edmondson and Roth, 1996). Chromatin can be altered by 
covalently modifying histone proteins. One such covalent modification, acétylation, is 
catalysed by histone acetyltransferase (HAT) enzymes (Eberharter and Becker, 2002). 
Acétylation is a reversible process and is catalysed by histone deacetylases 
(HDAC)(Eberharter and Becker, 2002). Acétylation o f histones is generally associated 
with transcriptional activation, whereas a lack of acétylation tends to correlate with 
repression (Eberharter and Becker, 2002).
Addition o f rapamycin decreases histone H4 acétylation at rRNA genes through the 
activation o f the HDAC complex Rpd3-Sin3 (Tsang et ah, 2003). Further to this, 
transcription o f pol II transcribed ribosomal protein genes is regulated in a similar 
manner. Again, H4 acétylation decreases in response to rapamycin and the effect is 
mediated by Rpd3-Sin3 (Rohde and Cardenas, 2003). Therefore, components o f the 
ribosome, either untranslated RNAs or proteins, are regulated in a similar chromatin- 
mediated fashion. However, in mammals a link between mTOR and alterations in 
histone acétylation has yet to be determined.
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mTOR/TOR controls pol I transcription through phosphorylation and alterations in 
histone acétylation (Hannan et al., 2003; James and Zomerdijk, 2004; Mayer et ah, 2004; 
Zhang et ah, 2005; Zhang et ah, 2003a). Such modification can alter promoter 
occupancy and cellular localization o f transcription factors that are required for pol I 
transcription (Mayer et ah, 2004; Tsang et ah, 2003; Zhang et ah, 2005). For pol III, 
work in yeast suggested that TFIIIB might be the target of TOR regulation. PP2A was 
speculated to be the mediator of TOR’s pol III regulation (Zaragoza et ah, 1998). This 
chapter will examine these mechanisms to see if  pol III in mammalian cells is regulated 
in a similar manner.
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4.2 Results
4.2.1 Levels of pol III, TFIIICllO and TFIIIB are unaffected by rapamycin 
treatment
Experiments in the previous chapter have shown that promoter occupancy o f TFIIIB and 
pol III change in response to rapamycin. To see if this is a direct result o f changes in 
abundance o f pol III and TFIIIB, western blot analysis was used to measure these factors 
at the protein level (figure 4,2). No change in the abundance of TFIIIC 110, TFIIIB (Brfl) 
and pol III is detected between rapamycin- and vehicle control- treated cells.
4.2.2 Levels of TFIIICllO are lower in TSC2  ^ MEF knockouts
In contrast to rapamycin treatment, TSC2 was shown to regulate the promoter occupancy 
of TFIIIC, along with TFIIIB and pol III. Again, western blot analysis was used to 
measure the presence o f these factors at the protein level (figure 4.3). The abundance o f 
both Pol III and TFIIIB (Brfl) are unaffected by the presence or absence of TSC2. 
However, TFIIIC 110 is elevated in the TSC2"' "^ MEF knockouts compared to the TSC2'*^ ’^^  
MEF wild types. To determine if  this effect is specific to the 110 subunit o f TFIIIC, the 
abundance o f both TFIIIC220 and TFIIIC 102 was also measured. As with pol III and 
TFIIIB, there was no change in the abundance o f TFIIIC220 and TFIIIC 102 in the TSC2' 
MEF knockouts compared to the TSC2^^^ MEF wild types. Therefore, TSC2 
specifically regulates the abundance o f the TFIIICllO subunit o f TFIIIC.
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Figure 4.2 The levels of pol III, TFIIICllO and Brfl a subunit of TFIIIB are 
unaffected by rapamycin treatment.
A31 mouse fibroblasts were treated with rapamycin (lOOnM; lane I ) or with 
vehicle (lane 2) for 4 hours. Whole cell extracts from these cells were resolved on 
SDS-PAGE, and western blotting was performed with antibodies against Brfl, 
TFinCl 10, RPC 155 and actin.
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Figure 4.3 The level TFIIICllO are higher in TSC2 MEF knockouts.
Whole cell extracts were harvested from TSC2  ^ MEF knockouts (lane 2) and wild type 
MEFs (lanel). Protein extracts were resolved on SDS-PAGE, and western blotting was 
performed with antibodies Brfl, TFIIICl 10, TFIIIC220, TFIIIC 102, RPC 155 and actin.
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4.2.3 Cellular localization of the pol III transcriptional machinery is unaltered by 
rapamycin
mTOR has been shown to regulate the cellular localization o f a number o f transcription 
factors. One example o f that is the pol Ï transcription factor TIF-IA. TIF-IA is 
sequestered in the cytoplasm when mTOR is repressed by rapamycin (Mayer et al., 
2004). To investigate whether pol III was regulated in a similar fashion, nuclear and 
cytoplasmic extracts were made from asynchronous mouse fibroblasts treated with either 
rapamycin or a vehicle-control (figure 4.4). Cellular localization o f pol III and its 
associated transcription factors were looked at via western analysis. The fractionation 
efficiency o f nuclear and cytoplasmic fractions was assessed by the presence o f c-Jun and 
p70/S6k, as they are nuclear and cytoplasmic markers, respectively. As expected, S6K1 
was found within the cytoplasmic fraction, whereas c-Jun was found within the nuclear 
fraction. Addition o f rapamycin resulted in a decrease in phosphorylation o f the mTOR 
target S6K, demonstrating the activity o f rapamycin in this assay. This is seen with both 
the phospho-specific S6K antibody and the electromobility shift seen when probing for 
total S6K. However, predominant nuclear localization of pol III and its associated 
transcription factors remains unchanged after the addition o f rapamycin.
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Figure 4.4 mTOR inhibition by rapamycin did not affect the cellular localization 
of the pol III transcriptional machinery.
Nuclear (lanes 3 and 4) and cytoplasmic (lanes 1 and 2) extracts were harvested from 
rapamycin (lOOnM; lanes 2 and 4) or vehicle-treated (lanes 1 and 3) A31 mouse 
fibroblasts. Protein extracts were resolved on SDS-PAGE, and western blotting was 
performed with antibodies to Brfl, TFIIICl 10, TFIIIC220, TFIIICl02, RPC 155, c- 
Jun, p70/S6K and phosphos p70/S6K (n=2).
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4.2.4 Inhibition of PP2A does not relieve inhibition of pol III transcription by 
rapamycin
There are a number of possible mechanisms that could regulate the transcriptional 
activity o f pol III in response to mTOR. One such mechanism is via protein phosphatase 
2A (PP2A), which has been shown to play a role in mTOR regulation of pol I (Mayer et 
al., 2004) and the mitotic repression of poi III (Fairley et al., 2003). To test for a 
potential PP2A role, asynchronous mouse fibroblasts were treated with rapamycin. 
Extracts from these cells were then treated with okadaic acid (100 or 0.2 nM) in an in 
vitro transcription assay. Okadaic acid is known to inhibit a range of protein 
phosphatases, but displays a greater efficiency for the protein phosphatase 1 (PPl) and 
PP2A at the nanomolar range (Cohen et al., 1990). Addition o f okadaic acid had no 
effect on tR N A ^“ synthesis in both vehicle-treated control cells and rapamycin-treated 
cells. Calyculin A was also tested, which is another potent inhibitor of PPl and PP2A 
(Cohen et al., 1990). Again, the addition o f calyculin A (100 or 0.2 nM), as with okadaic 
acid, had no effect on tRNA^®“ transcription in both the vehicle-treated control cells and 
the rapamycin-treated cells (figure 4.5).
Okadaic acid and calyculin A have both previously been shown to inhibit pol III 
transcription in mitotic extracts (Fairley et al., 2003). Therefore, a control experiment 
was performed to demonstrate that okadaic acid and calyculin A are active at the 
concentrations used in this assay (figure 4.5). Both phosphatase inhibitors repressed the 
transcription o f tR N A ^“ in mitotic extracts, as previously reported (Fairley et al., 2003).
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Figure 4.5 Inhibition o f PP2A does not relieve inhibition of pol III transcription 
by rapamycin.
A31 mouse fibroblasts were treated with rapamycin (lOOnM; lanes 1-5) or with 
vehicle (lanes 6-10) for 4 hours. Whole cell extracts derived from these cells were 
pre-incubated for 10 minutes at 30°C in the presence o f buffer alone (lanes 1 and 6), 
100 (lanes 2 and 7) or 0.2nM (lanes 3 and 8) okadaic acid and 100 (4 and 9) or 0.2 
nM (lanes 5 and 10) calyculin A. Mitotic HeLa nuclear extracts were pre-incubated 
for 10 minutes at 30°C with buffer alone (lane 11), lOOnM okadaic acid (lane 12) or 
lOOnM calyculin A (lane 13).
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4.2.5 Knockdown of endogenous S6K1 and S6K2 had no effect on the level of pol III 
transcripts
Small interfering RNA (siRNA) was used to determine if  either S6Klor S6K2 have a role 
in the expression o f pol Ill-transcribed genes. RNA was obtained from a previous study 
carried out by Richard Lamb’s group at The Institute of Cancer Research, London 
(Harrington et al., 2006). siRNA directed against S6K1 and S6K2 results in a near 
complete knock-down o f S6K1 and a 70-80% knock-down of S6K2 (Haiiington et al.,
2006). RT-PCR analysis revealed that knockdown o f both S6K1 and S6K2 had no effect 
on the levels o f 5S rRNA, tRNA^" and B2 transcripts compared to the control 
transfection (figure 4.6). As there is no effect on the levels o f pol III transcripts, two 
positive controls were used to demonstrate that the knockdown o f both S6K1 and S6K2 
could have an effect on transcription. Knockdown of S6K1 results in a decrease in the 
levels o f p21 mRNA. This is consistent with previous reports that have shown that S6K1 
is a known regulator o f p21 expression (Gu et al., 2000). The knock-down o f both S6K1 
and S6K2 resulted in a decrease in the levels o f the pol I-transcribed, pre-rRNA. Again, 
this is in agreement with previous reports that show that pol I transcriptional activity is 
regulated by S6K (Hannan et al., 2003; Zang et al., 2005).
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Figure 4.6 Knockdown of endogenous S6K1 and S6K2 in MEF cells by siRNA 
had no effect on the levels of pol III transcripts.
Knockdown o f S6K1 and S6K2 in MEF cells was performed in a previous study 
(Harrington et al., 2006). MEFs were transfected with S6K1 (lane 2), S6K2 (lane 3) 
and scrambled siRNA (control; lane 1). RNA was harvested and analysed by RT- 
PCR for the expression o f 5S rRNA, tRNA^", B2, p21, pre rRNA and ARPP PO 
(control) (n=2).
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4.2.6 mTOR inhibition by rapamycin decreases the level of acetylated histone H3 on 
pol Ill-transcribed genes
As previously stated, work in yeast has shown that TOR can control the pattern of histone 
acétylation, regulating gene expression by a chromatin-mediated process (Rohde and 
Cardenas, 2003; Tsang et al., 2003). However the link between mammalian mTOR and 
changes in histone acétylation has not been made. Therefore, ChIP assays were 
performed to determine if this was a potential mechanism for the regulation of pol III in 
response to rapamycin (figure 4.7). Formaldehyde cross-linked chromatin was prepared 
from asynchronously grown fibroblasts treated with a vehicle or rapamycin for 4 hours. 
To assess changes in histone acétylation, an anti-acetyl H3 and an anti-acetyl H4 
antibody were used. A pol III antibody was used as a positive control. PCR analysis 
showed that pol III promoter occupancy was reduced in the rapamycin-treated cells 
compared to the vehicle-treated cells. In parallel to this, there is a decrease in the levels 
o f histone H3 acétylation. This is in contrast to histone H4, which maintains a similar 
level o f acétylation in both the rapamycin and vehicle-treated cells.
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Figure 4.7 mTOR inhibition by rapamycin decreases the level of acetylated 
histone H3 on pol Ill-transcribed genes
Levels of histone acétylation at pol Ill-transcribed genes were measured in A31 mouse 
fibroblasts treated with either rapamycin (lOOnM) or vehicle control for 4 hours.
ChlPs were performed using antibodies against acetylated histone H3, acetylated 
histone H4, RPC 155 (pol III) and TFIIA (negative control). Samples were normalized 
by comparing the genomic DNA inputs and adjusting the samples accordingly. The 
samples were then analysed by PCR, alongside genomic DNA (10%, 2% and 0.4% of  
input), using 5S rRNA, tRNA " and B2 primers.
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Similar experiments were performed with the TSC2'^' MEF knockouts compared to the 
TSC2'^ '^  ^ wild type MEFs to see if  a similar pattern of histone acétylation is observed 
(figure 4.8). Again, to assess changes in histone acétylation an anti-acetyl H3 and an 
anti-acetyl H4 antibody were used. Two additional antibodies were used that specifically 
recognise acétylation of histone H4 Lys5 and histone H3 Lysl4, to see if these specific 
lysine residues were affected by the presence or absence o f TSC2. Consistent with 
rapamycin treatment, acétylation o f histone H3 was elevated when TSC2 is not present, 
whereas acétylation o f histone H4 is unaffected. In parallel, acétylation o f histone H4 
Lys5 and histone H3 Lysl4 appear to be unaffected by the presence or absence o f TSC2. 
However, the effect on histone acétylation is only mild and is not pronounced as the 
effect observed after rapamycin treatment.
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Figure 4.8 Knockout of TSC2 increases the level of acetylated histone H3 on pol 
Ill-transcribed genes
The level o f histone acétylation was measured in TSC2-/- knockouts MEF compared 
to TSC2+/+ wildtypes MEF. ChlPs were performed using antibodies against 
acetylated histone H3, acetylated histone H4, acetylated histone H4 lysine 5, 
acetylated histone H3 lysine 14 and TFIIA (negative control). Samples were 
normalized by comparing the genomic DNA inputs and adjusting the samples 
accordingly. The samples were then analysed by PCR, alongside genomic DNA 
(10%, 2% and 0.4% o f inputs), using 58 rRNA and tRNA^" primers.
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4.2.7 Raptor co-immunoprecipitates with TFIIIC
Previous work has shown that phosphorylation o f TFIIICl 10 decreases after the addition 
o f rapamycin (Emma Graham, personal communication). This led to the hypothesis that 
phosphorylation of TFIIICllO, by an as yet unidentified kinase, regulated pol I ll’s 
transcriptional activity in an mTOR-dependent fashion. I found that pol III transcription 
is not regulated by S6K, as the knockdown of both S6K1 and S6K2 had no effect on the 
expression o f pol Ill-transcribed genes. This led to the hypothesis that mTOR might 
itself be directly phosphorylating TFIIICllO. To test this idea, TFIIICllO was 
immunoprecipitated from extracts derived from asynchronous mouse fibroblasts, treated 
with either a vehicle or rapamycin. Western analysis of the immunoprécipitation was 
performed to test whether any factors from the mTOR complex co-immunoprecipitated 
with TFIIICllO (figure 4.9). Raptor co-immunoprecipitates with TFIIICl 10, whereas in 
immunoprecipitaions carried out with pre-immune serum no Raptor was detected.
4.2.8 mTOR is associated with pol III transcribed genes
To determine if mTOR is present on pol Ill-transcribed genes, ChIP assays were 
performed (figure 4.10). Formaldehyde cross-linked chromatin was prepared from 
asynchronously growing cells. An antibody against mTOR was used to detect its 
presence. TFIIA and beads were used as negative controls. mTOR is present on both 5S 
rRNA and tRNA^®“ genes, but not associated with the pol Il-transcribed gene encoding 
cyclin D2. Conversely, as expected, TFIIA is associated with the cyclin D2 gene, 
whereas it is not associated with either 5S rRNA or tRNA^™ genes. Therefore, the 
association o f mTOR with pol Ill-transcribed genes is specific.
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Figure 4.9 Rapator co-immunoprecipiates with TFIIIC.
A31 mouse fibroblasts were treated with Rapamycin (lOOnM) or vehicle control for 
4 hours. Whole cell extracts from these cells were immunoprecipitated with anti- 
TFIIICl 10 antibody or pre-immune (control). Precipitates were resolved by SDS- 
PAGE and immunoblotted with anti-raptor antibody.
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Figure 4.10 mTOR is associated with poi Ill-transcribed genes.
ChlPs were performed on asynchronous A31 mouse fibroblast cells using 
antibodies against acetylated mTOR and TFIIA (negative control). The samples 
were then analysed by PCR, alongside genomic DNA (10%, 2% and 0.4% of
Leuinputs), using 5S rRNA and tRNA gene primers
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4.3 Discussion
These results suggest that mTOR directly regulates the expression o f pol Ill-transcribed 
genes through a direct interaction with pol I ll’s transcriptional machinery. The data also 
suggest that there are a number of differences in the regulation o f pol I and pol III by 
mTOR.
Repression o f mTOR by rapamycin resulted in no change in the abundance o f TFIIICI10, 
TFIIIB and pol III at the protein level. Consistent with this, knockout of TSC resulted in 
no change in the abundance o f pol III, TFIIIB, TFIIIC220 and TFIIICI02. However, 
TFIIICI 10 was elevated in the TSC2‘^ ' MEF knockouts, compared to the wild type 
TSC2'^ '^  ^ MEFs. As previously suggested, this may reflect the two conditions observed, 
demonstrating a short and a long-term effect o f mTOR regulation. Rapamycin was used 
to inhibit mTOR over a period o f 4 hours, whereas the knockout o f TSC2 is a permanent 
effect. This would be consistent with a previous study where 24 hours o f rapamycin 
treatment resulted in a decrease in abundance o f UBF (a pol I transcription factor). By 
comparison, rapamycin treatment for 3 hours had no effect on the abundance o f UBF 
(Hannan et al., 2003). Therefore, a prolonged period where mTOR activity is altered can 
change the abundance of specific transcription factors.
The abundance o f pol III transcription factors is elevated in a number of transformed 
cells. More specifically, TFIIIC has been shown to be elevated in fibroblasts that were 
transformed by SV40 and the polyomavirus (Felton-Edkins and White, 2002). In ovarian 
tumours there is also an increase in the abundance o f TFIIIC, which is thought to promote 
the expression of pol Ill-transcribed genes (Winter et ah, 2000). Both studies
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demonstrated that all five components o f TFIIIC were overexpressed in the conditions 
observed (Felton-Edkins and White, 2002; Winter et ah, 2000). However, the results 
gained here are more consistent with the model where TFIIIC activity is regulated by the 
relative abundance o f just one TFIIIC subunit, TFIIICI 10 (Kovelman and Roeder, 1992; 
Sinn et al., 1995). As previously stated, TFIIIC was reported to be present in two forms, 
with or without TFIIICI 10, dubbed TFIIIC2a and TFIIIC2b, respectively (Hoeffler et ah, 
1988; Kovelman and Roeder, 1992). TFIIlC2a is able to support transcription whereas 
TFIIIC2b is not (Hoeffler et ah, 1988; Kovelman and Roeder, 1992). When TSC2 is 
knocked out you see an increase in the abundance of TFIIICI 10. This could promote a 
rise in the ratio of active TFIIIC2a compared to inactive TFIIIC2b, which increases the 
expression o f pol Ill-transcribed genes.
TFIIIC2a and TFIIIC2b have similar DNA-binding affinities (Hoeffler et ah, 1988; 
Kovelman and Roeder, 1992). Therefore, loss o f TFIIICI 10, should not affect the 
promoter occupancy o f the remaining subunits o f TFIIIC (TFIIIC220, TFIIICI02, 
TFIIIC90 and TFIIIC63). However, as shown in the previous chapter, the promoter 
occupancy o f both TFIIIC220 and TFIIICI 10 change in response to the presence or 
absence o f TSC2. This may suggest an alternative mode o f TFIIIC regulation, whereby 
the promoter occupancy o f more than one TFIIIC subunit is affected by the presence o f 
TSC2.
Previous studies in yeast have established that TOR can regulate the activity o f 
transcription factors through their cellular localization (Beck and Hall, 1999; Mayer et
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al., 2004). For example, TOR controls the transcription factor Gln3 through its cellular 
localization (Beck and Hall, 1999). Under nutrient rich conditions, TOR phosphorylates 
Ure2p, a cytoplasmic protein that binds and sequesters Gln3 in the cytoplasm. 
Rapamycin induces the dephosphorylation of Ure2p which disrupts its interaction with 
Gln3, allowing Gln3 to translocate into the nucleus (Beck and Hall, 1999). In 
mammalian cells, the cellular localization o f TIF-IA is controlled by mTOR (Mayer et 
al., 2004). During rapamycin repression, TIF-IA  translocates to the cytoplasm, thus 
inhibiting the expression o f pol I-transcribed genes (Mayer et al., 2004). In this study, 
the cellular localization o f pol III and its transcription factors appear to be unaffected by 
the presence or absence o f rapamycin. Therefore, mTOR probably does not control the 
expression of pol III transcripts genes via the cellular localization o f its transcriptional 
machinery.
Zaragoza et al. found that pol III and probably TFIIIB are under control o f  TOR in yeast 
(Zaragoza et ah, 1998). These authors speculated that TOR regulates TFIIIB and pol III 
through PP2A (Zaragoza et al., 1998). This was based on a previous yeast study, which 
found that mutations in the regulatory subunit o f PP2A reduced the transcription o f tRNA 
through inhibition of TFIIIB and pol III at the non-permissive temperature (Van Zyl et 
al., 1992). Furthermore, PP2A is very rapidly activated by rapamycin (Hartley and 
Cooper, 20002). Therefore, Zaragoza et al. proposed that inhibition o f TOR activates 
PP2A, which dephosphorylates and activates a repressor of TFIIIB and/or pol III 
(Zaragoza et ah, 1998). Other reports in yeast have highlighted the importance o f Mafl 
(a repressor of pol Ill-transcribed genes) as a key component for rapamycin repression o f
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pol Ill-transcribed genes (Oficjalska-Pham et al., 2006; Roberts et al., 2006; Upadhya et 
al., 2002a). M afl becomes dephosphorylated after the addition of rapamycin (Oficjalska- 
Pham et al., 2006; Roberts et al., 2006). This allows Mafl to accumulate in the nucleus 
where it binds to pol Ill-transcribed genes and inhibits their expression (Oficjalska-Pham 
et al., 2006; Roberts et al., 2006). Déphosphorylation is carried out by PP2A (Oficjalska- 
Pham et al., 2006), which reinforces the claims made by Zaragoza et al.. However, I 
found that repression of pol III activity by rapamycin was not reversed by the PP2A 
inhibitors okadaic acid and calyculin A. Pol III activity in asynchronously grown cells, 
which are not treated with rapamycin, are not affected by repression of PP2A. This is in 
contrast to mitotic cells, where inhibition of PP2A represses pol III (Fairley et al., 2003).
mTOR regulation o f rRNA gene transcription requires S6K (Hannan et al., 2003). 
Expression of a constitutively active, rapamycin-insensitive mutant o f S6K stimulated 
rRNA gene expression and rescued rapamycin repression o f rRNA gene transcription 
(Hannan et al., 2003). As pol I and pol III are often regulated by similar mechanisms 
(White, 2005), regulation o f pol III by mTOR was expected to require S6K. However, 
knockdown of S6K1 and S6K2 had no effect on the presence of pol III transcripts. 
Consistent with previous studies (Flannan et ah, 2003; Mayer et ah, 2004; Zhang et ah, 
2005), knockdown o f S6K1 and S6K2 resulted in a decrease in the expression o f the pol I 
transcript. Therefore, knockdown of S6K1 and S6K2 represses pol I but not pol III 
activity, highlighting a difference in the regulation o f these two polymerases. This does 
not rule out S6K as a regulator o f pol III, as there is a high level o f redundancy between 
S6K1 and S6K2 (Pende et ah, 2004; Shima et ah, 1998), For example, deletion o f the
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S6K1 gene leads to a compensatory increase in the expression of S6K2 (Shima et ah, 
1998). Thus, future studies will require simultaneous knockdown o f both S6K1 and 
S6K2 to determine if redundancy is masking the effect o f S6K1 and S6K2 on pol III 
activity.
Histone acétylation plays an important role in the regulation o f  gene expression and 
maintenance o f chromatin structure. An increase in histone acétylation is often correlated 
with the transcriptional activation o f the gene it is associated with. A decrease in 
acétylation is often correlated with transcriptional repression. Previous studies in yeast 
have shown that the expression o f  both pol I and pol 11 transcribed ribosomal genes are 
regulated in a chromatin-mediated manner by TOR (Rohde and Cardenas, 2003; Tsang et 
al., 2003). Both studies highlighted the importance o f histone H4 acétylation (Rohde and 
Cardenas, 2003; Tsang et al., 2003). However, in this present study, acétylation o f 
histone H3 changed in response to the inhibition o f mTOR or when TSC2 was knocked 
out. The change in histone H3 acétylation is consistent with that o f the transcriptional 
response. For example, inhibition o f mTOR causes a decrease in the presence of pol III 
transcripts, which is correlated with a decrease in histone H3 acétylation. Knockout o f 
TSC2, results in an increase in pol III activity that is seen in parallel with an increase in 
histone H3 acétylation. Therefore, histone H3 acétylation appears to change in parallel to 
the expression o f pol Ill-transcribed genes.
Although histone acétylation may provide a potential mechanism for the control o f pol III 
by mTOR, it cannot be the whole story. This is demonstrated by the in vitro transcription
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assay performed in the previous chapter (figure 3.2). This assay is performed on a naked 
DNA template, where no histones are incorporated into the template. Extracts from cells 
pre-treated with rapamycin showed that the inhibition of mTOR reduced pol I ll’s 
transcriptional activity on this naked DNA template. Therefore, mTOR can control pol 
III through a chromatin-independent mechanism.
Phosphorylation plays an important role in mTOR’s ability to regulate transcription 
factors. As stated previously, phosphorylation o f pol I transcription factors by mTOR is 
in part mediated by the kinase S6K (Hannan et al., 2003). mTOR can also directly 
phosphorylate other transcription factors. An example of this is the transcription factor 
STATl (signal transducer and activator o f transcription-1), which binds directly to 
mTOR (Kristof et al., 2003). STATl belongs to a family o f transcription factors that 
remain in a latent form in the cytoplasm. They become active following phosphorylation, 
leaving the cytoplasm and entering the nucleus where they regulate a number o f target 
genes (White, 2001a). This is consistent with mTOR being predominantly localized in 
the cytoplasm. However, a small fraction of mTOR is found within the nucleus at steady 
state (Kim and Chen, 2000). Therefore, mTOR could regulate pol III activity through 
direct interaction with components o f the pol III transcriptional machinery. Indeed, 
Raptor, a component o f the mTOR complex, has been found to co-immunoprecipitate 
with TFIIIC in this study. Raptor acts as a scaffold protein that facilitates mTOR’s 
interaction with its substrates. Oshiro et al. demonstrated that raptor is required 
absolutely for the mTOR-catalysed phosphorylation of 4E-BP1 in vitro (Hara et ah, 
2002). Thus, raptor could mediate an interaction o f TFIIIC with mTOR. Although
106
mTOR itself has not been co-immunoprecipitated with TFIIIC as yet, mTOR was found 
to be associated with pol III transcribed genes in a ChIP assay. This creates the 
possibility that mTOR regulation of pol III could be through a direct interaction with a 
component of the pol III transcriptional machinery.
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Chapter 5-The role of
acétylation in the regulation 
of pol Ill-transcribed genes
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5.1 introduction
The previous chapter highlighted a potential role for histone acétylation in the regulation 
o f pol III. More specifically, acétylation o f histone H3 was shown to change in response 
to mTOR activity. Therefore, this chapter will look more closely at acétylation and the 
role that it plays in the regulation o f pol III transcription.
5.1.1 Chromatin
Chromatin structure can be altered so that it produces a more open or closed state, 
whereby it is more or less permissive to transcription. Regulation o f chromatin structure 
is mediated through a number o f different covalent modifications that exit on histone 
tails; modifications include phosphorylation, ubiquitination, ADP-ribosylation, 
méthylation and acétylation. Two domains have been identified that bind to either 
acetylated or methylated histone tails marks; these are known as bromodomains and 
chromodomains, respectively (Cruz et al., 2005). Proteins containing bromo- or 
chromodomains can alter nucleosomal structure by utilising energy from ATP hydrolysis 
or via the addition of new covalent modifications. This can be achieved through their 
direct activity or the recruitment o f other proteins that catalyse these processes. These 
observations led to the histone code hypothesis, where different combinations of covalent 
modifications on histone tails provide binding sites for a variety of proteins that convert 
chromatin to either a repressed or active state (Strahl and Allis, 2000).
The most characterized modification is acétylation, catalysed by histone acetyltransferase 
(HAT) enzymes. This modification is a reversible process as a number of histone
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deacetylases (HDAC) have been characterized (DeRuijter et ah, 2003). Acétylation is 
generally associated with activation, whereas a lack o f acétylation tends to correlate with 
repression. The action o f HDACs and HATs is not restricted to histones, as a large 
number o f other proteins are acetylated; many of these proteins are transcription factors. 
For example, the HAT TIP60 acetylates UBF, a component o f the pol I transcriptional 
machinery (Halkidou et ah, 2004). TIP60 is localized to sites of newly synthesized 
rRNA (Halkidou et al., 2004). Its presence is correlated with an increase in the levels of 
histone H4 acétylation (Halkidou et al., 2004), a marker o f transcriptional activation. 
Thus, acétylation can control expression o f genes through acétylation o f both histone tails 
and the acétylation o f transcription factors.
5.1.2 Chromatin and pol III
Effects o f histones on pol III transcription cannot easily be defined, as they vary 
considerably between its various templates. Middle repetitive genes such as B2 and Alu 
are strongly repressed by chromatin, whereas the opposite can be said for tRNA, where 
chromatin appears to have a negligible effect (Russanova et al., 1995). 5S rRNA
templates have been shown to respond to alterations in levels of the linker histone HI 
(Bouvet et al., 1994; Kandolf, 1994). During Xenopus embryo development, the 
injection o f mRNA encoding histone HI results in considerable repression of oocyte 5S 
rRNA gene expression (Bouvet et al., 1994). The opposite effect is observed when 
histone HI is depleted using ribozymes, resulting in an increase in the expression o f these 
genes (Bouvet et ah, 1994; Kandolf, 1994). Neither of these histone manipulations has
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an effect on transcription o f tRNA and somatic rRNA genes (Bouvet et al., 1994; 
Kandolf, 1994).
Alus are repetitive elements, constituting a major part of the human genome, numbering 
1,090,000. This potentially creates an extensive sink for transcription factors and a 
tremendous transcriptional potential. However, this potential is not realised, as Alu 
transcripts are usually very low in tissue and cultured cells (Liu et al., 1994; Sinnett et al., 
1992). Much of this can be attributed to chromatin-mediated repression. Histone 
octamers in both reconstituted systems and in native chromatin are positioned over Alu 
transcriptional start site and A block regions of their promoters (Englander and Howard, 
1995; Englander et al., 1993). This decreases the accessibility o f DNA to transcription 
factors, diminishing the expression o f Alus. In HeLa cells -99%  of potentially active Alu 
repeats are silenced by chromatin, whereas the same HeLa chromatin preparations 
showed that the vast majority of tRNA and 5S rRNA genes remain unaffected by 
chromatin (Russanova et ah, 1995). The B2 middle repetitive family (a murine tRNA 
derived gene) is also transcriptionally repressed by chromatin (Russanova et al., 1995). 
Depletion of HI increases B2 transcription by ~ 17-fold in 3T3 cells (Russanova et al., 
1995). By comparison, in HeLa cells removal o f HI only gives a -2  fold increase in Alu 
transcription (Russanova et al., 1995). This demonstrates that between families 
chromatin-mediated repression o f pol Ill-transcribed genes can vary.
In comparison to Alus, tRNA gene transcription seem to be relatively unaffected by 
chromatin-mediated repression. Expression o f the SUP4 tRNA^^"  ^gene in yeast can even
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take place when nucleosome-positioning signals are fused to its promoter, so that the 
predicted nucleosome would incorporate the transcriptional start site and the A block 
(Morse et ah, 1992). This is the nucleosome positioning observed in Alu repeats. 
However, nucleosomes were only observed at these predicted points when the SUP4 
tRNA^^"  ^ gene is transcriptionally inactivated by mutations in the B box o f the internal 
promoter (Morse et al., 1992). Thus, transcriptionally active tRNA genes are able to 
override nucleosome positioning in vivo. Furthermore, an in vitro reconstituted human 
tRNA chromatin template was relieved o f chromatin-mediated repression by highly 
purified TFIIIC (Kundu et ah, 1999). Other studies have changed histone composition by 
removing histone HI from murine chromatin, or histone H4 from yeast. Neither o f these 
manipulations had a significant effect on tRNA transcription (Han and Grunstein, 1988; 
Russanova et al., 1995).
Promoter integrity o f the U6 gene is important in its ability to overcome nucleosome- 
mediated repression. Deletion o f the histone H4 gene in yeast does not promote the 
expression of U6 transcription (Marsolier et al., 1995). However, when the same deletion 
was made with a mutant U6 promoter, there is an increase in the level o f U6 transcription 
(Marsolier et al., 1995). Characterization o f the promoter has revealed that a functional B 
block is required to overcome nucleosome repression, due to its ability to bind TFIIIC 
(Burnol et al., 1993b). This interaction allows TFIIIC to displace nucleosomes from the 
template, allowing transcription (Burnol et al., 1993a). Furthermore, binding o f TFIIIC 
to the promoter leads to remodelling o f chromatin found on U6 genes in an ATP-
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dependent fashion (Shivaswamy et al., 2004). Chromatin remodelling facilitates a more 
open state allowing transcription to take place.
TFIIIC has been proposed to have a histone-specific acetyltransferase activity. Previous 
studies have demonstrated that TFIIIC can acetylate both free and nucleosomal H3 and 
H4, as well as nucleosomal H2A. This activity was attributed to the subunits TFIIICI 10, 
TFIIIC220 (Kundu et al., 1999) and TFIIIC90 (Hsieh et al., 1999a; Kundu et al., 1999) o f 
the TFIIIC complex. TFIIIC90 predominately acetylates both free and nucleosomal H3, 
preferentially acetylating lysine 14 on the N-terminal tail (Hsieh et al., 1999a). 
Therefore, recruitment o f TFIIIC promotes transcription of its target genes through the 
acétylation o f histone tails.
TFIIIC plays an important role in relieving chromatin-mediated repression of pol Ill- 
transcribed genes. This is perhaps o f no surprise, as in most cases TFIIIC is the first 
component o f the pol III transcriptional machinery to make contact with DNA. This 
initial step may therefore convert pol Ill-transcribed genes from closed to an open state, 
allowing expression o f the gene to take place.
To look at the role o f TFIIIC as a HAT, a TFIIICI 10 inducible cell line will be used. As 
previously stated, TFIIIC exits in two forms, with or without the TFIIICI 10 subunit, 
dubbed TFIIIC2a and TFIIIC2b, resectively (Kovelman and Roeder, 1992; Sinn et al., 
1995). Although both forms produced identical footprints, the complex without 
TFIIICI 10 was unable to support transcription (Hoeffler et al., 1988; Kovelman and
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Roeder, 1992). This led to the model where the activity o f TFIIIC could be regulated by 
its interaction with TFIIICI 10. Interaction might be controlled by the abundance o f 
TFIIIC 110. This potential mechanism was suggested as expression o f TFIIICI 10 is 
diminished under low serum conditions in HeLa cells, whereas TFIIÏC220 levels are 
unchanged (Sinn et al., 1995). In parallel, low serum conditions also led to a decrease in 
the ratio o f active TFIIIIC2a to inactive TFIIIC2b (Sinn et al., 1995). Experiments in 
chapter 4 have shown that expression o f TFIIIC 110 is elevated in TSC2 ‘^" MEF 
knockouts, whereas the levels of TFIIIC220 and TFIIIC 102 are unaltered. This was 
correlated with a rise in the expression o f pol Ill-transcribed genes and an increase in 
histone H3 acétylation. Thus, selective expression of TFIIICI 10 may provide a 
mechanism for controlling TFIIIC activity. Furthermore, TFIIICI 10 along with 
TFIIIC220 and TFIIIC90 have been proposed to have HAT activity (Hsieh et al., 1999a; 
Kundu et al., 1999).
Experiments in this chapter will focus on the role o f acétylation in the regulation of pol 
III transcriptiion. This will be done using the drug trichostatin A (TSA), a potent HDAC 
inhibitor (Jung, 2001). Leading on from this, a TFIIICI 10-inducible cell line was used to 
see if  overexpression o f TFIIIC led to an increase in the expression o f pol Ill-transcribed 
genes. In parallel, changes in histone acétylation were observed on these genes.
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5,2 Results
5.2.1 TSA promotes pol III transcriptional activity
To determine the general effect o f acétylation, the HDAC inhibitor trichostatin A (TSA) 
was used. TSA is thought to mimic the acetyl-lysine side chain and thereby inhibit 
HDACs (Jung, 2001). Asynchronous A31 mouse fibroblasts treated with TSA for 6, 12, 
24 and 48 hours. RT-PCR analysis revealed a bi-phasic response, where transcript levels 
o f tRNA^" and B2 had two peaks at 6 and 24 hours compared to the vehicle treated 
control cells (figure 5.1). At 12 hours the levels of both tRNA^^" and B2 were similar to 
that o f the vehicle control treated cells. 5S rRNA transcripts do not display an increase 
after 6 hours o f TSA treatment. Instead, expression is only elevated after 24 hours o f 
TSA treatment. This is probably due to the fact that the primers are designed for the 
mature 5S rRNA, and the half-life o f 5S rRNA is relatively long. By comparison, B2 has 
a relatively short half-life (Bladon et al., 1990). The primers for tRNA^^" are designed to 
detect the unspliced tRNA^®“ precursor; this allows the detection o f newly synthesised 
tRNA^®“ (Gomez-Roman et al., 2003). Thus, B2 and tRNA^^" provide a more direct 
indication o f transcriptional output compared to 5S rRNA. These effects are specific, as 
levels o f the pol II transcribed control ARPP PO mRNA remain unaltered by TSA.
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Figure 5.1. TSA produces two peaks of pol III transcripts.
RNA was harvested from A31 mouse fibrobroblasts treated with TSA (lOOnM) for 
6, 12, 24 and 48 hours (lanes 2-5) or vehicle control hours (lane 1). RNA was 
analysed by RT-PCR for the expression of 5S rRNA, B2, tRNA^^, and ARPP PO 
mRNA(control).
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As previously stated, in vitro transcription assays are performed on naked DNA, where 
no histones are incorporated onto the template. Therefore, performing this assay with 
extracts treated with TSA should demonstrate if TSA has an effect independent of histone 
acétylation. Asynchronously grown A31 mouse fibroblasts were treated with TSA for 6, 
12 and 24 hours. An in vitro transcription assay was performed using extracts derived 
from these cells and extracts from vehicle-treated control cells to measure pol IITs 
activity in response to TSA. After 6 hours o f TSA treatment there was an increase in pol 
III transcriptional activity (figure 5.2). However, the activity o f pol III after 12 and 24 
hours o f TSA treatment was comparable to the vehicle-treated control.
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Figure 5.2. TSA increases pol I l l ’s transcriptional activity only after 6 hours of 
treatment.
Whole cell extracts were made from A 31 mouse fibroblasts treated with vehicle (lane 
1) or TSA (200nM) for 6, 12 and 24 hours (lanes 2-4). ISpg of extract was used in an
in vitro transcription assay using a tRNA 
(250ng) gene template.
lÆU (250ng), 5S rRNA (250ng) and 7SL
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5.2.2 TSA promotes the recruitment of TFIIIB and pol III to the promoter
The addition of TSA caused an increase in the expression of pol Ill-transcribed genes. 
Past studies have shown that the promoter occupancy of transcription factors is elevated 
during TSA treatment (Kwon et a l ,  2006). Therefore, a ChIP assay was used to 
determine the effects o f acétylation on the promoter occupancy o f the pol III 
transcriptional machinery. Formaldehyde cross-linked chromatin was prepared from 
asynchronously growing A31 mouse fibroblasts treated for 0, 6, 12 and 24hrs with 
200nM TSA. Antibodies against RPC 155 (a component o f pol III), TFIIICI 10 and the 
TFIIIB subunit Brfl were used to determine their occupancy. To assess changes in 
histone acétylation, an anti-acetyl H3 and an anti-acetyl H4 antibody were used. TFIIA 
was used as a negative control, as it is not present on pol Ill-transcribed genes. PCR 
analysis showed that the promoter occupancy o f pol III and TFIIIB (Brfl) were elevated 
after 6 hours of TSA treatment on tRNA^^“ and 5S rRNA genes (figure 5.3), In contrast, 
the promoter occupancy o f TFIIIC remains unchanged after the addition of TSA. In 
parallel to changes in the promoter occupancy o f TFIIIB and pol III, an increase in the 
acétylation o f  histone H3 and H4 were observed. Thus, TSA increases the promoter 
occupancy of TFIIIB and pol III and the acétylation o f histone H3 and H4 on pol Ill- 
transcribed genes.
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Figure 5.3 TSA promotes the promoter ooccupancy of TFIIIB, pol III, but not 
TFIIIC
Promoter occupancy of pol 111, TFIIIB and TFIIIC, along with histone acétylation was 
measured in TSA-treated A31 mouse fibroblasts. Cells were treated with TSA 
(200nM) for 6, 12 and 24 or with vehicle. ChlPs were performed using antibodies 
against acetylated histone H3, acetylated histone H4, TFIIICI 10, Brfl (a component 
of TFIIIB), RPC 155 (pol 111) and TFIIIB (negative control). Samples were 
normalized by comparing the genomic DNA inputs and adjusting the samples 
accordingly. The samples were then analysed by PCR, alongside genomic DNA 
(10%, 2% and 0.4% of input), using 5S rRNA and tRNA^^" primers (n=2).
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5.2.3 TSA does not affect the level of the pol III transcriptional machinery
The increase in promoter occupancy of TFIIIB and pol III in response to TSA might be as 
a direct result o f changes in abundance o f pol 111 and TFIIIB. Therefore, western blot 
analysis of extracts treated for 0, 6, 12 and 24hrs with 200nM TSA was used to measure 
the levels o f these transcription factors. No change in the abundance o f TFIIICI 10, 
TFIIIB (Brfl) and pol III (RPC 155) is detected after the addition o f TSA (figure 5.4). By 
comparison, levels o f acetylated histone H3 and acetylated histone H4 are elevated after 6 
hours o f TSA treatment.
5.2.4 P300 and TIP60 mildly promote pol III activity
TSA promotes the accumulation of acetylated proteins through the repression of HDACs. 
However, HATs are required for acétylation to take place in the first instance. To 
investigate the role of HATs in the expression of pol Ill-transcribed genes, recombinant 
HATs PCAF, p300 and TIP60 were used in an in vitro transcription assay. Recombinant 
p300, TIP60 and PCAF were pre-incubated for 15 minutes with A31 whole cell extract. 
An in vitro transcription assay was then subsequently performed. p300 and TIP60 mildly 
promoted the expression o f 7SL and tRNA^""" genes in a dose-dependent manner, 
whereas PCAF if anything had a repressive effect on pol III activity (figure 5.5). This 
would suggest that p300 and TIP60 stimulate the activity o f pol III through the 
acétylation of non-histone targets, as in vitro transcription assays are performed on naked 
DNA.
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Figure 5.4. Levels o f pol III, TFIIICI 10 and the Brfl subunit of TFIIIB are 
unaffected by TSA treatment.
A31 mouse fibroblasts were treated with TSA (200nM) for 6, 12, and 24 hours 
(lanes 2-4) or with vehicle (lane 1) for 4 hours. Whole cell extracts from these 
cells was resolved on SDS-PAGE. Western blotting was performed with 
antibodies against Brfl, TFIIICI 10, RPC 155, acetyl H3, acetyl H4 and actin.
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Figure 5.5. HATs p300 and T1P60 have a mild stimulatory effect on pol I l l ’s 
transcriptional activity 15pg o f whole cell extracts were made from A 31 mouse 
fibroblasts were pre-treated with 2, 1, and 0.5pl o f HATs PCAF (lanes 2-4), TIP60 
(lanes 10-12) and p300 (lanes 6-8) or with vehicle control (lanes 1, 5 and 9). An in
vitro transcription assay was performed using a tRNA 
template to measure the effects o f these HATs.
l^u (250ng) and 7SL (250ng)
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5.2.5 Induction of HA-TFIIICllO had no effect on poi III transcriptional activity
To look at the role o f TFIIIC as a HAT, a TFIIICI 10 inducible cell line was used. This 
was obtain from co-worker Fiona Innes (Innes et al., 2006). TFIIIC 110 cDNA was sub- 
cloned into pTRE2hyg, which carries a doxycycline-responsive promoter. This was 
stably transfected into HeLa cells, where addition o f doxycyline induces the expression 
o f HA-TFIIICllO. Expression o f HA-TFIIICllO was confirmed through western blot 
analysis (figure 5.6). An empty vector control cell line was used to demonstrate that the 
band detected is HA-TFIIICl 10 and not a non-specific effect o f doxycyline.
An in vitro transcription assay was performed to see if  the overexpression o f HA- 
TFIIICl 10 had an effect on the activity o f pol 111. Extract made from doxycyline-treated 
HA-TFIIIC 110-inducible and control cell lines were used in an in vitro transcription 
assay. No change in the transcription o f 7SL and tRNA’"™ genes was observed using cell 
extracts from the inducible cell line before or after the addition o f doxycyline (figure 5.7).
In vitro transcription assays are performed on naked DNA templates, where no histones 
are incorporated into the template. Therefore, an effect o f histone acétylation on 
transcription would be lost in such an assay. RT-PCR analysis was performed to see the 
effect o f HA-TFIIICllO induction in vivo. The levels of both 5S rRNA and tRNA’"^ " 
transcripts are unaffected by the overexpression of HA-TFlIICllO (figure 5.8). 
However, TFIIICI 10 transcripts are elevated when HA-TFIIICllO is induced.
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Figure 5.6. HA-TFIIICllO induction results in an increase of HA-TFlIICllO at 
the protein level
The abundance o f HA-TFIIICl 10 was measured using a HA-TFIIIC 110 inducible cell 
line (lanes 3 and 4). Cells were either untreated (-) (lanes 1 and 3) or induced with 
doxycyclin (+) (lanes 2 and 4). A control cell line containing an empty vector was 
also used (lanes 1 and 2). Protein extracts from these cells were resolved on SDS- 
PAGE, and western blotting was performed with antibodies to the HA tag and actin.
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Figure 5.7. Induced expression of HA-TFIIICllO had no effect on pol III 
transcriptional activity.
The effect o f TFIIICl 10 on the level o f pol 111 transcription was measured using a HA- 
TFIIICI10 inducible cell line (lanes 3 and 4). Cells were either untreated (-) (lanes 1 
and 3) or induced with doxycyclin (+) (lanes 2 and 4). A control cell line containing an 
empty vector was also used (lanes 1 and 2). Whole cell extracts were made from these 
treated cell lines. 15pg o f  extract was used in an in vitro transcription assay using a
LeutRNA " (250ng) and 7SL (250ng) template.
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Figure 5.8. Induced expression of HA-TFIIICllO had no effect on the levels of 
pol III transcripts
The effect of TFIIICl 10 on the level of pol 111 transcripts was measured using a HA- 
TFIIICl 10 inducible cell line (lanes 3 and 4). Cells were either untreated (-) (lanes 1 
and 3) or induced with doxycycline (+) (lanes 2 and 4). A control cell line containing 
an empty vector was also used (lanes 1 and 2). RNA was analysed by RT-PCR for the 
expression of 5S rRNA, tRNA^", TFIIICl 10 and ARPP PO mRNA(control).
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5.2.6 Induction of HA-TFIIICllO had no effect on the recruitment of the pol III 
transcriptional machinery
Chip analysis was used to verify that exogenous HA-TFlIICllO is present on pol Ill- 
transcribed genes. Formaldehyde cross-linked chromatin was prepared from the ITA- 
TFIIICllO inducible cell line along with the control cell line grown either in the presence 
or absence o f doxycyline. Antibodies against TFIIIC 110, TBP and the HA epitope were 
used. A TFIIB antibody was used as a negative control. HA-TFIIICl 10 is detected on 
tRNA^^“ and 5S rRNA, but not at the gene encoding TFIIIC220, which was used as a pol
II-transcribed negative control (figure 5.9). However, the promoter occupancy o f total 
TFIIICl 10 (both HA-TFIIICllO and endogenous TFIIICl 10 combined) remains 
unaffected by the induction o f HA-TFIIICl 10 on 5S rRNA and tRNA^" genes.
Chip experiments were also performed to determine if the induction o f HA-TFIIICl 10 
had any effect on the promoter occupancy of pol III and TFIIIB. Antibodies against 
RPC155 (a subunit o f pol III), TFIIICl 10 and Brf (a component o f TFIIIB) were used. 
Promoter occupancy o f pol III and TFIIIB are unaffected by the induction of HA- 
TFIIICl 10 on 5S rRNA and tRNA^^" genes (figure 5.10). Consistent with the previous 
Chip, promoter occupancy of total TFIIICl 10 remained unchanged after the induction o f 
HA-TFIIICl 10.
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Figure 5.9. HA-TFIIICl 10 is found at the promoter of pol Ill-transcribed 
genes
The level o f TFIIIC/HA-TFIIICI10 promoter occupancy was measured in a HA- 
TFIIICI10 inducible cell line. Cells were either untreated (-) or induced with 
doxycycline (+).A control cell line containing an empty vector was also used. 
ChlPs were performed using antibodies against TFIIICl 10, HA, TBP and TFIIA 
(negative control). Samples were normalized by comparing the genomic DNA 
inputs and adjusting the samples accordingly. The samples were then analysed by 
PCR, alongside genomic DNA (10%, 2% and 0.4% of input), using 5S rRNA,
LeutRNA^“ and TFIIIC220 primers.
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Figure 5.10. Induction of HA TFIIICl 10 had no effect on the promoter occupancy 
of pol HI and TFIIIB
The level o f histone acétylation was measured in a HA-TFIIICl 10 inducible cell line. 
Cells were either untreated (-) or induced with doxycycline (+). A control cell line 
containing an empty vector was also used. ChlPs were performed using antibodies 
against acetylated histone H3, acetylated histone H4, RPC 155 (pol 111) and TFIIA 
(negative control). Samples were normalized by comparing the genomic DNA inputs 
and adjusting the samples accordingly. The samples were then analysed by PCR, 
alongside genomic DNA (10%, 2% and 0.4%of input), using 5S rRNA and tRNA^" 
primers.
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5.2.7 Induction of HA-TFIIICl 10 had no effect on the acétylation of histone H3 and 
H4 found on pol Ill-transcribed genes
A third ChIP using the inducible cell line was used to see if  the overexpression o f HA- 
TFIIICllO had an effect on the acétylation o f histone tails found on pol Ill-transcribed 
genes. To assess changes in histone acétylation, an anti-acetyl H3 and an anti-acetyl H4 
antibody were used. In addition, an antibody against acetyl histone H3 Lysl4  was used 
to see if  this specific lysine residue was acetylated by the induction o f HA-TFIIICl 10. 
Lysine 14 on histone H3 tails is reported to be a specific target o f TFIIIC’s HAT activity 
(Hsieh et al., 1999a). PCR analysis revealed that acétylation of histone H3 is unaffected 
by the induction of HA-TFIIICl 10 (figure 5.11). Acétylation o f histone H4 was shown 
to increase when HA-TFIIICl 10 was induced. However, the same effect was obseiwed 
when doxycycline was added to the control cell line. Therefore, this may reflect a 
doxycycline effect. Consistent with the previous ChIP, the promoter occupancy o f pol III 
was also unaffected by this induction.
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Figure 5.11. Induction of HA-TFIIICl 10 had no effect on the acétylation of 
histones H3 and H4 on pol Hl-transcribed genes
The level o f histone acétylation was measured in a HA-TFIllCl 10-inducible cell line. 
Cells were either untreated (-) or induced with doxycycline (+). A control cell line 
containing an empty vector was also used. ChlPs were performed using antibodies 
against acetylated histone H3, acetylated histone H4, acetylated histone H3 lysine 14, 
RPC 155 (pol HI) and TFIIA (negative control). Samples were normalized by 
comparing the genomic DNA inputs and adjusting the samples accordingly. The 
samples were then analysed by PCR, alongside genomic DNA (10%, 2% and 0.4% of 
input), using 58 rRNA and tRNA*^“.
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5.3  Discussion
Data from this chapter suggest that pol III is regulated by acétylation. Treatment o f cells 
with the HDAC inhibitor TSA resulted in an increase in the acétylation o f histone found 
on pol Ill-transcribed genes. Furthermore, a hi stone-free in vitro transcription assays 
showed that pol III activity was elevated in extracts treated with TSA, demonstrating that 
acétylation o f a non-histone target is important.
TSA produced different effects in in vitro transcription assays and RT-PCRs. Both 
assays show an increase in the expression o f pol Ill-transcribed genes after 6 hours o f 
TSA treatment. Flowever, RT-PCR analysis reveals a second peak at 24 hours, which is 
not observed in the in vitro transcription assay. It would be easy to suggest that this is a 
histone effect, as in vitro transcription assays are performed on naked DNA. However, 
TSA is a potent drug and over a 24-hour time a number of secondary effects will take 
place. Therefore, these results should be viewed with caution and only suggest that 
acétylation is important for pol III activity in both a histone and histone-free 
environment.
Previous studies have shown that both histone and factor acétylation play important roles 
in the regulation o f gene transcription (Glozak et al., 2005; Strahl and Allis, 2000). In 
this study, addition o f TSA increased the promoter occupancy of both pol III and TFIIIB. 
This was seen in parallel with an increase in the level o f histone H3 and histone H4 
acétylation. Much o f the previous work on histone acétylation and transcription has been 
purely correlative and has not identified a direct link. A number of studies have
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developed in vitro models where the effect o f histone acétylation on transcription can be 
measured (An et al., 2004; An et al., 2002). In this case there is no direct evidence to say 
that histone acétylation is directly regulating the expression of pol Ill-transcribed genes. 
However, it can be viewed as a marker for transcriptional activation. This is reinforced 
by the results from chapter 4 where rapamycin caused a decrease in the levels of histone 
H3 acétylation was observed.
TSA promotes the accumulation o f acetylated histone through the repression of HDACs. 
However, HATs are needed in the first instance to facilitate this acétylation. Both histone 
H3 and histone H4 have elevated levels o f acétylation in response to TSA. This response 
would suggest that HATs capable o f acetylating histone H3 and histone H4 are recruited 
onto pol Ill-transcribed genes. HATs often show a level of specificity for lysines on 
histone tails in vivo (Lachner et al., 2003). Therefore, further work is needed to 
characterize which HATs and specific lysines are involved in this process.
There are two HDAC protein families: the SIR2 family of NAD’^ -dependent HDACs, and 
the classical HDAC family (which includes HDAC 1-10) (DeRuijter et ah, 2003). TSA 
inhibits the latter of these two families by blocking access to their active site (DeRuijter 
et ah, 2003). As pol III activity is increased by TSA, the classical HDAC family must 
therefore repress the expression o f pol Ill-transcribed genes either directly or indirectly. 
This is in contrast to pol I transcription which is also regulated by acétylation but is not 
affected by the addition of TSA (Muth et ah, 2001). The SIR2 family of HDACs
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regulates pol I, whereas the classical HDAC family regulates the expression of pol Ill- 
transcribed genes.
Initial studies concerning the role o f acétylation focused on its effects on core histones. 
In addition to histone, a number o f other targets have been identified including 
transcription factors. The recombinant HATs used in this study, p300, TIP60 and PCAF, 
have all been shown to acetylate transcription factors (Halkidou et al., 2004; Muth et al., 
2001; Perrot and Rechler, 2005). Furthermore, TIP60 and PCAF have been implicated in 
the acétylation and regulation o f pol I transcription factors (Halkidou et al., 2004; Muth et 
al., 2001). This present study demonstrates that both p300 and TIP60 mildly promote the 
expression of pol Ill-transcribed genes. This was demonstrated in an in vitro 
transcription assay where no histones are present on the DNA template. Therefore, p300 
and TIP60 regulate the activity of pol III through the acétylation o f a non-histone target. 
Targets could include components o f the pol III transcriptional machinery, although 
further work is needed to address this suggestion. The results o f this experiment do not 
rule out the possibility that PCAF still may regulate the expression o f pol Ill-transcribed 
genes. PCAF could potentially regulate pol III activity through its classical target of 
histone tails.
Previous reports have proposed TFIIICl 10 as the limiting component for transcription by 
pol III. Its relative abundance was thought to control the ratio o f active TFIIIC2a to 
inactive TFIIIC2b in HeLa cells (Sinn et al., 1995). Therefore, specific induction of 
TFIIICl 10 in HeLa cells should be sufficient to stimulate the expression o f pol III-
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transcribed genes. However, data in this chapter do not support this idea. Induction o f 
HA-TFIIIC 110 does not increase the expression of pol Ill-transcribed genes, seen in both 
RT-PCR analysis and in vitro transcription assays. Furthermore, overexpression of HA- 
TFIIICl 10 had not effect on the promoter occupancy o f TFIIIC, pol III and TFIIIB. 
Work from this study on the induction of HA-TFIIICl 10 combined with that o f a co­
worker Fiona Innes has now been published (Innes et al,, 2006).
Experiments carried out by Kovelman et al. demonstrated that purified TFIIIC was only 
able to support transcription when TFIIICl 10 was part o f this complex (Kovelman and 
Roeder, 1992), highlighting TFIIICl 10 as an essential component for transcription by pol 
III. This present study does not disprove this idea; instead it demonstrates that in HeLa 
cells, TFIIICl 10 is not the rate-limiting component for pol III transcription. Hoffler et al. 
showed that treating TFIIIC2a with a phosphatase could generate TFIIIC2b (Hoeffler et 
al., 1988). Therefore, phosphorylation could be regulating the interaction o f TFIIICl 10 
with the remainder o f the TFIIIC complex.
The idea that TFIIICl 10 is a limiting factor for the expression o f pol Ill-transcribed genes 
is based on correlative data. When HeLa cells are grown in the presence of El A or high 
serum, transcription by pol III is elevated. In parallel, relatively high ratios o f TFIIIC2a 
to TFIIIC2b and o f TFIIICl 10 to TFIIIC220 are observed (Hoeffler et al., 1988; 
Kovelman and Roeder, 1992; Sinn et al., 1995). As TFIIICl 10 is not the rate-limiting 
component for transcription by pol III in HeLa cells, other mechanisms may account for 
pol III regulation under these circumstances. For example, E l A can overcome RB-
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mediated repression o f pol III transcription, both in vivo and in vitro (White et ah, 1996). 
Serum leads to the phosphorylation and inactivation RB, which promotes pol III activity 
(Scott et ah, 2001). Furthermore, pol III is directly activated by c-Myc and Erk (Felton- 
Edkins et ah, 2003a; Gomez-Roman et ah, 2003), both o f which are serum-inducible. 
These alternative mechanisms may go some way to explain pol I ll’s regulation by E l A 
and serum.
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Chapter 6-The role of 
histone méthylation in the 
expression of pol Ill- 
transcribed genes
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6.1 Introduction
The previous chapter focused on the role o f histone and factor acétylation and how this 
covalent modification contributes to the regulation o f pol Ill-transcribed genes. A 
number of other covalent modifications exist on histone tails, which are also thought to 
regulate gene expression. One such modification, méthylation, has recently become the 
focus o f intense research due to the characterization o f a number o f proteins that regulate 
its presence on histone tails (Huang et ah, 2006; Klose et ah, 2006; Tsukada et ah, 2006). 
This chapter will look at the presence o f this covalent modification on pol Ill-transcribed 
genes.
6.1.2 Histone méthylation
Histone méthylation occurs on both lysine and arginine residues (Lachner et ah, 2003). 
Méthylation o f these two amino acids correlates with the formation of heterochromatin, 
x-chromosome inactivation and transcriptional regulation. Lysine méthylation can either 
signal for a repressed or active transcriptional state (Lachner et ah, 2003). This is in 
contrast to acétylation, which generally correlates with transcriptional activation. 
Furthermore, there is an additional level o f regulation, lysine can either be mono-, di-, or 
trimethylated (Lachner et ah, 2003). Méthylation is also seen as a more stable 
modification, frequently having a half-life in a time-scale of hours. It is thought that this 
may contribute to histone memory, where inheritance of this epigenetic mark takes place 
following replication (Bannister et ah, 2002).
Five lysine residues on histone H3 can be methylated (K4, K9, K27, K36 and K79) 
(Lachner et ah, 2003). Histone H3 lysine 4 (H3 Lys'^) and histone H3 lysine 9 (H3 Lys^)
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are perhaps the best studied o f these modifications and are known to have opposing roles 
(Liang et al., 2004; Nakayama et al., 2001). H3 Lys"^  méthylation is associated with 
transcriptional activation, whereas H3 Lys^ méthylation is associated with transcriptional 
repression and the assembly o f heterochromatin (Liang et al., 2004; Nakayama et aï., 
2001). As previously stated, chromodomain proteins bind to methylated histone tails. 
One such protein, HPl binds to methylated H3 Lys^. HPl participates in chromatin 
packaging and gene silencing by directing the binding of other proteins that control 
chromatin structure and gene function (Lachner et al., 2001). Another prominent 
example o f a chromodomain protein is Chdl (chromo-ATPase/helicase-DNA binding 
domain 1). Chdl is a chromatin remodelling protein that recognizes methylated H3 Lys"^  
(Pray-Grant et al., 2005). It is a component o f SAGA (Spt-Ada-Gcn5 acetyltransferases) 
and SLIK (SAGA-like) complexes, which preferentially acetylate histones H3 and H2B. 
The presence o f Chdl is associated with transcriptional activation (Pray-Grant et al., 
2005). Thus, Chdl and HPl form part o f the histone code hypothesis, where different 
covalent modifications on histone tails provide binding sites for a variety of proteins that 
convert chromatin to either a repressed or active state.
6.1.2 AIu histone méthylation
Previous studies have highlighted a role for histone méthylation on pol III-transcribed 
Alu genes (Hakimi et al., 2002; Kondo and Issa, 2003). Kondo and Issa demonstrated 
that Alus are enriched for H3 Lys^ méthylation (Kondo and Issa, 2003). This would 
suggest that Alus have a low level of expression, as K9 is associated with transcriptional 
silencing (Lachner et al., 2001). Indeed, Alu transcript levels are usually very low in
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tissue and cultured cells (Liu et al., 1994; Sinnett et al., 1992), even though Alus 
constitute a major part of the human genome, numbering over a million copies. 
Chromatin is known to have a prominent role in the repression of Alus, as in HeLa cells 
-99%  o f potentially active Alu repeats are silenced by chromatin, whereas the vast 
majority of tRNA remain unaffected by chromatin (Russanova et al., 1995). A direct link 
between H3 Lys* méthylation and the repression of Alu transcription by chromatin has
yet to be determined.
6.1.3 Histone méthylation, a reversible process
Work over recent years has led to the discovery o f a number of proteins that regulate 
histone méthylation. Suv39h was the first histone methyltransferase to be identified (Rea 
et ah, 2000). It catalyzes the méthylation o f H3 Lys", creating a high-affmity binding site 
for the chromodomain protein H Pl (Lachner et ah, 2001). The methyltransferase activity 
o f Suv39h is mediated through a highly conserved structure known as the SET domain. 
Analysis o f the human genome has shown that there are a total o f 73 SET-domain 
proteins (Kouzarides, 2002). Identification of this domain led to the discovery o f a 
number of other histone methyltransferases, including the protein Setl (the yeast 
homologue of mammalian MLL) (Milne et ah, 2002). Setl forms part o f a larger 
complex called COMPASS (complex of proteins associated with Setl) (Schineider et ah, 
2005). Past studies have shown that Setl is responsible for the méthylation of H3 Lys 
(Milne et ah, 2002; Schneider et ah, 2005). Thus, Suv39h and Setl are two prominent 
examples o f proteins that methylate specific lysines on histone tails.
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For a number of years méthylation has been seen as an irreversible process as previous 
studies reported that the half-life o f methylated lysine and histones are the same (Byvoet, 
1972; Duerre and Lee, 1974). This idea is consistent with heterochromatin, where 
histone méthylation could mediate ‘permanent’ transcriptional silencing. However, 
recent work has identified a number o f histone demethylases, demonstrating that this 
mark is reversible (Klose et al., 2006; Shi et al., 2004; Tsukada et al., 2006). LSDl 
(lysine specific demethylase 1) was the first o f these to be characterized (Shi et al., 2004). 
It specifically demethylates both mono- and dimethylated H3 Lys'^ (Shi et al., 2004). 
Following on from this work, a new family o f histone demethylases have been identified 
containing the so called Jmjc domain (Klose et al., 2006; Tsukada et al., 2006; Whetstine 
et al., 2006; Yamane et al., 2006). A member o f this family, JMJD2A, has been the first 
demethylase identified to remove a trimethylated lysine mark (Klose et al., 2006; 
Whetstine et al., 2006). Thus, histone méthylation can now be viewed as a reversible 
process where demethylases can remove mono- di- and trimethylated histone marks.
Thus far, limited work has been carried out on the role o f histone méthylation on pol Ill- 
transcribed genes. Therefore, this chapter will investigate the dynamics of histone 
méthylation on pol Ill-transcribed genes. Work will focus on H3 Lys"  ^ and H3 Lys^ 
méthylation and how these modifications relate to gene expression.
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6.2 Results:
6.2.1 Poï Ill-transcribed genes contain H3 Lys'* méthylation.
Initial experiments were performed to look at the pattern of histone méthylation found on 
pol Ill-transcribed genes. ChIP samples were obtained from Nicol Keith’s lab. The 
University o f Glasgow. Levels o f H3 Lys'* and H3 Lys^ di- and trimethylation were 
examined in an ovarian carcinoma cell line (A2280) and a bladder cancer carcinoma cell 
line (5637) (figure 6.1). PCR analysis o f the two cells lines revealed that all pol Ill- 
transcribed genes observed had a high level o f H3 Lys"* trimethylation. A lower level of 
H3 Lys'* dimethylation was also observed in 5637 cells on 5S rRNA, 7SL, tRNA^® and 
U6 gene, but this was not observed in A2280 cells. Neither cell line displayed much H3 
Lys^ méthylation. A2280 cells had a low level o f H3 Lys^ dimethylation on 5S rRNA, 
7SL and tRNA*^^  ^ genes, whereas 5637 cells had a faint level o f H3 Lys^ trimethylation 
on 5S rRNA genes.
A second ChIP looking at the same modifications was performed comparing WI-38 lung 
fibroblasts to transformed C-33A cervical carinoma cells (figure 6.2). Again, samples 
were obtained from Nicol Keith’s lab, the University o f Glasgow. PCR analysis showed 
that all genes observed had an elevated level o f H3 Lys'* di- and trimethylation in the 
transformed C-33A compared to the untransformed WI-38. However, no H3 Lys^ 
méthylation was observed in either cell line.
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Figure 6.1 A high level of trimethylted H3 Lys'* is found in both ovarian 
carcinoma and bladder carcinoma cell lines
Histone méthylation on pol Ill-transcribed genes was observed in ovarian carcinoma 
(A2280) and bladder carcinoma (5637) cell lines. ChlPs were performed using 
antibodies against di- and trimethylted H3 Lys'* and H3 Lys .^ Samples were 
normalized by comparing the genomic DNA inputs and adjusting the samples 
accordingly. The samples were then analysed by PCR, using 58 rRNA, tRNA*^", 
tRNA'^ '^ *, 7SL and U6 primers (n=l).
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Figure 6.2 Trimethylted H3 Lys'* is elevated in transformed cervical cancer cells 
compared to human lung fibroblasts
Histone méthylation on pol Ill-transcribed genes was observed in human lung 
fibrioblasts (Wi38) and cervical cancer cells (C33a). ChlPs were performed using 
antibodies against di- and trimethylted H3 Lys'* and H3 Lys .^ Samples were 
normalized by comparing the genomic DNA inputs and adjusting the samples 
accordingly. The samples were then analysed by PCR, using 5S rRNA, tRNA*^", 
tRNA'^ *^, 7SL and MRP primers (n=l).
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6.2.2 Myc has a negligible effect on histone méthylation found on pol Ill-transcribed 
genes
A recent study has shown that Myc influences global chromatin structure through 
alteration in histone méthylation and acétylation (Knoepfler et al., 2006). As previously 
stated, Myc has been shown to regulate the expression o f pol Ill-transcribed genes 
(Gomez-Roman et al., 2003). Therefore, rat lA  c-myc-/- knockout cells were compared 
to wildtype rat lA cells in a ChIP assay to see if Myc has an effect on histone 
méthylation on pol Ill-transcribed genes (figure 6.3). Antibodies against K4 
trimethylated histone H3 and K9 trimethylated histone H3 antibody were used to measure 
changes in méthylation. An antibody designed against TFIIB was used as a negative 
control. The presence o f histone H3 K4 méthylation is unaltered by the presence or 
absence of c-Myc on the genes encoding tRNA*^“, 5S rRNA and B2. H3 Lys^ 
méthylation appears to be very mildly diminished in the rat lA  c-myc-/- knockout when 
compared to wiltype rat lA  on the genes encoding 5S rRNA and B2. Thus, the presence 
or absence of Myc had very little effect on the méthylation o f H3 Lys'* and H3 Lys^ on 
pol Ill-transcribed genes.
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Figure 6.3 Trimethylated H3 Lys'* and H3 Lys’ on pol Ill-transcribed genes is 
comparable in wild type and myc null cells.
Histone méthylation was compared between rat 1A Myc '^' knockout and rat 1A wildtype
fibroblasts 
Lys'* and H3 Lys’
A Chip assay was performed using antibodies against trimethylated H3 
TFIIB was used as a negative control. Samples were normalized by 
comparing the genomic DNA inputs and adjusting the samples accordingly. The 
samples were then analysed by PCR, alongside genomic DNA (10%, 2% and 0.4%),
using 5S rRNA, tRNA*^" and B2 primers (n=2).
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6.2.3 TSA does not alter the histone méthylation pattern on pol Ill-transcribed 
genes
HATs and histone methyltransferases have been shown to cooperate together in 
modifying nucleosomal histones. Acétylation o f lysines on a histone tail can promote the 
méthylation o f another residue (An et al., 2004). To determine if  acétylation could alter 
the pattern o f histone méthylation found on pol Ill-transcribed genes, a ChIP assay using 
TSA was performed (figure 6.4). Asynchronous A31 mouse fibroblasts cells were treated 
with TSA (200nm) for 6, 12 and 24 hours. Antibodies against trimethylated H3 Lys'* and 
H3 Lys’ were used to measure changes in méthylation. A TFIIB antibody was used as a 
negative control. TSA had no effect on the méthylation o f H3 Lys'* and H3 Lys’ on 5S 
rRNA, tRNA*^^ and B2 genes. However, a different pattern of méthylation was observed 
on the three genes. tRNA*^ ®“ genes have a higher level of H3 Lys'* méthylation compared 
to H3 Lys’ méthylation. The opposite can be said for B2, which have a high level o f H3 
Lys’ méthylation compared to H3 Lys'* méthylation. The genes encoding 5S rRNA have 
a similar amount o f H3 Lys'* and H3 Lys’ histone méthylation. Thus, pol Ill-transcribed 
genes display different patterns o f histone méthylation.
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Figure 6.4 TSA does not alter the pattern of trimethylated H3 Lys'* and H3 Lys’ 
on pol Ill-transcribed genes.
A31 cells were treated with TSA (200nM) for 6, 12, and 24 hours (lanes 2-4) or with 
vehicle (lane 1). ChlPs were performed using antibodies against trimethylated H3 
Lys'* and H3 Lys’. TFIIB was used as a negative control. Samples were normalized 
by comparing the genomic DNA inputs and adjusting the samples accordingly. The 
samples were then analysed by PCR, alongside genomic DNA (10%, 2% and 0.4%),
Leuusing 5S rRNA, tRNA and B2 primers
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6.2.4 Aïu genes contain a high level of pol III promoter occupancy and H3 Lys’ 
méthylation
A previous study has shown that Alus are enriched for H3 Lys’ méthylation (Kondo and 
Issa, 2003). The presence o f this mark was thought to be a marker for the transcriptional 
repression o f Alus. Therefore, a high level o f H3 Lys’ méthylation should correlate with 
a low pol III promoter occupancy. To test this idea, formaldehyde cross-linked 
chromatin was prepared from asynchronously growing HeLa cells (figure 6.5). 
Antibodies against RPC 155 (a component o f pol III), TFIIICl 10 and the TFIIIB subunit 
Brfl were used to determine the promoter occupancy o f the pol III transcriptional 
complex. To assess the levels of histone acétylation and méthylation, antibodies against 
acetyl H3, acetyl H4, K4 trimethylated histone H3 and K9 trimethylated histone H3 were 
used. A TFIIB antibody was used as a negative control, as TFIIB is not present on pol
Ill-transcribed genes. Consistent with previous data in this chapter (figure 6.4), genes 
encoding tRNA*^™ showed a greater level o f H3 Lys'* méthylation compared to H3 Lys’ 
méthylation. Furthermore, 5S rRNA genes have a similar amount o f H3 Lys'* and H3 
Lys’ méthylation. As expected, both genes have pol III, TFIIIB and TFIIIC present. 
Single Alu genes on different chromosomes were looked at to measure to presence or 
absence of H3 Lys'* and H3 Lys’ méthylation. O f the 6 single copy Alu genes looked at, 
5 had a greater level o f H3 Lys’ méthylation compared to H3 Lys** méthylation. 
However, apart from the Alu on chromosome 6, all had pol III present. Additionally, H3 
Lys'* méthylation was found on all the Alu genes looked at.
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Figure 6.5 Alu genes contain trimethylated H3 Lys^ and H3 Lys’.
A Chip assay was performed using HeLa cells. Antibodies were used against 
acetylated histone H3, acetylated hi stone H4, trimethylated H3 Lys"*, trimethylated 
H3 L ys\ TFlllCl 10, Brfl (a component of TFlllB), RPC 155 (pol 111) and TFllB 
(negative control). The samples were then analysed by PCR, alongside genomic 
DNA (10%, 2% and 0.4% o f input) using 5S rRNA, tRNA*^“, Alu chromosome 6, 
Alu chromosome 8, Alu chromosome 10, Alu chromosome 19, Alu chromosome 20, 
and Alu chromosome 22 primers (n=2).
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6.2.5 The promoter occupancy o f the pol III transcriptional complex is correlated 
with histone méthylation
Results from this chapter demonstrate that pol Ill-transeribed genes have both H3 Lys"^  
and H3 Lys^ méthylation along with pol III and its associated factors TFIIIB and TFIIIC. 
A problem with conventional ChIP assays is that they do not tell you if  two proteins are 
found together or separately. This is because the result gained is hom  a pool o f cells. 
For instance, when looking at a single gene half the cells might have a high level o f H3 
Lys^ méthylation and no pol 111 present, whereas the other half might have no H3 Lys^ 
méthylation and a high level o f pol III. When the two sets o f cells are pooled in a ChIP 
assay it would appear that both methylated H3 Lys^ and pol III are found on the same 
gene, it does not discriminate between the two sub populations o f cells. This becomes 
even more o f a problem when you are looking at multi-copy genes at the same time. 
Therefore, a sequential ChIP was performed to determine if  pol 111, TFIIIB and TFllIC 
are found on genes that contain methylated H3 Lys'^ or H3 Lys^. Formaldehyde cross- 
linked chromatin was prepared from asyiichronously growing HeLa cells. Antibodies 
against trimethylated H3 Lys'^and trimethylated H3 Lys^ were used along with a 4E-BP1 
antibody which was used as a negative control. This primary immmunoprecipitation 
separates two subpopulations o f genes that contain trimethylated H3 Lys"^  or H3 Lys^. 
The material gained from the first set o f immunoprécipitations was then subject to a 
second immunoprécipitation using antibodies against trimethylated H3 Lys" ,^ 
trimethylated H3 Lys^, RPC 155 (a component of pol 111), TFIIIC 110 and the TFIIIB 
subunit B rfl. Thus, PCR analysis o f the second immunoprécipitation should demonstrate
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if  components of the pol III transcription machinery are present at the same gene as either 
trimethylated H3 Lys"^  or H3 Lys^.
ChlPs using HeLa cells have shown that genes encoding 5S rRNA have an equal level of 
trimethylated H3 Lys"^  or H3 Lys^. Therefore, immunoprécipitations using trimethylated 
H3 Lys'^ or H3 Lys^ antibodies will contain an equal amount o f the 5S rRNA gene. By 
subjecting this material to a second round o f immunoprécipitations using an antibody 
against pol III you should be able to determine which modification has more pol III 
associated with it on genes encoding 5S rRNA. Thus, sequential ChlPs in this instance 
provide a powerful tool for looking at promoter occupancy in relation to histone tail 
modifications. The sequential ChIP described here was performed (figure 6.6). More pol 
III was associated with trimethylated H3 Lys'^ compared to trimethylated H3 Lys^. 
Further sequential ChlPs were performed using antibodies against Brfl (a component of 
TFIIIB) (figure 6.7) and TFIIIC 110 (figure 6.8), instead o f pol III. A similar pattern is 
observed in these experiments, with there being more TFIIIB and a small increase in 
TFIIIC associated with trimethylated H3 Lys'^ compared to trimethylated H3 Lys^.
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Figure 6.6 Pol III promoter occupancy is associated with the presence of 
trimethylated H3 Lys^.
To look at the correlation between histone méthylation and the promoter occupancy of 
TFIIIB a sequential ChIP was performed, (a) A primary immunoprécipitation was 
performed using antibodies against trimethylated H3 Lys'* and H3 Lys .^ 4EBP-I was 
used as a negative control. Material from the primary immunoprécipitation was then 
subject to a second immunoprécipitation using antibodies against RPC 155 (a 
component of pol III), trimethylated H3 Lys"* and H3 Lys .^ 4EBP-I was again used as 
a negative control. The samples were then analysed by PCR using 5S rRNA primers, 
(b) Results from the second immunoprécipitation were quantified. Fold enrichment 
was obtained by dividing the intensity of the band by that of the background (4EBP-I) 
(n=2).
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Figure 6.7 TFIIIB promoter occupancy is associated with the presence of 
trimethylated H3 Lys'*.
To look at the correlation between histone méthylation and the promoter occupancy of 
TFIIIB, a sequential ChIP was performed, (a) A primary immunoprécipitation was 
performed using antibodies against trimethylated H3 Lys"^  and H3 Lys^ 4EBP-I was 
used as a negative control. Material from the primary immunoprécipitation was then 
subject to a second immunoprécipitation using antibodies against Brfl (a component 
of TFIIIB), trimethylated H3 Lys'* and H3 Lys^ 4EBP-I was again used as a negative 
control. The samples were then analysed by PCR using 5S rRNA primers, (b) Results 
from the second immunoprécipitation were quantified. Fold enrichment was obtained 
by dividing the intensity of the band by that of the background (4EBP-I) (n=2).
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Figure 6.8 TFIIIC promoter occupancy is associated with the presence of 
trimethylated H3 Lys^.
To look at the correlation between histone méthylation and the promoter occupancy 
of TFIIIC, a sequential ChIP was performed, (a) A primary immunoprécipitation 
was performed using antibodies against trimethylated H3 Lys'^  and H3 Lys .^ 4EBP-I 
was used as a negative control. Material from the primary immunoprécipitation was 
then subject to a second immunoprécipitation using antibodies against TFIIIC 110, 
trimethylated H3 Lys  ^ and H3 Lys .^ 4EBP-I was again used as a negative control. 
The samples were then analysed by PCR using 5S rRNA primers, (b) Results from 
the second immunoprécipitation were quantified. Fold enrichment was obtained by 
dividing the intensity of the band by that of the background (4EBP-I) (n=2).
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6.2.6 H3 Lys'  ^or H3 Lys® méthylation on pol III genes are not mutually exclusive
Sequential ChlPs were also performed to see if  trimethylated H3 Lys'^ and trimethylated 
H3 Lys® were mutually exclusive or could be found on the same 5S rRNA genes (figures 
6.6, 6.7 and 6.8). Again formaldehyde cross-linked chromatin was prepared from 
asynchronously growing HeLa cells. Antibodies against trimethylated H3 Lys"^  and 
trimethylated H3 Lys® were used. Both immunoprécipitations were then subject to a 
second immunoprécipitation using the same trimethylated H3 Lys"* and trimethylated H3 
Lys® antibodies. PCR analysis revealed that when trimethylated H3 Lys"  ^is found on 58 
rRNA genes, trimethylated H3 Lys® is also present but to a lesser degree. However, there 
is little trimethylated H3 Lys^ found on genes that have been immunoprecipitated with 
trimethylated H3 Lys® in the first instance. Conversely, this may reflect the 
immunoprécipitation efficiency of the two antibodies used. Alternatively the result 
obtained could be from a group o f genes as 58 rRNA genes occur in clusters. Thus, there 
could be a 58 rRNA gene with H3 Lys"^  méthylation and no H3 Lys® méthylation, and 
another 58 rRNA gene with H3 Lys® méthylation and no H3 Lys"^  méthylation which are 
found in close proximity to each other. The resolution of a ChIP may not stringent 
enough to differentiate between these two 58 rRNA genes, therefore, the result gained is 
from a combination o f a number o f genes.
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6.3  Discussion:
Results from this chapter have shown that both H3 Lys^ and H3 Lys® méthylation are 
present on pol III-transcribed genes. Different genes show different patterns o f H3 Lys"^  
and H3 Lys® méthylation and the presence o f these marks is correlated with the promoter 
occupancy o f TFIIIB, TFIIIC and pol III.
Methylated H3 Lys"^  is predominantly associated with the promoters o f transcriptionally 
active genes (Liang et al., 2004), whereas methylated H3 Lys® is associated with inactive 
heterochromatin (Nakayama et ah, 2001). Sequential ChIP data from this present study is 
consistent with these observations, as there is a greater promoter occupancy o f pol III, 
TFIIIB and TFIIIC associated with H3 Lys"^  méthylation compared to H3 Lys® 
méthylation on genes encoding 5S rRNA. Thus, a correlation is observed between 
methylated histone marks and the promoter occupancy o f the pol III transcriptional 
machinery. Sequential ChlPs also highlighted the possibility that H3 Lys"^  and H3 Lys® 
méthylation are not mutually exclusive on the same 5S rRNA gene. A past study using 
the sequential ChIP technique has also shown that both H3 Lys"^  and H3 Lys® méthylation 
can be found on the same gene (Vakoc et ah, 2005). They found that H3 Lys® 
méthylation actually increased during activation of transcription and was associated with 
elongation by pol II on the (3-major globin gene (Vakoc et ah, 2005). Furthermore, a 
recent study has shown that H3 Lys"^  méthylation is required for the repression o f a pol II 
transcribed rRNA gene (Briggs et ah, 2006). This was shown to be dependent on the 
activity o f the FI3 Lys"^  methylatransferase, SET I (Briggs et ah, 2006). Therefore, the
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black and white image o f active H3 Lys^ méthylation and inactive H3 Lys méthylation 
appears to be changing.
Comparison o f WI38 and C33A cells have shown that histone H3 Lys"^  méthylation is 
elevated in a transformed cell line when compared to an untransformed cell line. Indeed, 
previous studies have shown that global changes in histone méthylation are associated 
with cancer and that these changes are predictive of the clinical outcome (Seligson et ah,
2005). More specifically, H3 Lys^ méthylation has been shown to change on specific 
genes during ovarian carcinogenesis (Caslini et ah, 2006). However, the cell lines used 
in this study are from different tissues and may have different patterns of méthylation 
independent o f their transformed state. Therefore, a more meaningful result would be 
obtained by comparing a single cell line before and after transformation.
Kondo and Issa found that Alus are enriched for methylated H3 Lys®, highlighting a 
potential mechanism that may repress the expression of these repetitive elements (Kondo 
and Issa, 2003). Another study has shown that methylated H3 Lys"^  was also present on a 
number o f Alus (Hakimi et ah, 2002). This present study is in agreement with these 
results as both methylated H3 Lys'^ and H3 Lys® were found to be present on Alu genes. 
However, pol III was present on the majority o f these genes, even when they displayed a 
high level of methylated H3 Lys® compared to methylated H3 Lys"^ , Alus constitute a 
major part o f the human genome, numbering 1,090,000. The vast majority of these genes 
were not expressed, as -99%  of potentially active Alu repeats are thought to be silenced
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by chromatin (Russanova et al., 1995). It seems unlikely that by chance all the Alus 
looked at in this study are being transcribed if work by Russanova et al. is correct. 
Therefore, the presence o f pol III on these genes represents a surprising result.
Histone méthylation has been shown to be associated with the binding o f a number o f 
different proteins that can alter chromatin structure (Cruz et ah, 2005; Pray-Grant et ah,
2005), making genes more or less permissive to transcription. Therefore, méthylation of 
histones found on pol Ill-transcribed genes may facilitate the recruitment of chromatin 
modifying enzymes that help control expression. Indeed, Hakimi et al. has shown that 
the present of methylated H3 Lys'^ on Alu genes is associated with the binding of the 
chromatin remodelling complex SNF2h-NuRD (Hakimi et ah, 2002). This may therefore 
provide a mechanism by which the expression of pol Ill-transcribed genes is controlled 
through histone méthylation. However, work by Hakimi et at. is purely correlative and 
further work is needed to see if the SNF2h-NuRD complex is required for the direct 
activation o f Alu gene transcription.
The different pattern of histone méthylation observed on pol Ill-transcribed genes may 
reflect their copy number within the genome. Results from this chapter demonstrate that 
genes eAlus and B2s have a high level o f H3 Lys® méthylation compared to H3 Lys"^  
méthylation. Both genes are repetitive elements; Alus number 1,090,000 in the human 
genome, whereas B2 genes number 328,000 in the mouse genome. However, not all 
these genes are active, as the majority of Alu and B2 genes are known to be repressed by
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chromatin (Russanova et a l ,  1995). Thus, the high level o f H3 Lys9 méthylation 
observed on these genes may in part mediate their transcriptional repression. Genes 
encoding 5S rRNA are also regulated by chromatin (Russanova et ah, 1995), but have a 
much lower copy number, ranging between 200-300 within the human genome. Results 
in this chapter have shown that genes encoding 5S rRNA in mouse fibroblast and HeLa 
cells, have a similar level of H3 Lys"^  and H3 Lys® méthylation. The higher level o f H3 
Lys"^  méthylation on 5S rRNA genes compared to genes encoding Alus could indicate 
that the former could proportionately have more active genes compared to the latter. 
Indeed, a past study has shown that chromatin has a much greater repressive effect on 
Alu genes compared to 5S rRNA genes (Russanova et al., 1995). Finally tRNA genes are 
relatively unaffected by chromatin (Kundu et al., 1999; Morse et al., 1992; Russanova et 
al., 1995) and have a low copy number compared to 5S rRNA, Alu and B2 genes, 
averaging 10 genes per amino acid tRNA adaptor. Experiments in this chapter have 
shown that tRNA genes have a high level o f H3 Lys"^  méthylation and almost no H3 Lys® 
méthylation. Thus, correlative data would suggest that the higher the copy number of pol 
Ill-transcribed genes the lower the H3 Lys"^  to H3 Lys® méthylation ratio. Conversely, a 
low copy number gene has a higher ration o f H3 Lys"^  to H3 Lys® méthylation. It may 
also suggest a reason why genes with a high copy number transcribed by pol III are 
highly repressed by chromatin whereas genes with a low copy number are not.
Under the conditions looked at, histone méthylation on pol Ill-transcribed genes does not 
change, A recent report has shown that Myc influences global chromatin structure 
through alterations in histone méthylation and acétylation (Knoepfler et al., 2006). Myc
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has previously been shown to regulate pol III activity (Gomez-Roman et al., 2003). 
Therefore, histone méthylation might provide a potential mechanism for Myc’s 
regulation of pol Ill-transcribed genes. However, histone méthylation was not found to 
change when comparing wild-type cells to Myc knockouts. Furthermore, addition of 
TSA, which has been shown to elevate the expression of pol Ill-transcribed genes 
(chapter 5) had no effect on the pattern of histone méthylation. Thus, alteration in the 
expression of pol Ill-transcribed genes either through histone acétylation or through the 
absence or presence o f Myc has no effect on the histone méthylation pattern observed on 
these genes. This may be consistent with the idea that in some cases histone méthylation 
is a permanent mark and may contribute to memory where inheritance o f this epigenetic 
mark takes place following replication (Bannister et al., 2002). This permanent mark 
may then make the histone more or less susceptible to an additional, reversible 
modification such as histone acétylation (Bannister et ah, 2002).
Data presented in this chapter has shown that histone méthylation varies between the 
different pol Ill-transcribed templates. Sequential ChlPs highlighted a correlation 
between histone méthylation and the presence o f the pol III machinery. Méthylation was 
not shown to change in the conditions looked at, suggesting a more permanent mark that 
is associated with epigenetic inheritance.
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Chapter 7-Final discussion
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Work from chapters 3 and 4 has shown that the mTOR pathway plays an important role 
in the regulation o f pol III activity. Furthermore, components o f the mTOR pathway, 
PKB, TSC2 and Rheb, were all shown to play a role in the regulation o f pol III. Histone 
acétylation was also shown to change in response to the activity o f mTOR, highlighting a 
potential mechanism for the regulation o f pol III. Work was then carried out on the 
general effect o f histone acétylation and méthylation, and what affect this had on the 
expression of pol Ill-transcribed genes.
7.1 mTOR regulates pol III
Addition of the mTOR inhibitor rapamycin decreased the expression of pol Ill- 
transcribed genes. This is only seen on type 1 and type 2 promoters, as previous work by 
Emma Graham has shown that rapamycin had no effect on U6 transcription. ChIP 
analysis revealed that the promoter occupancy of TFIIIB and pol 111 decreased in 
response to rapamycin treatment. TFIIIC’s promoter occupancy remained unchanged. 
Further ChlPs also demonstrated that mTOR is present on Pol Ill-transcribed genes. This 
would suggest that mTOR is controlling the expression of genes transcribed by pol 111 
through a direct mechanism. Previous work by Emma Graham (data unpublished) has 
shown that mTOR controls the phosphorylation o f TFIIIC 110. This was demonstrated in 
vivo, where addition of rapamycin led to a decrease in the phosphorylation o f TFIIIC 110. 
Preliminary work in this present study has shown that raptor, an essential component of 
the mTOR complex, was found to co-immunoprecipitate with TFIIIC 110. This led to the 
model where mTOR directly binds and phosphorylates the llOkDa subunit of TFIIIC,
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promoting its interaction with TFIIIB, which in turn elevates the expression o f pol Ill- 
transcribed genes.
A very recent study has speculated a similar mechanism for the control of pol I 
transcription in Saccharomyces cerevisiae (Li et al., 2006). ChIP analysis showed that 
Tori (a yeast homologue to mTOR) was found on the 35S rDNA promoter (Li et ah,
2006). This led to the authors speculating that binding may be important for the 
phosphorylation o f components o f the pol 1 transcriptional machinery by Tori (Li et ah,
2006). Experiments by Li et al. also characterized the presence o f Tori in the region 
between the enhancer and promoter elements o f the 35S rDNA gene. In S. cerevisiae, 
this region carries a gene encoding pol Ill-transcribed 5S rRNA. In agreement with work 
carried out in chapter 4, ChIP analysis showed that Tori was bound to 5S rRNA genes. 
Furthermore, the association o f Tori with 5S rRNA genes was diminished by the addition 
of rapamycin. This was thought to be controlled through cellular localization, as the 
addition of rapamycin led to the cytoplasmic retention of T o ri.
Future experiments are needed to characterize the response of the pol Ill-transcriptional 
machinery to rapamycin. ChIP experiments will be required to look at the promoter 
occupancy o f mTOR on pol Ill-transcribed genes during rapamycin treatment. Following 
on from this, the cellular localization of mTOR will need to be determined following 
rapamycin treatment, to see if there is conservation between the response observed in 
yeast and in mammalian systems. A previous study in mammalian cells has shown that 
mTOR has a predominant nuclear localization in a number of normal and malignant cell 
lines (Zhang et al., 2002). Furthermore, a separate study has shown that mTOR shuttles 
between the nucleus and the cytoplasm (Kim and Chen, 2000). This was demonstrated
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using leptomycin B, which is an inhibitor o f the nuclear export receptor Crml (Kim and 
Chen, 2000). Therefore, further work is needed to investigate these potential 
mechanisms and how they regulate the expression of pol Ill-transcribed genes. (See 
figure 7.1 for the proposed mechanism o f mTORs regulation of pol III).
7.2 PKB/Akt
Results from chapter 3 suggest that PKB may regulate the expression of pol Ill- 
transcribed genes direcetly. This was suggested by an in vitro transcription assay using a 
competitive substrate inhibitor for PKB. Addition o f this competitive inhibitor reduced 
the expression of tRNA^^" in a dose-dependent manner. PKB is a proto-oncogene 
(Bellacosa et al., 1991) and has been implicated in cell suiwival and cell cycle 
progression. This is achieved through its phosphorylation o f a number of key targets 
such as p53, forkhead transcription factors, BAD, caspase 9, p21 and p27 (Downward, 
2004). Its overexpression or over-activation is thought to play an important role in 
cancer (Besson et al., 1999; Mirza et al., 2000; Tang et al., 2006). PKB is activated by 
phosphatidylinositol 3 phosphates, the product o f phosphatidylinositol 3 phosphate kinase 
(P13K) (Wullschleger et al., 2006). PKB is commonly overactive in a number of 
different tumours because o f the frequent inactivation of the phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN) (Besson et al., 1999; Tang et al., 2006), 
which negatively regulates levels o f phosphatidylinositol 3 phosphate levels 
(Wullschleger et al., 2006). Furthermore, overexpression o f PKB transforms mammalian
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Figure 7.1 Proposed model of how mTOR regulates pol III transcription.
mTOR activity is controlled by growth factor and nutrient availability. Active mTOR 
translocates from the cytoplasm to the nucleus where it directly binds to TFIIIC on the 
promoter o f  pol Ill-transcribed genes (I). Once bound, mTOR phosphorylates TFIIIC 
(2), which promotes the recruitment o f  TFIIIB and pol III (3), allowing transcription to 
take place.
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cells in culture (Mirza et a l , 2000). Thus, PKB is an important regulator of cellular 
carcinogenesis.
PKB’s ability to regulate the expression o f pol Ill-transcribed genes may reflect its 
involvement in the mTOR pathway, as it has been shown to phosphorylate and inactivate 
TSC2 (Cai et al., 2006). PKB has also been shown to regulate the activity of a number of 
transcription factors. It is known to directly phosphorylate forkhead transcription factors 
(Brunet et al., 1999). Furthermore, it also regulates the activity o f the transcription 
factors p53 and NF-kB (Downward, 2004). Several papers have shown PKB becomes 
active and undergoes nuclear translocation upon growth factor stimulation (Borgatti et 
al., 2000; Wang and Brattain, 2006). Therefore, PKB could be regulating the expression 
o f pol Ill-transcribed genes through a direct phosphorylation event, which could be 
controlled by its cellular localization. Future experiments will be needed to determine the 
mechanism by which PKB regulates the expression of pol Ill-transcribed genes. An 
initial experiment will again use the substrate competitive inhibitor in an in vitro 
transcription assay using extract from cells that have previously been treated with 
rapamycin. This should help determine if  PKB is working through mTOR to regulate the 
expression o f pol Ill-transcribed genes in vitro.
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7.3 TSC2
Experiments carried out in chapters 3 and 4 demonstrated that TSC2 regulates the 
expression of genes transcribed by pol III. Knockout o f TSC2 results in an elevation in 
pol III transcription along with an increase in the promoter occupancy o f TFIIIC, TFIIIB 
and pol III. This is in contrast to rapamycin-treated cells, where the promoter occupancy 
o f TFIIIC was unaltered. Western analysis revealed that the llOkDa subunit o f TFIIIC 
was elevated in the TSC2 knockouts, whereas the other subunits remain constant. This is 
consistent with previous reports that have suggested that this subunit is the rate-limiting 
component o f pol III transcription (Hoeffler et al., 1988; Kovelman and Roeder, 1992; 
Sinn et al., 1995). Thus, TSC2 might regulate the expression of pol Ill-transcribed genes 
through the expression o f TFIIIC 110.
An inducible HeLa cell line was used to test the theory that TFlllC l 10 is the rate-limiting 
component o f pol III transcription. Results from chapter 5 demonstrated that induction o f 
HA-TFllICl 10 had no effect on the expression o f pol Ill-transcribed genes. This 
disputes the mechanism proposed in previous papers where TFlllC l 10 was suggested to 
be ‘the central controlling subunit for transcription by RNA polymerase IIT in HeLa cells 
(Sinn et al., 1995). Instead, B rfl, a component o f TFIIIB, has been shown to be the rate- 
limiting component. Its overexpression has been shown to induce the expression o f 58 
rRNA and tRNA^^" in HeLa cells (Innes et al., 2006). It should be remembered that TSC2 
was knocked out in MEF cells, whereas the overexpression o f TFIIIC 110 was performed 
in HeLa cells. However, work in chapter 5 has gone some way to dispel the idea that 
TFIIIC 110 is the rate-limiting component o f pol III transcription.
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Disruption of TSC2 function leads to the development o f tuberous sclerosis, 
characterized by the formation o f benign tumours in the central nervous system, kidney, 
heart, lung and skin (Mak and Yeung, 2004). Loss of TSC2 function in tumours results 
in the elevation of mTOR signalling (El-Hashemite et ah, 2003). Rodent models have 
shown that germline mutations within TSC2 result in the formation o f tumours that are 
sensitive to rapamycin treatment (Kenerson et ah, 2002). Thus, loss o f TSC2 function 
results in the formation of tumours, which is mediated through an elevation in the activity 
o f mTOR. Work in chapters 3 and 4 have shown that mTOR controls the expression of 
pol Ill-transcribed genes. Therefore, TSC2’s ability to control the expression o f pol Ill- 
transcribed highlights a novel role for this tumour suppressor
7.4 Rheb
Rheb acts downstream of TSC1/TSC2 and upstream of mTOR to regulate cellular growth 
(Inoki et al., 2003a). Work in chapter 3 demonstrated that the knockdown o f Rheb 
resulted in a decrease in the presence o f pol III transcripts. This, along with other data 
from chapters 3 and 4, would suggest that the knockdown o f Rheb causes a decrease in 
the activity o f mTOR, which leads to a reduction in the expression of pol Ill-transcribed 
genes.
Rheb is ubiquitously expressed in human tissue (Gromov et al., 1995) and plays a role in 
cellular transformation (Basso et al., 2005; Gromov et al., 1995; Mak and Yeung, 2004).
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Its expression has been shown to be upregulated in SV40-transformed cells (Gromov et 
al., 1995). Furthermore, as previously stated, Rheb is known to be regulated by the 
tumour suppressor TSC2 (Inoki et al., 2003a). Overexpression o f the TSCÎ/TSC2 
complex results in a decrease in the activity of Rheb (Inoki et al., 2003a). Rheb is also 
known to be a target for an anticancer drug, SCH66336 (Basso et al., 2005). SCH66336 
inhibits Rheb’s farnesylation, which is thought to be required for its membrane 
localization (Basso et al., 2005). Addition o f this drug reduces Rheb’s activity and 
results in a decrease in mTOR signalling which is correlated with the anti-tumour 
properties o f SCH66336 (Basso et al., 2005). Therefore, Rheb is an important factor in 
the control o f cellular growth and a target for cancer tr eatment.
7.5 S6K
Previous studies have shown that S6K, a kinase downstream of mTOR, regulates the 
expression of pol I-transcribed genes (Hannan et al., 2003). As pol I and pol III are 
regulated by similar mechanisms (White, 2005), it was thought that regulation o f pol III 
by mTOR might also require S6K. However, knockdown of either S6K1 or S6K2 had no 
effect on the expression o f pol Ill-transcribed genes, whereas the presence o f pol I 
transcripts was diminished, highlighting a difference in the regulation o f pol I and pol Ill- 
transcribed genes.
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7.6 Mafi and mTOR
mTOR coordinates cell growth with nutrient availability. Previous studies in yeast have 
shown that the addition of the mTOR inhibitor rapamycin reduces the expression o f pol 
III transcripts (Upadhya et al., 2002b). This effect is lost when MafI (a repressor o f pol 
III transcription) is deleted (Upadhya et al., 2002b). Cells that lack Mafi are also unable 
to repress the expression of pol Ill-transcribed when subjected to nutrient deprivation, 
DNA damage or oxidative stress (Desai et al., 2005; Upadhya et ai., 2002b). Thus, Mafi 
is a common component o f multiple signalling pathways that repress pol III transcription 
in yeast. Recent studies in yeast have shown that Mafi binds to pol Ill-transcribed genes 
(Oficjalska-Pham et al., 2006; Roberts et al., 2006). Furthermore, its binding is elevated 
after the addition of rapamycin, which is correlated with a decrease in the promoter 
occupancy o f TFIIIB and pol III (Oficjalska-Pham et al., 2006; Roberts et al., 2006). 
Results in chapter 3 show a similar response to rapamycin treatment with a decrease in 
the promoter occupancy o f both pol III and TFIIIB. Therefore, Mafi may be an 
important mediator o f the rapamycin response.
M afl’s activity is controlled through its phosphorylation (Oficjalska-Pham et al., 2006; 
Roberts et al., 2006). When cells are treated with rapamycin, Mafi becomes 
hypophosphorylated through the phosphatase PP2A (Oficjalska-Pham et al., 2006). This 
allows M afi to accumulate in the nucleus where it represses the expression o f pol Ill- 
transcribed genes (Oficjalska-Pham et al., 2006). However, work in chapter 4 has shown 
that rapamycin-mediated repression o f pol Ill-transcribed genes is not alleviated with the 
use of PP2A inhibitors. This preliminary result may reflect differences in response
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observed in yeast and mammalian systems, though further work is needed to look at this 
in greater detail.
Although homologues o f M afi have been discovered in higher eukaryotes (Pluta et al., 
2001) its cellular role thus far has only been reported in yeast. Therefore, future 
experiments will look at M afi to see if  it also represses the expression of pol Ill- 
transcribed genes in a mammalian system. ChIP analysis will be used to determine the 
promoter occupancy o f M afi on pol Ill-transcribed genes, to see if  it has a similar role to 
that observed in yeast. Current work, subsequent to the completion o f this thesis has 
indicated that M afi plays a pivotal role in the regulation of pol Ill-transcribed genes in 
response to rapamycin.
7.7 mTOR and histone acétylation
Chip assays in chapter 3 showed that the promoter occupancy o f pol III and TFIIIB is 
diminished when mTOR signalling is blocked by rapamycin. In parallel, there is a 
decrease in the level of histone H3 acétylation. Indeed, previous studies in yeast have 
shown that mTOR regulates the acétylation o f histones found on pol I-transcribed genes 
(Claypool et al., 2003; Tsang et al., 2003). Experiments in chapter 5 demonstrated that 
acétylation is important for the expression o f pol Ill-transcribed genes. Addition o f the 
HDAC inhibitor TSA led to an increase in the acétylation o f histone H3 and H4 and an 
elevation in the promoter occupancy o f TFIIIB and pol III. Therefore, on pol Ill- 
transcribed genes, correlative data suggest that the promoter occupancy of pol III and
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TFIIIB is elevated when there is an increase in the level o f histone acétylation. 
Consistent with this, histone acétylation is seen as a marker for transcriptional activation 
in many systems (Eberharter and Becker, 2002). Previous in vitro studies have also 
shown that the acétylation o f histone tails by HATs promotes transcriptional activation 
(An et al., 2004; An et al., 2002). Thus, mTOR might promote the expression o f pol Ill- 
transcribed genes through the recruitment o f  HATs.
Future experiments will look at the role o f histone acétylation and how this is affected by 
the inhibition o f the mTOR pathway. Work will focus on the recruitment of HATs and 
HDACs that are associated with histone H3 acétylation and deactylation. This will be 
carried out using ChIP assays to observe the promoter occupancy o f these proteins on pol 
Ill-transcribed genes in response to the activity o f mTOR.
7.8 Factor acétylation
The role o f acétylation is not confined to histones, as a number o f other proteins, 
including transcription factors, are known to be regulated by this covalent modification 
(Glozak et al., 2005). Work in chapter 5 using TSA demonstrated that acétylation has an 
effect on pol III activity on naked DNA templates where no histones are. This highlights 
a potential role for factor acétylation instead o f histone acétylation in the regulation of 
genes transcribed by pol III. Furthermore, use o f recombinant HATs in an in vitro 
transcription assay demonstrated that p300 and TIP60 mildly stimulate the expression o f 
pol Ill-transcribed genes. This would suggest that they are mediating their effects
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through factor acétylation instead of histone acétylation. Both p300 and TIP60 have 
previously been shown to acetylate transcription factors (Halkidou et al., 2004; Perrot and 
Rechler, 2005). Therefore, future work will focus on the role o f these HATs and their 
histone-independent function. ChIP assays will be used to determine if  they are found on 
pol Ill-transcribed genes. Co-immunoprécipitation will then be used to identify any 
potential target within the pol III transcriptional machinery.
7.9 Histone méthylation
Work in chapter 6 has shown that pol Ill-transcribed genes are associated both histone H3 
Lys"* and histone H3 Lys® méthylation. H3 Lys'  ^ méthylation is associated with 
transcriptionally active genes (Liang et al., 2004), whereas H3 Lys® méthylation is 
associated with transcriptionally repressed genes (Nakayama et al., 2001). Consistent 
with this, sequential ChlPs demonstrated that the pol III transcriptional machinery had 
greater promoter occupancy when there was an elevated level of H3 Lys'^ méthylation 
compared to H3 Lys® méthylation.
Future work is needed to identify the histone methyItransferases and demethylases 
involved in the regulation of histone H3 Lys"^  and histone H3 Lys® méthylation on pol Ill- 
transcribed genes. Over the last few years, a number of studies have identified histone 
methyltransferases which target histone H3. Examples include setl and Suv391i, which 
methylate H3 Lys^ and H3 Lys®, respectively (Lachner et al., 2001; Milne et al., 2002; 
Rea et al., 2000; Schneider et al., 2005). Following on from this, reeent publications
175
have demonstrated that histoire méthylation is a reversible process, with the discovery of 
histone demethylases. These include LSDl and members of the Jmjc family, which have 
been shown to demethylate both H3 Lys"^  and H3 Lys^ (Klose et al., 2006; Shi et al., 
2004; Tsukada et al., 2006; Whetstine et al., 2006; Yamane et al., 2006). Thus, histone 
methyltransferases and demethylases described here may provide potential targets when 
looking at the regulation o f pol Ill-transcribed genes.
Histone méthylation provides binding sites for the recruitment of chromodomain proteins 
that regulate the expression o f genes. Méthylation of histone H3 Lys"^  can promote the 
recruitment of Chdl, which is associated with the transcriptional activation of genes 
(Pray-Grant et al., 2005). Conversely, methylated histone H3 Lys^ is associated with the 
recruitment of H Pl, a protein associated with gene silencing (Lachner et al., 2001). 
Again, these proteins may provide potential targets when looking at the regulation of pol 
Ill-transcribed genes through histone méthylation.
7.10 Importance of these findings
The rate o f cellular growth is dependent on the rate of protein synthesis (Baxter and 
Stanners, 1978). The process o f translation mediates protein synthesis, where ribosomes 
synthesize proteins from mRNA templates. Therefore, ribosomes assume a central role 
in the process o f growth. This is reinforced by the finding that ribosome content is 
directly proportional to the rate o f cellular growth (Kief and Warner, 1981). During 
mitogenic stimulation, there is an increase in the synthesis o f rRNA and ribosomal
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proteins which help facilitate an increase in protein synthesis (Johnson et a l ,  1974; Kief 
and Warner, 1981; Mauck and Green, 1974). Mitogenic stimulation also leads to an 
increase in transcription by pol III (Clarke et a l ,  1996; Felton-Edkins et a l ,  2003a; Scott 
et a l ,  2001; White et a l ,  1995). Levels o f pol III transcripts, such as tRNA play 
important role in protein synthesis (Francis and Rajbhandary, 1990). Thus, the regulation 
o f pol III is an important determinant o f the cells translational capacity and gi'owth.
mTOR also responds to mitogenic stimuli by regulating cellular growth and proliferation 
(Inoki et a l ,  2005; Wullschleger et a l ,  2006). This is in part mediated through its 
phosphorylation o f S6K and 4E-BP1, both o f which are involved in protein translation 
(Inoki et a l , 2005; Wullschleger et a l , 2006). However, recent studies have 
demonstrated that mTOR controls rRNA expression through its regulation o f components 
o f the pol I transcriptional complex (Hannan et a l, 2003; James and Zomerdijk, 2004, 
Mayer et a l ,  2004). Work in this present study demonstrates that mTOR also controls 
the expression of genes encoding rRNA through the regulation o f the pol III 
transcriptional machinery. This highlights a mechanism by which the expression o f pol 
Ill-transcribed genes are controlled through mitogenic stimuli. Furthermore, ChIP assays 
demonstrated that mTOR directly binds to pol Ill-transcribed genes. This suggests, for 
the first time, that mTOR regulates transcription through a direct interaction with a genes 
transcriptional machinery in situ on DNA.
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PKB, TSC2 and Rheb have all been shown to regulate the expression o f pol Ill- 
transcribed genes and are components o f the mTOR pathway. Each has been shown to be 
a target for oncogenic activation (Basso et ah, 2005; Besson et al., 1999; Gromov et al., 
1995; Mak and Yeung, 2004; Tang et al., 2006). The pol III transcriptional machinery 
has been shown to be the target o f a number o f other oncogenes and tumour suppressors 
(White, 2005). High levels o f pol III activity activity are required to sustain rapid growth 
(White, 2003). Therefore, mTOR’s ability to control the expression of pol Ill-transcribed 
genes and its deregulation in cancer may provide a mechanism by which cellular growth 
is increased in transformed cells.
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